C-C bond forming reactions catalyzed by artificial metalloenzymes based on the biotin-streptavidin technology by Chatterjee, Anamitra
C-C Bond Forming Reactions Catalyzed by Artificial 
Metalloenzymes Based on the Biotin-Streptavidin 
Technology 
 
Inauguraldissertation 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der  
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
Anamitra Chatterjee 
Aus Indien 
Basel, 2015 
 
 
Originaldokument gespeichert auf dem Dokumentenserver der Universitat Basel 
edoc.unibas.ch 
ii 
 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von: 
Prof. Dr Thomas R. Ward 
Prof. Dr Olivier Baudoin 
 
 
 
 
 
Basel, den 13.10.2015                                                                         
 
 
Prof. Dr. Jörg Schibler 
           Dekan  
iii 
ACKNOWLEDGMENTS 
 
Firstly, I would like to express my sincere gratitude to my advisor Prof. Thomas R. Ward 
for the continuous support of my Ph.D study and related research, for his patience, 
motivation, and immense knowledge. His guidance helped me in all the time of research 
and writing of this thesis. I could not have imagined having a better advisor and mentor 
for my Ph.D study. 
  
Besides my advisor, I would like to thank the rest of my thesis committee: Prof. Olivier 
Baudoin for agreeing to co-referee this thesis and Prof. Dennis Gillingham, for agreeing 
to be faculty representative.  
  
My sincere thank also goes to Dr. Raphael Reuter, Dr. Valentin Köhler, Dr. Anna 
Kajetanowicz, Dr. Mark Ringenberg and Dr. Hendrik Mallin, who taught me various 
laboratory and research skills. Without their precious support it would not be possible to 
conduct this research. Special thanks to Maxime Barnet for his generous help and support 
in docking and Bernhard Jung to solve all computer related problems, Mrs. Isa Worni and 
Mrs. Beatrice Erismann for all administrative help.  
  
I thank my past and present fellow labmates: Jingming Zhao, Dr. Vincent Lebrun, Jaicy, 
Dr. Gaetano Angelici, Dr. Tillmann Heinisch, Martina Hestericova, Juliane Klehr, Sascha 
Keller, Yasunori Okamoto, Michela Maria Pellizzoni, Fabian Schwizer, Christian 
Trindler, Ewa Milopolska, Dr. Praneeth Vijayendran, Livia Knörr, Dr. Yvonne Wilson, 
Dr. Maurus Schmid, Dr. Christian Tagwerker, Julian Ruoss, Dr. Nobutaka Fujieda, Dr. 
Tommaso Quinto, Dr. Todd Hyster, Dr. Marc Duerrenberger, Dr. Marc Creus, Aping 
Niu, Narasimha Rao Uda and Dr. Zhe Liu for the stimulating discussions and for all the 
fun we have had in the last four years. 
  
The most important, I would like to thank my family, especially my mother Parul 
Chatterjee and my father  Debasish Chatterjee for the  support  they  provided  me  
through  my  entire  life  and  in  particular during  my  thesis.  I don’t forget my sister 
Sanghyamitra and brother-in-law Ritabrata. Finally, it is impossible to finish without 
addressing my deep love and gratitude to Somdutta. Her love, encouragement and help 
during my thesis make my life beautiful and the best days of my life. 
iv 
 TABLE OF CONTENTS 
 Page 
ABSTRACT ...................................................................................................................... VI 
PUBLICATION ............................................................................................................... VII 
CHAPTER 1 INTRODUCTION ........................................................................................1 
1.1 C-C Bond Formation................................................................................................2 
   1.2 Artificial Metalloenzymes ....................................................................................3 
1.3 Catalytic Scope of ArMs ....................................................................................6 
   1.4 Aim of the Thesis ............................................................................................6 
 1.5 References ....................................................................................................7 
CHAPTER 2 RECENT ADVANCES IN THE PALLADIUM CATALYZED SUZUKI-
MIYAURA CROSS-COUPLING REACTION IN WATER ...........................................10 
2.1 Introduction ............................................................................................................11 
  2.2 Homogeneous SMC in Water ..............................................................................11 
2.2.1 P-donors Ligands ..........................................................................................11 
2.2.2 N-donor Ligands ...........................................................................................15 
            2.2.3 N-heterocyclic Carbene (NHC) Ligands ......................................................26 
            2.2.4 SMCs for Chemical Biology Applications ...................................................33 
2.3 Heterogeneous SMC in water ..............................................................35 
   2.3.1 Supported catalysts ........................................................................35 
   2.3.2 Unsupported catalysts ....................................................................45 
   2.3.3 SMCs for Chemical Biology Applications ....................................49 
         2.4 Conclusion ..................................................................................50 
             2.5 References ...............................................................................50 
CHAPTER 3 ENANTIOSELECTIVE ARTIFICIAL SUZUKIASE FOR THE 
SYNTHESIS OF AXIALLY CHIRAL BIARYL COMPOUNDS RELYING ON 
STREPTAVIDIN-BIOTIN TECHNOLOGY ....................................................................57 
3.1 Introduction ............................................................................................................58 
   3.2 Aim of the Project ...............................................................................................59 
      3.3 Outline of the Project .......................................................................................59 
         3.4 Results and Discussion .................................................................................60 
            3.4.1 Chemical Optimizations ..........................................................................60 
            3.4.2 Genetic Optimizations ............................................................................61 
            3.4.3 Substrate Scopes .....................................................................................65 
            3.4.4 X-ray Structure........................................................................................68 
v 
                  3.5 Conclusions ..........................................................................................70 
                     3.6 References .........................................................................................70 
CHAPTER 4 DEVELOPMENT OF ARTIFICIAL METATHESASE FOR RING 
CLOSING METATHESIS ................................................................................................73 
4.1 Introduction ............................................................................................................74 
   4.1.2 Mechanism of the Olefin Metathesis ...............................................................76 
4.2 Aim of the Project ............................................................................................76 
   4.3 Outline of the Project ....................................................................................77 
                  4.4 Results and Discussion ..............................................................................78 
                     4.4.1 Synthesis of Biotinylated Metathesis Catalysts ...................................78 
                     4.4.2 Activity Test in Organic and Aqueous Organic Solvent .....................82 
                     4.4.3 Comparison of Artificial Metalloenzymes ..........................................87 
                     4.4.4 Screening of Different Mutants with Biot-3 Catalyst ..........................88 
                     4.4.5 HPLC measurements ...........................................................................90 
                     4.4.6 Catalysis in the Periplasm of E. coli with Biot-3 .................................92 
                           4.5 Conclusion ........................................................................................94 
                              4.6 References ......................................................................................95 
CHAPTER 5 ASYMMETRIC C–H ACTIVATION REACTION CATALYZED BY AN 
ARTIFICIAL BENZANNULASE USING UNPURIFIED PROTEIN SAMPLES .........97 
5.1 Introduction ............................................................................................................98 
  5.1.1 Biocatalysts for C–H Activation .......................................................................98 
        5.1.2 Biotin-(strept)avidin Artificial Metalloenzyme Technology ..........................100 
        5.1.3 Prior Works .....................................................................................................101 
            5.2 Aim of the Project ..........................................................................................103 
               5.3 Outline of the Project ..................................................................................103 
5.4 Results and Discussion ......................................................................104 
   5.5 Conclusion ......................................................................................115 
   5.6 References .......................................................................................115 
    
CHAPTER 6 CONCLUSION AND OUTLOOK ..........................................................118 
APPENDICES ....................................................................................................................... 
Appendix 1 ...........................................................................................................120 
Appendix 2 ...........................................................................................................164 
Appendix 3 ...........................................................................................................205 
vi 
ABSTRACT 
           The research in Ward group is merging organometallic chemistry with 
Biotechnology. With the aim of exploiting most attractive and 
complementary features of catalysts, it is proposed to merge homogeneous 
and enzymatic catalysis to yield artificial metalloenzymes. In the past, the 
incorporation of an active metal moiety within a protein environment 
afforded hybrid catalysts with very promising properties, including high 
activities and selectivity, reminiscent of both homogeneous and enzymatic 
catalysts.  
          Herein we discovered an artificial metalloenzymes for enantioselective 
Suzuki-Miyaura cross-coupling reaction. For this purpose, we synthesized 
a variety of biotinylated N-heterocycliccarbene- (NHC) and bulky 
phosphine ligands and tested these in the presence of a Pd-source combined 
with various streptavidin isoforms. We were able to achieve 90% ee with 
artificial suzukiase for the synthesis of a variety of axially chiral biaryl 
compounds. 
          We discovered an artificial metathesase which, in the presence of 
streptavidin displayed remarkable ring-closing metathesis activity either in 
the periplasm or on untreated cell-free extracts. The olefin functionality is 
underrepresented functional group in cellular media and displays only 
modest reactivity towards the various reactants present in complex media. 
This property makes it ideal for biorthogonal chemistry. Different 
biotinylated “Hoveyda-Grubbs” type catalysts were synthesized, 
characterized and screened for ring-closing metathesis. In order to speed up 
screening efforts, ring-closing metathesis leading to umbelliferone was 
used. 
           Efforts to implement the asymmetric C-H activation relying on rhodium 
(III) complexes bearing Cp* ligand in streptavidin in the presence of 
cellular extracts were also described herein. 
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Chapter 1 
 
 
Introduction 
 
 
 
 
 
 
 
  
2 
1.1 C-C Bond Formation  
 
The formation of carbon–carbon bonds is of fundamental importance in organic 
synthesis. Such reactions are important in the production of many valuable chemicals 
in various fields such as pharmaceuticals, crop-protection, chemical industry, energy 
supply, materials science, nutrition, fragrances and flavors.
1
 As a result, there are an 
ever-growing number of methods available for the carbon–carbon bond formation. 
Some examples of reactions which yield carbon–carbon bonds include: the Aldol 
reaction, the Diels–Alder reaction, the addition of a Grignard reagent to a carbonyl 
group, the Heck reaction, the Michael addition and the Wittig reaction. There are 
many existing strategies for catalytic C-C bond formation reactions.  These have been 
classified as i) homogeneous ii) heterogeneous and iii) bio catalysis.  
 
i) Transition metal catalyzed homogeneous C-C bond formation reactions 
have been developed over five decades. There are more than hundred types 
of reactions which have been developed by homogeneous catalysis. For 
example, the olefin metathesis, the cross-coupling, the Wittig reaction, the 
Diels-Alder, the Grignard reaction etc.
2–4
 
 
ii) Tethering an organometallic complex to a silica particle or to the internal 
surface of a mesoporous host can be used to design heterogeneous catalysts 
for a variety of C-C bond forming reactions.
5
  
 
iii) Only a limited number of enzymatic C–C bond forming reactions have 
been applied in biocatalytic organic synthesis.
6
 For instance the Stetter and 
the Pictet–Spengler reaction or the oxidative C–C bond formation, the 
benzylation of aromatics, the intermolecular Diels-Alder or the reductive 
coupling of carbon monoxide. These reactions are catalyzed by aldolases, 
transketolases, lyases, oxidoreductases, transferases etc.
7–9
 
 
3 
1.2 Artificial Metalloenzymes 
In the past century, homogeneous-, enzymatic- and heterogeneous catalysis have 
evolved independently. Each catalytic system offer distinct advantages and 
disadvantages. In the context of high-added value chemicals, homogeneous and 
enzymatic catalysts are preferred.
10
 In many cases, homogeneous catalysts and 
enzymes display complementary features. In the past decade, artificial 
metalloenzymes (hereafter ArMs) have attracted increasing attention as they have 
been shown to combine attractive features of both homogeneous- and enzymatic 
catalysts.
11–13
 Such systems aim at bridging the gap between the transition metal 
catalysis and biocatalysis. Such hybrid catalysts result from anchoring a catalytically 
competent cofactor within a macromolecular scaffold (oligonucleotide or protein), 
Scheme 1.1.  
 
 
Scheme 1.1 Construction of an artificial metalloenzyme based on the biotin-streptavidin technology. 
An achiral metal complex linked to biotin via a spacer is incorporated within a biotin-binding protein by 
supramolecular anchoring. Chemogenetic optimization of the hybrid system affords versatile 
enantiselective hybrid catalysts for a variety of organic transformations. M = metal, L = ligand, X = 
donor atom or ligand. 
 
Various anchoring strategies have been pursued to ensure the localization of the 
abiotic cofactor within the macromolecular scaffold. These can be classified as: i) 
covalent, ii) dative and iii) supramolecular, Scheme 1.2. 
4 
 
 
Scheme 1.2 Various anchoring strategies used in the generation of artificial metalloenzymes: covalent, 
dative and supramolecular 
 
i) The covalent anchoring strategy relies on the creation of a covalent bond 
between nucleophilic amino acids (mostly cysteine, lysine or serine) and 
cofactors bearing an electrophilic moiety (or a thiol)
14,15
 (Scheme 1.2). 
Recently, Lewis and coworkers have engineered an azide containing 
unnatural amino acid that undergoes spontaneous 1,3-dipolar cycloaddition 
with abiotic cofactors bearing an cyclooctyne moiety.
16
  
 
ii) In the dative anchoring strategy, one Lewis-basic amino acid (histidine, 
cysteine, methionine, aspartate and glutamate etc.) of the biomolecule acts 
as a ligand for the coordinatively unsaturated metal cofactor. In this 
context, zinc-substitution within human carbonic anhydrase has proved 
propituous.
17
 Recently, Song and Tezcan reported the design and evolution 
of a metalloprotein assembly with in vivo hydrolytic activity (ampicilin 
hydrolysis in E. coli’s periplasm).18 
 
iii) The supramolecular anchoring strategy relies on weak interactions between 
small molecules and the biomolecular scaffold. The critical parameter in 
this strategy is the affinity of the guest molecule for the host biomolecular 
scaffold. Wilson and Whitesides outlined in 1978 the use of avidin as host 
for the supramolecular anchoring of biotinylated cofactors.
19
 They were the 
first to exploit the nearly irreversible binding of biotin (vitamin H) with 
5 
avidin (Kd = ca. 10
-14
 M) to generate an artificial metalloenzyme for 
enantioselective hydrogenetion.
20
 Since then, several groups have picked 
up on this technology to engineer ArMs.
21,22
  
 
Chemical Optimization of the ArMs: 
The chemical catalyst is generally optimized by screening different active metal 
complexes. Compared to the traditional transition metal catalysis, the advantage is that 
the ligand in most instances is not chiral, which reduces the synthetic complexity. 
Introduction of various spacers between the biotin anchor and the organometallic 
moiety allows probing the protein cavity in search of beneficial second coordination 
sphere interactions. 
 
Genetic Optimization of ArMs: 
Optimization of the protein scaffold can be achieved by design in combination with 
evolutionary approaches, such as designed and directed evolution.
21
 The different 
approaches to rationally (re)design a metal binding site in a protein have been recently 
summarized by Lu et al.
23
 
1) The empirical approach that includes the design by inspection, homology, and by 
replacement of modular units;  
2) The theoretical approach that uses computer search algorithms that make 
predictions and help designing a new active site into a native scaffold by finding the 
optimal locations for ligands;  
3) The semi theoretical approach that combines visual inspection of proteins to 
identify optimal locations for ligands to create a new metal binding site and computer 
program evaluation for the energetics of positioning appropriate amino acid residues.  
 
 
 
6 
1.3 Catalytic Scope of ArMs 
The combination of a well-defined second coordination sphere (biomolecule) and the 
first coordination sphere (water compatible transition metal complex) opens 
fascinating perspectives towards the generation of ArMs for a wide range of organic 
transformations. Example of C-C bond formation reactions catalyzed by artificial 
metalloenzyme implemented to date include: allylic substitution,
24
 cross-coupling,
25
 
benzannulation,
26
 metathesis,
27
 polymerisation,
28
 Diels-Alder reaction,
29
 Friedel-Crafts 
alkylation,
30
 cyclopropanation,
16
 hydroformylation,
17
 etc.
11,13
 
 
1.4 Aim of the Thesis 
The high stability of (strept)avidin combined with its high affinity towards 
biotinylated compounds offer a large number of promising and challenging 
applications. In this thesis, we focused our efforts on developing bio-orthogonal C–C 
bond forming reactions exploiting the potential of artificial metalloenzymes based on 
the biotin (strept)avidin technology. In this context, i) the Suzuki-Miyaura cross-
coupling, ii) the olefin metathesis and iii) C-H activation reactions were investigated.  
i) In the past few years, the Suzuki cross-coupling reaction has attracted 
significant attention as a versatile, water compatible cross-coupling 
reaction.
31,32
 Importantly, several groups have demonstrated the 
biocompatibility and bio-orthogonality of the Suzuki cross-coupling, thus 
revealing interesting avenues for chemical biology applications.
33–36
 In this 
context, they have performed cross-coupling reactions on proteins and even 
in vivo.
33
 To the best of our knowledge, however, these reactions are not 
catalytic as they require very high loadings of palladium.
37
 In Chapter 2, 
we summarize recent developments of Suzuki-Miyaura cross-coupling 
reaction in water. 
ii) In Chapter 3, we present our efforts to develop an artificial enantioselective 
Suzukiase based on the biotin-streptavidin technology and test its bio-
compatibility in cellular extracts.  
7 
iii) The olefin functionality is an underrepresented functional group in cellular 
media. In addition, this functionality displays only modest reactivity 
towards the various reactants present in this complex media. In Chapters 4 
and 5, we present our efforts to develop bio-orthogonal reactions using 
olefins as partner. In Chapter 4, we present our efforts to develop the ring 
closing olefin metathesis in vivo by developing biotinylated N-heterocyclic 
ligands to anchor a Hoveyda-Grubbs type catalyst within streptavidin. 
 
iv) Rhodium (III) complexes bearing Cp* ligands proved to be highly versatile 
catalysts for the directed carbon-hydrogen (C–H) bond functionalizations 
of hydroxamic acid derivatives.
26
 Previous work in the group demonstrated 
that high levels of both selectivity and reactivity could be achieved by an 
artificial metalloenzyme by engineering a basic carboxylate aminoacid 
residue in the proximity of the biotinylated Rh(III) center. In Chapter 5, we 
summarize our efforts to perform this asymmetric C–H activation in 
cellular extracts. 
Finally, Chapter 6 presents an overview of the progress towards cell-compatible, 
catalytic C–C bond forming reactions.  
 
1.5 References 
(1)  Jacobsen, E. N.; Pfaltz, A.; Yamamoto, H. Comprehensive Asymmetric 
Catalysis, Springer, Berlin, 1999. 
(2)  Zultanski, S. L.; Fu, G. C. J. Am. Chem. Soc. 2013, 135, 624. 
(3)  Watson, I. D. G.; Toste, F. D. Chem. Sci. 2012, 3, 2899. 
(4)  Roscales, S.; Csákÿ, A. G. Chem. Soc. Rev. 2014, 43, 8215. 
(5)  Thomas, J. M. Angew. Chem. Int. Ed. 1999, 38, 3588. 
(6)  Resch, V.; Schrittwieser, J. H.; Siirola, E.; Kroutil, W. Curr. Opin. Biotechnol. 
2011, 22, 793. 
8 
(7)  Müller, M.; Gocke, D.; Pohl, M. FEBS J. 2009, 276, 2894. 
(8)  Clapés, P.; Fessner, W.-D.; Sprenger, G. A.; Samland, A. K. Curr. Opin. Chem. 
Biol. 2010, 14, 154. 
(9)  Schneider, S.; Gutiérrez, M.; Sandalova, T.; Schneider, G.; Clapés, P.; 
Sprenger, G. A.; Samland, A. K. Chembiochem 2010, 11, 681. 
(10)  Ward, T. R. Acc. Chem. Res. 2011, 44, 47. 
(11)  Yu, F.; Cangelosi, V. M.; Zastrow, M. L.; Tegoni, M.; Plegaria, J. S.; Tebo, A. 
G.; Mocny, C. S.; Ruckthong, L.; Qayyum, H.; Pecoraro, V. L. Chem. Rev. 
2014, 114, 3495. 
(12)  Heinisch, T.; Ward, T. R. Eur. J. Inorg. Chem. 2015, 21, 3406. 
(13)  Lewis, J. C. ACS Catal. 2013, 3, 2954. 
(14)  Qi, D.; Tann, C.-M.; Haring, D.; Distefano, M. D. Chem. Rev. 2001, 101, 3081. 
(15)  Basauri-Molina, M.; Riemersma, C. F.; Würdemann, M. A.; Kleijn, H.; Klein 
Gebbink, R. J. M. Chem. Commun. 2015, 51, 6792. 
(16)  Yang, H.; Srivastava, P.; Zhang, C.; Lewis, J. C. Chembiochem 2014, 15, 223. 
(17)  Jing, Q.; Kazlauskas, R. J. ChemCatChem 2010, 2, 953. 
(18)  Song, W. J.; Tezcan, F. A. Science  2014, 346, 1525. 
(19)  Wilson, M. E.; Whitesides, G. M. J. Am. Chem. Soc. 1978, 100, 306. 
(20)  Davies, R. R.; Kuang, H.; Qi, D.; Mazhary, A.; Mayaan, E.; Distefano, M. D. 
Bioorg. Med. Chem. Lett. 1999, 9, 79. 
(21)  Reetz, M. T.; Peyralans, J. J.-P.; Maichele, A.; Fu, Y.; Maywald, M. Chem. 
Commun. 2006, 41, 4318. 
(22)  Ilie, A.; Reetz, M. T. Isr. J. Chem. 2015, 55, 51. 
(23)  Lu, Y.; Yeung, N.; Sieracki, N.; Marshall, N. M. Nature 2009, 460, 855. 
(24)  Pierron, J.; Malan, C.; Creus, M.; Gradinaru, J.; Hafner, I.; Ivanova, A.; Sardo, 
A.; Ward, T. R. Angew. Chem. 2008, 120, 713. 
9 
(25)  Abe, S.; Niemeyer, J.; Abe, M.; Takezawa, Y.; Ueno, T.; Hikage, T.; Erker, G.; 
Watanabe, Y. J. Am. Chem. Soc. 2008, 130, 10512. 
(26)  Hyster, T. K.; Knörr, L.; Ward, T. R.; Rovis, T. Science 2012, 338, 500. 
(27)  Lo, C.; Ringenberg, M. R.; Gnandt, D.; Wilson, Y.; Ward, T. R. Chem. 
Commun. 2011, 47, 12065. 
(28)  Abe, S.; Hirata, K.; Ueno, T.; Morino, K.; Shimizu, N.; Yamamoto, M.; Takata, 
M.; Yashima, E.; Watanabe, Y. J. Am. Chem. Soc. 2009, 131, 6958. 
(29)  Podtetenieff, J.; Taglieber, A.; Bill, E.; Reijerse, E. J.; Reetz, M. T. Angew. 
Chem. Int. Ed. 2010, 49, 5151. 
(30)  Boersma, A. J.; Megens, R. P.; Feringa, B. L.; Roelfes, G. Chem. Soc. Rev. 
2010, 39, 2083. 
(31)  Lipshutz, B. H.; Taft, B. R.; Abela, A. R.; Ghorai, S.; Krasovskiy, A.; Duplais, 
C. Platinum Metals Review. 2012, 62. 
(32)  Suzuki, A. Angew. Chem. Int. Ed. 2011, 50, 6722. 
(33)  Chankeshwara, S. V; Indrigo, E.; Bradley, M. Curr. Opin. Chem. Biol. 2014, 
21, 128. 
(34)  Yang, M.; Li, J.; Chen, P. R. Chem. Soc. Rev. 2014, 43, 6511. 
(35)  Prescher, J. A.; Bertozzi, C. R. Nat. Chem. Biol. 2005, 1, 13. 
(36)  Chalker, J. M.; Wood, C. S. C.; Davis, B. G. J. Am. Chem. Soc. 2009, 131, 
16346. 
(37)  Völker, T.; Meggers, E. Curr. Opin. Chem. Biol. 2015, 25, 48.  
 
 
 
 
 
10 
 
 
 
 
 
CHAPTER 2 
 
Recent Advances in the Palladium Catalyzed 
Suzuki-Miyaura Cross-Coupling Reaction in 
Water 
 
 
 
 
 
 
 
 
 
11 
 
2.1 Introduction 
The Suzuki-Miyaura cross-coupling reaction (SMC hereafter) is one of the most 
important synthetic transformations developed in the 20
th
 century.
1,2
 This is the most 
versatile methods for the synthesis of biaryls and alkene derivatives. These are 
structural constituents of numerous agrochemicals, natural products, pharmaceuticals, 
and polymers.
2–5
 Several reviews on the SMC have been published in the literature.
6–11
 
Recently, green chemistry awareness attempts to address the environmental impact of 
both chemical products and the processes by which these are produced.
12,13
 Around 
80% of the chemical waste from a reaction mixture corresponds to the solvent. From 
environmental, economic and safety points of view, the use of water as solvent in 
organic reactions is a clear goal, although challenging and in most cases requires high 
reaction temperatures.
14
 In the case of the SMC, the stability of boronic acids in 
aqueous solvent are viewed as advantageous compared to other cross-coupling 
reactions to be performed in water. The literature on the SMC in water up to 2010 has 
been reviewed by Polshettiwar et al.
15
 Herein we focus on the use of water as a 
medium for SMC in homogeneous and heterogeneous systems. This review covers the 
period from 2011 up to August 2015. Current challenges of palladium catalysed SMC 
in water include a) the reactivity with low-cost aryl chlorides, b) low catalyst loading, 
c) the functional group tolerance and d) mild reaction conditions. To address these 
challenges, several groups developed the palladium catalysed SMC in water with 
either the homogenous or the heterogeneous system. 
2.2 Homogeneous SMC in Water 
2.2.1 P-donors Ligands 
Because of the undesired decomposition of P-donors ligands, its use for aqueous SMC 
has remained limited compared to N-donor and NHC ligands. A handful example was 
found in recent literatures.  
12 
For example, Yu and co-workers reported SMC in water catalyzed by a 
supramolecular assembly held together with noncovalent interactions in the presence 
of palladium (Scheme 2.1).
16
 For this purpose, they designed the tridentate ligand 
Phenylphosphinacalix[3]trifuran 1. In the presence of palladium acetate, the resulting 
catalyst proved extremely active with turnover numbers as high as 3.05×10
7
 with 
2×10
-8
 mol% Pd loading. The author suggested that these high TONs are not due to a 
facilitated oxidative addition step but longevity of the catalyst can be a key to reach 
high TONs. 
 
Scheme 2.1 Phenylphosphinacalix[3]trifuran as an efficient ligand for for the SMC in water.
16
 
An efficient and recyclable protocol for the SMC in water was reported by Liu et al. 
based on the cloud point (Cp) of the thermoregulated ligand 2 (Scheme 2.2).
17
 The 
palladium catalyst remains in the aqueous phase at lower temperature (< Cp, 93
o
C) but 
transfers into the substrate phase at higher temperature (> Cp, 93
o
C). This method 
allowed the preparation of a variety of biaryls in high yields (up to 99%) with 0.05 
mol% Pd loading. The catalytic system can be recycled four times with high 
efficiency. 
13 
 
Scheme 2.2 A thermoregulated catalytic system for the SMC in water.
17
 
Recently, Liu and co-workers
18
 reported a catalytic system consisting of the (2-
mesitylindenyl)dicyclohexylphosphine ligand 3 in combination with [Pd(OAc)2] and 
[Me(octyl)3N]
+
Cl
−
  as the phase transfer reagent. The resulting systems displayed high 
catalytic activity in the SMC of various aryl- and heteroaryl chlorides in water 
(Scheme 2.3). 
 
Scheme 2.3 Bulky monophosphine ligand for the SMC in water developed by Liu and co-workers.
18
  
More recently, Eppinger and co-workers used palladacycle 4, under air and at room 
temperature, for the coupling of aryl iodides and bromides with a variety of boronic 
acids.
19
 The biaryl products were obtained in excellent yields (up to 99%) with 0.02 
mol% catalyst loading (Scheme 2.4). Poisoning experiments support the hypothesis of 
the homogenous nature of the catalytically active species, although the pre-catalyst 4 
is insoluble in water. 
14 
 
Scheme 2.4 Palladacycle 4 for SMC in water developed by Eppinger and co-workers.
19
 
Later Gröger and co-workers reported the combination of a palladium-catalyzed SMC 
in aqueous medium with an enzymatic reduction in a one-pot process at room 
temperature.
20,21
 For the SMC, a water-soluble palladium catalyst was prepared from 
palladium chloride and TPPTS (TPPTS = tris(3-sulfonatophenyl)phosphine hydrate, 
sodium salt). After completion of the reaction and adjustment of the pH to 7.0, the 
biaryl ketone product was reduced in situ via alcohol dehydrogenase (ADH). The 
desired biarylalcohol 5 was produced in up to >95% conversion (over the two steps) 
and excellent enantioselectivities (>99% ee) (Scheme 2.5).  
 
Scheme 2.5 SMC and subsequent enzymatic reduction for the synthesis of chiral biarylalcohols in 
water.
20
 
In an independent study, zwitterionic palladium complexes were reported by Lee and 
co-workers for the SMC in water.
22
 The zwitterionic phosphine complex 6 was 
efficient in catalyzing the SMC of sterically hindered aryl chlorides and arylboronic 
acids in dioxane/water (4:1) or neat water at room temperature (Scheme 2.6).   
15 
 
Scheme 2.6 Zwitterionic palladium complexes for the SMC in water.
22
 
In a very recent study, Khazalpour and co-workers reported the palladium–phosphine 
system 7 as an active and recyclable pre-catalyst for SMC in water.
23
 A five-
membered chelate ring is formed upon coordination of the ligand through the 
phosphine and the ylidic carbon atom. The  catalytic  system could  be  reused  four  
times  without  significant  loss  of activity (Scheme 2.7).  
 
Scheme 2.7 A palladium–phosphine catalytic system for SMC in water developed by Khazalpour  and 
co-workers.
23
 
2.2.2 N-donor Ligands 
Although N-donor ligands have been widely neglected in homogeneous 
organometallic catalysis,
24
 there has been a resurgence of interest for N-donor ligands 
in SMC. Various types of N-donor ligands are presented below: i) pyridines/imines, ii) 
16 
imidates iii) pyrimidines iv) amines v) orthometallated palladacycles vi) amides and 
vii) hydrazones. 
i) Pyridines/imines: 
Planas and co-workers developed o- and m-carborane-based NBN pincer palladium 
complexes for SMC in water. These catalyst require remarkably low catalyst loadings 
(10
-4
 mmol%) and display good functional group tolerance.
25
 They used NBN pincer 
complex instead of NCN pincer complex because of the stronger electron donating 
ability of the boron moiety which exhibited stronger trans-influence. Complex (o-CB-
L1)Pd 8 displayed a better catalytic profile than (m-CB-L1)Pd 9 and with excellent 
conversions and TON values ranging from 770’000 to 990’000 (Scheme 2.8). 
Although potentially chiral, no mention is made on whether the ligands were used as a 
racemate, in their meso-form or in enantiopure form. 
 
Scheme 2.8 SMC in water with o- and m-carborane-based NBN pincer palladium complexes.
25
  
A set of water soluble pincer pyridine-diamine ligands 10, 11 was developed by the 
Morales group for the SMC (Scheme 2.9). The presence of hydroxy-groups on the 
ligand ensures water solubility. Excellent yields were achieved (950 TON) for the 
formation of biphenyls at 95
o
C in pure water.
26
 Purification is readily achieved by 
decantation as the product is insoluble in water. The easy synthesis of the ligand from 
commercial starting materials, combined with the high catalytic activity of the 
corresponding complex deserves particular mention.  
17 
 
 
Scheme 2.9 SMC in water with water soluble pincer palladium complexes.
26
  
Recently, Tu and co-workers reported a hydrophilic pyridine-bridged bis-
benzimidazolylidene palladium pincer complex 12 which is a highly efficient catalyst 
towards the SMC in water (Scheme 2.10).
27
  
 
Scheme 2.10 Palladium-pincer complex for the SMC in water.
27
 
The Pd(OAc)2–(DHQD)2PHAL 13 catalyzed SMC was reported by Saikia and co-
workers (Scheme 2.11). This is a very simple, mild and efficient protocol for the 
synthesis of biaryls/heterobiaryls in neat H2O at room temperature. Furthermore, the 
catalyst system is recyclable and can be employed in several consecutive runs without 
significant loss in catalytic activity.
28
 No mention was made concerning the 
enantioselective SMC with this system. 
18 
 
Scheme 2.11 Pd(OAc)2–(DHQD)2PHAL catalyzed SMC in water.
28
  (DHQD)2PHAL = Hydroquinidine 
1,4-phthalazinediyl diether. 
Wang and coworkers reported the synthesis of the palladium chelating complex 14 
and its application for the SMC in air and water (Scheme 2.12).
29
 The biaryl products 
were obtained in good to excellent yields with 0.1 mol% catalyst loading. 
 
Scheme 2.12 Palladium chelating complex for SMC in water developed by Wang and coworkers.
29
 
A self-assembled hexanuclear cluster Pd6L8 (L = 1,3,5-tris(4'-pyrirdyloxadiazol)-
2,4,6-triethylbenzene) ball 15 was reported by Dong for the SMC at very low catalyst 
loadings (i.e.100 ppm) (Scheme 2.13).
30
 Depending on the solvent used for the SMC, 
19 
the system was either homogeneous or heterogeneous: the reaction was homogeneous 
in water-ethanol whereas it was heterogeous in xylene.  
 
Scheme 2.13 A self-assembled Pd6L8 cluster for the SMC in water developed by Dong.
30
 
Senemoglu reported a microwave-assisted aqueous SMC catalyzed by unsymmetrical 
sulfonated water-soluble Pd(II)-pyridyl  imine  complexes 16 (Scheme 2.14).
31
 The 
compounds proved to be effective catalysts with up to 980 TON.  
 
Scheme 2.14 Unsymmetrical sulfonated water-soluble Pd(II)-pyridyl  imine  complexes for SMC in 
water.
31
 
Recently, Hor and Young reported a supramolecular recyclable catalyst for the 
aqueous SMC (Scheme 2.15).
32
 Upon host–guest incorporation of 17 within 
20 
heptakis(2,6-di-O-methyl)-β-CD 18 in aqueous media, a water soluble supramolecular 
assembly 19 was generated. This catalyst 19 (0.5 mol%) efficiently catalyzed the SMC 
(>97% yield) between hydrophilic aryl bromides with aryl boronic acid at room 
temperature.  
 
Scheme 2.15 Supramolecular catalyst for aqueous SMC developed by Hor and Young.
32
 
Lang and Li reported a PdCl2/sulfonate-tagged phenanthroline precatalyst 20 for the 
SMC at 100
o
C in water (Scheme 2.16).
33
 The cross-coupling products were obtained 
in good to excellent yields (TON upto 1980). 
 
Scheme 2.16 Sulfonate-tagged phenanthroline palladium precatalyst for SMC in water.
33
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ii) Imidates: 
Water-soluble palladium(II) complexes trans-[Pd(imidate)2(PTA)2] (imidate = 
succinimidate (suc) 21, maleimidate (mal) 22, phthalimidate (phthal) 23 or 
saccharinate (sacc) 24) have shown to efficiently catalyze SMC of synthetically 
challenging substrates. The antiviral nucleoside analogue 5-iodo-2’-deoxyuridine 
25 was used as substrate for the formation of the corresponding biaryl 26 in water 
under mild conditions (TON = 96).
34
 Upon increasing the reaction time (48 hours), 
lower catalyst loadings (0.1 mol %) could also be used, without any appreciable 
erosion of the yield (Scheme 2.17). 
 
 
Scheme 2.17 Imidate as ligands for the SMC of 5-iodo-2’-deoxycytidine developed by Serrano 
and co-workers.
34
 
 
iii) Pyrimidines: 
Ben Davis reported an active pyrimidine ligand 27a in 2009 for the aqueous SMC.
35
 
Inspired by this work, Chalker and coworkers
36
 developed a melamine-palladium 
22 
catalyst 27b for the SMC in water (Scheme 2.18). The advantages of the melamine 
ligand over pyrimidine ligands are as follows:  
i) It is less expensive than the pyrimidine.  
ii) It is soluble in both water and organic solvents.  
iii) The melamine-palladium catalyst can be cross-linked by reaction with 
formaldehyde to generate an insoluble polymeric catalyst 28 that can be 
recovered after the cross-coupling.  
 
Scheme 2.18 Davis’ ligand 27a for aqueous SMC. Crosslinked and related insoluble 
melamine-palladium catalysts for the SMC in water developed by Chalker and coworkers.
36
  
 
iv) Amines: 
Zhou and coworkers
37
 investigated the influence of the chelate ring size (i.e. 5 or 6), 
and the relative position of both N-donors and bulkiness of N-aryl substituents in 
amine-bridged bis(phenol) ligands (29, 30 and 31) on the palladium-catalyzed SMC 
(Scheme 2.19). The homocoupling of arylboronic acid could be completed in neat 
water with the aid of a catalytic amount of p-toluenesulfonyl chloride (TsCl) in a very 
short time under anaerobic or aerobic conditions. Interestingly, the same catalytic 
system was efficient for the SMC in aqueous acetone under aerobic conditions in the 
absence of TsCl.  
23 
 
Scheme 2.19 Amine-bridged bis(phenol) ligands for the aqueous C-C coupling reaction.
37
 
v) Orthometallated palladacycles: 
Palladacycles are interesting because they are believed to release highly active Pd(0) 
species at a very slow rate, which prevents the deactivation of Pd(0) such as 
nanoparticle formation, thus achieving high turnover numbers. Palladacycles are   
 
Scheme 2.20 SMC in water with an orthometallated aryltriazole palladium complex bearing a PEG 
solubilizing unit.
38
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formed by C-H activation of aromatic moiety near a coordination site in the ligand. A 
novel water-soluble palladacycle 32 has been reported by Ding
38
 (Scheme 2.20). The 
catalyst exhibited superior catalytic activity towards the SMC in neat water with 
TONs of up to 9.8×10
5
. In addition, the catalyst could be reused at least 3 times 
without significant loss of activity. 
Bora and coworkers studied O-Aryloxime ether analog 33 as ligands in the palladium-
catalyzed SMC of aryl bromides and aryl boronic acids in water at room 
temperature.
39
 Reaction conditions for the cross-coupling were optimized using PdCl2 
and Pd(OAc)2 under aerobic conditions (Scheme 2.21). To the best of our knowledge, 
this is the only example of oxime ether used as a ligand. The aryl ring of the aryloxime 
ether is expected to undergo orthometalation through C-H activation to form highly 
active palladacycle.  
 
Scheme 2.21 O-Aryloxime ether as ligand in palladium-catalyzed SMC in water.
39
 
 
vi) Amides: 
Jiang and Tan recently reported a SMC in water relying on the amide-bearing 
quinoline derivative 34 as a ligand.
40
 With 0.05 mol% Pd loading, they obtained up to 
98% yield at 60–90 °C under air (Scheme 2.22). 
25 
 
Scheme 2.22 Bidentate amide ligand based on a quinoline derivative used for the SMC in water.
40
 
 
vii) Hydrazones: 
Nallasamy and co-workers reported a palladium(II) complex 35 bearing a series of 
ONO tridentate heterocyclic hydrazone ligands for SMC of substituted aryl boronic 
acids with aryl chlorides in a water–toluene system (9 : 1).41 The catalyst was highly 
active with 0.01 mol% loading to afford 99% yield of the coupled product (Scheme 
2.23).  
 
Scheme 2.23 Tridentate heterocyclic hydrazone ligand for SMC in water.
41
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2.2.3 N-heterocyclic Carbene (NHC) Ligands 
NHC ligands are strong electron donors and can be sterically demanding. 
Recently, their use in aqueous media has received attention. The carbene carbon of an 
NHC is strongly basic (pKa about 20), which generally precludes their use as free 
ligands in aqueous media. Because of the strong metal-NHC bond, metal complexes of 
water-soluble NHCs are often water soluble. The Haag group reported a highly active 
glycerol-dendron-supported N-heterocyclic carbene ligand 36 with Pd(OAc)2 as a 
catalyst (Scheme 2.24). A symmetrical ligand structure was designed to provide a 
larger micro-environment with the catalytic site at the core position. Deprotection of 
the dendritic-supported catalysts allowed to perform the catalytic reaction in neat 
water.
42
 
 
Scheme 2.24 Dendritic supported NHC-palladium catalysts for SMC with a L/Pd Ratio of 1.1:1.  
Four water-soluble PEPPSI-type (pyridine, enhanced, precatalyst, preparation, 
stabilization and initiation) Pd-NHC complexes (37–40) were developed by Kühn and 
Pöthig for the SMC in water under air (Scheme 2.25).
43
 Complex 37, bearing a 2,6-
diisopropylphenyl substituent, displayed the best catalytic activity for a variety of aryl 
bromides with a catalyst loading of 0.1 mol% even at room temperature. The catalyst 
can be used in at in least four consecutive runs without significant loss of activity.   
27 
 
Scheme 2.25 Water-soluble PEPPSI-type -Pd-NHC complexes for aqueous SMC.
43
 (PEPPSI = 
pyridine, enhanced, precatalyst, preparation, stabilization and initiation) 
An asymmetric SMC using chiral PEPPSI complex 41 incorporating bulky 
enantiopure N-heterocyclic carbenes was developed by Kündig and coworkers.
44
 They 
obtained up to 85% yield and 80% ee for coupling of 1-halo-2-methylnaphthalene 
with naphthylboronic acid. Unfortunately, the product was contaminated with an 
inseparable homocoupling product (Scheme 2.26).  
 
Scheme 2.26 Asymmetric SMC with chiral PEPPSI complexes incorporating bulky N-heterocyclic 
carbene ligands.
44
 
 
Water-soluble Pd(II)(NHC) complexes 42 containing two sterically-hindered 
sulfonated groups have been prepared by Jesus.
45
 These complexes are active catalysts 
for the SMC of aryl chlorides and boronic acids in mixtures of isopropyl alcohol/water 
28 
or, in the case of water-soluble aryl chlorides, in pure water (Scheme 2.27). For some 
of the most hindered aryl chlorides, small amounts of monoarenes are formed via a 
competitive hydro dehalogenation process.   
 
Scheme 2.27 Synthesis of biphenyls by SMC catalyzed by palladium(II) complexes bearing sulfonated 
N-Heterocyclic Carbenes.
45
 
Palladium complexes with chelating, oligo ethylene glycol-substituted bis-NHC 
ligands have been prepared by Strassner.
46
 The resulting Pd-complex 43 displays 
excellent water solubility and very high catalytic activity. Up to 80’000 TONs could 
be achieved in a 1 : 1 water methanol mixture at 100 
o
C (Scheme 2.28). The palladium 
complexes showed excellent solubility in water. Very high catalytic activity was 
achieved even at ppm catalyst loadings.  
 
Scheme 2.28 Oligo ethylene glycol substituted bis-NHC ligands for SMC in a water-methanol 
mixture.
46
  
A very similar complex 44 was also prepared by Wang and coworkers.
47
 
Deprotonation of carboxylic acid group rendered it water-soluble (Scheme 2.29).  
29 
 
Scheme 2.29 Chelating-NHC-palladium complex for the SMC in water.
47
 
In a study, Peris and Godoy compared four bis-NHC-palladium complexes 45 – 48 for 
the SMC in water.
48
 The bis-NHC-palladium complex 45, in which the two NHC 
ligands are in a relative cis configuration, afforded the best catalytic system, with 
TONs > 10
5
 for 4-bromoacetophenone and 3.7 × 10
4 
for 4-chloroacetophenone 
(Scheme 2.30).  
 
Scheme 2.30 Palladium catalysts with sulfonate-functionalized-NHC ligands for the SMC in water.
48
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Nolan and coworkers recently reported the SMC using a Pd-NHC catalyst at low 
catalyst loading.
49
 The commercially available and air-stable [Pd(IPr)(cin)Cl] pre-
catalyst 49 led to the formation of various functionalized biaryls from aryl chlorides 
and boronic acids under very mild conditions using a mixture of ethanol/water as 
solvent and an inorganic base (Scheme 2.31). 
 
Scheme 2.31 Commercially available precatalyst for SMC in water.
49
 
Liu and coworkers
50
 reported the synthesis of water-soluble imidazolium salts 50 
bearing poly(ethyleneglycol) moieties directly attached to an N-atom of imidazole. 
The catalytic system generated in situ from a source of [Pd(OAc)2], a precursor of 
imidazolium salt, and triethylamine catalyzes the SMC in water (Scheme 2.32). 
 
Scheme 2.32 Poly(ethylene glycol)-functionalized imidazolium salts–palladium-catalyzed SMC in 
water.
50 
31 
Karimi and coworkers showed that Pd-NHC polymers 51 can be used as catalyst for 
SMC in water (Scheme 2.33).
51,52
 Although the mechanism is not clear, this polymer 
showed very high activity for the coupling of aryl chlorides, together with excellent 
recyclability. 
 
Scheme 2.33 Pd-NHC oligomers for aqueous SMC developed by Karimi.
51
 
Recently, Nechaev and co-workers synthesized the six-membered ring NHC 
containing complex 52, which was used for the cross-coupling of heteroaryl bromides 
and chlorides with heterocyclic boronic acids in water (Scheme 2.34).
53
 The cross-
coupled products were obtained in very good yield with 0.5 mol% catalyst loading 
(TON up to 200). 
 
Scheme 2.34 Expanded ring NHC palladium complexes for the SMC in water.
53
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The same year Cazin and co-workers reported on the synthesis of a mixed PR2Ar 
/NHC Pd complex 53 that were used in SMC of aryl chlorides using very low catalysts 
loadings in aqueous solutions (water/isopropanol 9:1) (Scheme 2.35).
54
 
 
Scheme 2.35 Mixed phosphine/N-heterocyclic carbene palladium complexes for SMC in water.
54
  
In an alternative strategy relying on acyclic carbene ligands, Boyarskiy and 
Luzyanin
55
 reported palladium complexes with acyclic diaminocarbenes [Pd-(ADCs)] 
(Scheme 2.36). The catalyst 54 efficiently catalyzed the SMC of organohalides with a 
range of aryl boronic acids at 80°C within 2h (100°C and 3 h for the chlorides). 
Biaryls were obtained in yields up to 99% and with maximum TONs of 9.9×10
3
 (for 
aryl iodides), 4.7×10
4 
(for aryl bromides), and 9.2×10
3
 (for aryl chlorides).  
 
Scheme 2.36 Acyclic diaminocarbene (ADC) based palladium complexes for SMC in water.
55
  
 
33 
2.2.4 Homogeneous SMC for Chemical Biology Applications  
More recently, the SMC has found applications in the context of chemical biology. 
Indeed, both reactants (i.e. arylhalides and boronic acids) and products (i.e. biaryls) 
can be regarded as bio-orthogonal.
35,56–61
 In this context however, high catalyst 
loadings are routinely required for reactions performed in a biological 
environment.
35,56,57,60,62–70
 Ueno and coworkers anchored a palladium moiety within a 
ferritin container to yield an artificial metalloenzyme. The resulting artificial 
metalloenzyme however did not outperform the free cofactor (no enantioselectivity, 
turnover frequency: 3500 h
-1
).
57
 
The Davis group reported a convenient catalyst for the SMC using a modified protein 
as substrate.
35,59,71,72
 An effective ADHP (2-amino-4,6-dihydroxypyrimidine)-based 
catalyst system [Pd(OAc)2(ADHP)2] 55 was gave full conversion (>95% yield, 95 
TON) between a protein bearing aryl iodide moiety and a broad range of aryl-/vinyl-
boronic acids.
63
 Recently, in a continuous effort to apply transition-metal-mediated 
reactions in living systems, the Davis’ group demonstrated the first application of the 
SMC on the outer-membrane protein OmpC of Escherichia coli cells.
60
 Here, a 
bacterial surface protein, OmpC was engineered by incorporation of 4-iodo-
phenylalanine (Scheme 2.37). A reaction in the presence of a fluorescent boronic acid 
as coupling partner, catalyzed by [Pd(OAc)2(ADHP)2] (200 mol%), afforded the 
fluorescent cross-coupled product, anchored on the bacterial surface. The ADHP-
based catalysts showed excellent labelling efficiency and low cytotoxicity in bacteria 
cells, although the reaction was not catalytic..
73
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Scheme 2.37 (2-amino-4,6-dihydroxypyrimidine)-based catalyst system for SMC on the outer-
membrane protein OmpC of E. coli developed by Davis group.
60 
Wang and Chen reported on a water-soluble N-heterocyclic carbene (NHC)-stabilized-
palladium complex for the SMC of biomolecules under mild conditions in water 
(Scheme 2.38).
67
 The Pd–NHC complex 56 bearing hydrophilic groups was an 
efficient catalyst for the SMC of various unnatural arylhalide-bearing amino acids 
(TON up to 95). The authors further exploited this catalytic system for the rapid 
bioorthogonal labeling of proteins on the surface of mammalian cells. In this case, 
they used a stoichiometric amount of catalyst but there is no mention of yield or TON.  
 
Scheme 2.38 Pd-NHC catalyzed SMC on a cellular system developed by Wang and Chen.
67
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2.3 Heterogeneous SMC in water 
In view of the high cost and the shortage of palladium, its recovery and recycling is an 
important issue for any large scale application. Therefore, a variety of inorganic and 
organic solid-supported catalytic systems have been developed to address these 
challenges. In this context, heterogeneous Pd-catalysts are more attractive than the 
homogeneous Pd-catalysts as their recovery is facilitated. Residual palladium is a 
particular concern in the synthesis of pharmacophores, where very stringent precious 
metal restrictions apply. Unfortunately, compared to their homogeneous counterparts, 
solid-supported catalysts often suffer from lower activity and selectivity. It is thus 
highly desirable to develop highly efficient supported SMC catalysts.  
2.3.1 Supported catalysts 
Polymer-modified nanoparticle-supported catalysts have generated a lot of interest due 
to their unique properties. Polymer supports can be chemically modified easily with 
functional groups to coordinate with transition metals, potentially improving the long-
term stability of the catalyst. Moreover, the nanoparticles may enhance the catalytic 
performance thanks to their large surface-to-volume ratios and high densities of active 
sites relative to the bulk metals. Polymer-modified nanoparticles are expected to 
combine the advantages of both the homogeneous and heterogeneous catalysts. 
Isfahani and colleagues
74
 recently prepared a catalyst 57 by immobilizing palladium 
nanoparticles on a nano-silica triazine dendritic polymer. This catalyst exhibited high 
activity for the SMC even with 0.006 mol% palladium loading (Scheme 2.39). In 
addition, it could be reused six times with no apparent decrease in yield. The catalyst 
was recovered by centrifugation, which might be a limitation for large scale 
applications. 
36 
 
Scheme 2.39 Palladium nanoparticles on the nano-silica triazine dendritic polymer as catalyst for 
aqueous SMC.
74
  
To circumvent the challenge associated with separation of catalyst from reaction 
medium by filtration or centrifugation, magnetically-separable catalysts have attracted 
much attention recently. A magnetically responsive polymer nanocomposite 
Fe3O4@poly(undecylenic acid-co-4-vinyl pyridine-co-sodium acrylate) (PUVS) 58 
was introduced by Bian.
75
 This catalyst exhibited excellent catalytic activity for both 
Heck and SMC in water, and could be conveniently separated and recovered by 
applying a permanent magnet (Scheme 2.40). The supported catalyst could be used 
consecutively for six runs without significant loss of catalytic activity.    
37 
 
Scheme 2.40 Magnetic polymer-nanocomposites as catalyst for SMC in water developed by Bian.
75
 
PUVS = poly(undecylenic acid-co-4-vinyl pyridine-co-sodium acrylate)  
A novel magnetic nanoparticle-supported oxime palladacycle catalyst 59 was prepared 
and characterized by Gholinejad.
76
 The magnetically recoverable catalyst was 
employed at room temperature for the SMC of aryl iodides and bromides in aqueous 
media. The catalyst was shown to be highly active under low Pd loading (0.3 mol%) 
(Scheme 2.41). The catalyst could be easily recovered from the reaction mixture using 
an external magnet and reused for six consecutive runs without significant loss of  
 
Scheme 2.41 Magnetic nanoparticle-supported oxime palladacycle catalyst for the SMC in water.
76
 
activity. A similar kind magnetically-separable palladium catalyst was also developed 
by Karimi and co-workers relying on imidazolium ionic liquid bearing triethylene 
glycol moieties on the surface of silica-coated iron oxide nanoparticles.
77
 The biaryl 
38 
products were obtained upto 95% yield with 0.25 - 0.50 mol% Pd loading under argon 
atmosphere. 
Li and co-workers recently reported on a recyclable ordered mesoporous magnetic 
organometallic catalyst 60 for SMC in water (Scheme 2.42).
78
 They immobilized the 
catalyst precursor onto undoped and functionalized ordered mesoporous silicas 
(MCM-41) coated on Fe3O4 magnetic microspheres. The catalytic efficiencies were 
comparable with those of the homogeneous catalysts, and they could be easily 
recycled (eight times) for reuse by applying an external magnet.  
 
 
Scheme 2.42 Palladium complexes anchored to an MCM-41 thin layer coated on Fe3O4 microspheres as 
catalyst for the SMC in water.
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Trzeciak and co-workers reported palladium supported on triazolyl-functionalized 
polysiloxane 61, 62 as a recyclable catalyst for the SMC of aryl bromides with 
phenylboronic acid at 60 
o
C in a 2-propanol-water mixture (Figure 2.1).
79
 In recycling 
experiments, very good results were obtained in eight consecutive runs. 
39 
 
Figure 2.1 Triazole-functionalized siloxane co-polymers as suppors for palladium-catalyzed SMC.
79
  
To overcome less accessible active sites for immobilized or supported palladium 
catalysts, Ma and co-workers recently developed a self-supported hollow material with 
tunable cavities. This material is potentially interesting thanks to its inherent features 
including: i) high surface area, ii) low density iii) easy recovery, iv) low cost, and v) 
surface permeability. Relying on tetrabutylphosphonium bromide (Bu4PBr) as 
template, Ma prepared a mesoporous Pd–Fe alloy magnetic spheres catalyst with a  
 
Scheme 2.43 Pd nanoparticles immobilized on modified hollow magnetic spheres (HMMS) for SMC in 
water developed by Ma.
81
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hollow chamber.
80
 This catalyst displays high activity in the SMC. In a subsequent 
study, Ma reported a high-performance palladium catalyst 63 resulting from the 
covalent anchoring of a Schiff-base ligand, N,N’-bis(3-salicylidenaminopropyl)amine 
(salpr), on the surface of hollow magnetic mesoporous spheres (HMMS) followed by 
immobilization of Pd(0) (Scheme 2.43).
81
 The heterogeneous catalyst could readily be 
recovered from the reaction mixture and recycled six times without any loss of 
activity.  
Recently, Siril and co-workers reported a palladium–polyaniline (Pd–PANI) 
nanocomposite for the SMC in aqueous media (Scheme 2.44).
82
 PANI is a conducting 
polymer which was used as a catalyst support. With this system, they showed that the 
SMC proceeds much faster in water than in toluene.  
 
Scheme 2.44 Palladium-polyaniline nanocomposite for SMC in water.
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Dipak and co-workers reported on the application of the modified Montmorillonite 
clay supported Pd(0)-nanoparticles as an efficient catalyst for the SMC (Scheme 
2.45).
83
 This naturally occurring clay requires no surface functionalization and its pore  
 
Scheme 2.45 Pd(0)-Montmorillonite clay composites catalyzed SMC in water.
83
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sizes can be tuned by an acid activation. The modification of Montmorillonite clay 
was carried out by activating with H2SO4 under controlled conditions to generate 
nanopores on the surface, thus serving as a ‘Host’ for the Pd(0)-nanoparticles. The 
supported Pd(0)-nanoparticles were efficient catalysts for the SMC (up to 94% yield) 
in water under ligand free conditions. The nano-catalyst could be recycled at least 
three consecutive runs with a little loss of catalytic activity. 
Recently, Li
84
 reported on a highly dispersed palladium chloride catalyst anchored in 
triphenylphosphine-functionalized knitting aryl network polymers (KAPs) 64. These 
exhibited excellent activity for the SMC of aryl chlorides in aqueous media (Scheme 
2.46). A potential reason for high catalyst activity was that the microporous polymers 
not only played the role of support, but also protected the Pd(0) species from 
aggregation and precipitation.  
 
Scheme 2.46 Aqueous SMC catalyzed by KAPs(Ph-PPh3)-Pd.
84
 
Huang and co-workers reported on the use of Pd nanoparticles on a porous ionic 
copolymer 65 of an ionic liquid and divinylbenzene for the coupling of aryl bromides 
and chlorides under air and in water, using Pd loadings as low as 10 ppm (Scheme 
2.47).
85
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Scheme 2.47 A Pd(OAc)2/porous ionic copolymer (PIC) catalyzes the SMC in water.
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Hu and co-workers embedded Pd nanoparticles in carbon thin film-lined nanoreactors 
67. The resulting embedded nanoparticles 68 catalyzed the SMC yielding good results, 
allowing the recycling of the heterogeneous catalyst (Scheme 2.48).
86
 Thanks to their 
controllable size, composition and morphology, mesoporous silica (e.g. SBA-15 66) 
are highly attractive supports for immobilizing Pd nanoparticles. 
 
Scheme 2.48 Pd nanoparticles-embedded nanoreactor catalyzed SMC in water.
86
  
Firouzabadi and Iranpoor used an agarose hydrogel to contain the Pd for the SMC in 
water (Scheme 2.49).
87
 The catalyst was efficiently recycled five times. 
43 
 
Scheme 2.49 Agarose hydrogel supported Pd nano catalyst for the SMC in water.
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Ma and Lei prepared a heterogenous biopolymer complex consisting of wool-PdCl2 69 
that performed the SMC of aryl chlorides in water (Scheme 2.50). 
 
Scheme 2.50 A wool-Pd complex the the SMC in water.
87
 
Li and co-workers used recyclable monodispersed zeolitic hollow spheres 70 
containing [PdCl2(pyridine)2] to couple aryl bromides and iodides in a 60% aqueous 
ethanol solution (Scheme 2.51).
88
 This catalyst afforded fast conversions for the SMC 
44 
of various aryl halides and arylboronic acids even at Pd loadings of 0.0188 mol%. 
Under mild and aerobic conditions, a TOF 63210 h
−1 
is reported. This catalyst could 
be recycled at least 10 times without any loss of activity. 
 
Scheme 2.51 Monodisperse zeolitic hollow spheres containing [PdCl2(pyridine)2] catalyze the SMC in 
water.
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Yamada and Uozumi
89
 developed a metalloenzyme-inspired polymer catalyst 71: a 
self-assembled catalyst consisting of poly(imidazole-acrylamide) and [(NH4)2PdCl4] 
that promoted the allylic arylation, alkenylation, and vinylation of allylic esters with 
aryl/alkenylboronic acids in water with TON varying between 20,000–1,250,000 
(Scheme 2.52).  
45 
 
Scheme 2.52 A Metalloenzyme-inspired polymeric imidazole Pd catalyst (MEPI-Pd) for the SMC in 
water.
89
 
2.3.2 Unsupported catalyst 
In a very recent study, Lipshutz and co-workers reported that nanoparticles formed 
from inexpensive FeCl3 that contains parts-per-million (ppm) levels of Pd catalyze the 
SMC in water (Scheme 2.53).
90
 This system however requires the use of designer 
surfactant TPGS-750-M 72. This surfactant is composed of a lipophilic α-tocopherol 
moiety and a hydrophilic PEG-750-M chain, joined by an inexpensive succinic acid 
linker, spontaneously forms micelles upon dissolution in water.  
46 
 
Scheme 2.53 Fe–ppm Pd nanoparticle catalyzed SMC in water.90 
NHC-ligand is very common in homogeneous catalysis (vide supra), although it is 
rarely used in the heterogeneous catalysis to stabilize Pd(0). Recently, Schmitzer used 
an unsupported Pd-NHC complex 73 for SMC (Scheme 2.54).
91
 The catalyst is 
insoluble in water and the mercury drop test suggested the heterogeneity of the 
system. This heterogeneous catalyst was used in low loadings (10
-3
 mol%) for the 
SMC in pure water with very good recyclability (10 times) and high yield (TON = 
10
5
).  
 
Scheme 2.54 Support-free palladium−NHC catalyst for SMC in water.91  
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The first ligand-free SMC of aryl halides with potassium aryl-trifluoroborates in water 
was reported by Molander et al. in 2003.
92
 Following this report, many groups 
developed ligand free strategies for SMC in water. In this context, Bora
93
 and Liu
94,95
 
have recently shown that the only use of PdCl2 and Pd(OAc)2, respectively, in the 
presence of an adequate base can couple a variety of aryl bromides in water. Boruah 
and co-workers reported Pd(OAc)2-catalyzed SMC of aryl bromides with arylboronic 
acids in aqueous tea extract at room temperature.
96
 Recently, Corma and co-workers 
developed palladium clusters with three- or four palladium atoms (characterized by 
UV–visible spectroscopy) which were found to be the catalytically active species (3-
300 ppm Pd, TOF up to 10
5
 h
-1
) for the SMC.
97
 These palladium cluster could be 
stabilized in water and stored for long periods of time for use on demand with no loss 
of activity. Qiu and Xu reported Pd–Pt nanodendrites for a ligand free SMC in an 
ethanol-aqueous solution.
98
 Liu and co-workers reported an aerobic, ligand-free SMC 
catalyzed by Pd/C (3 mol%) in aqueous media.
99
 Control experiments demonstrated 
that the Pd/C-catalyzed the SMC was much quicker when performed in air or oxygen 
(98% yield in 30 minutes) than under nitrogen (62% yield in 40 minutes). Deveau and 
coworkers
100
 reported synthesis of Ethyl(4-phenylphenyl)acetate, a biaryl with anti-
arthritic potential using Pd(OAc)2 with no additional ligand in aqueous acetone (0.5 
mol% catalyst loading, 90% yield). Liu and co-workers reported the SMC of 
potassium aryl-trifluoroborates with aryl bromides in water using Pd(OAc)2 as a 
catalyst (1-3 mol%) with [bmim]PF6 ionic liquid as an additive and Na2CO3 as a base 
under air.
101
 They obtained biaryl products upto 99% yield in 2-3 hours. Sarma and 
Saikia reported recently a recyclable Pd(OAc)2 catalyzed SMC in neat “Water Extract 
of Rice Straw Ash” (WERSA) at room temperature.102 They obtained 45 – 90% yield 
for the synthesis of biaryl product with 1 mol% Pd loading. 
Palladium nanoparticles (Pd-NPs) are nowadays widely used in catalysis and have 
become a strategic tool for organic transformations, thanks to their high catalytic 
activity. Pd-NPs are valuable alternatives to molecular catalysts as they do not require 
costly ligands. Astruc and co-workers showed that the SMC of aryl chloride proceeds 
48 
efficiently in water (or in organic-water mixtures) at high temperatures with ppm 
amounts of Pd-NPs.
103
  
Veisi and coworkers reported palladium nanoparticles (Pd-NPs) stabilised by Pistacia 
atlantica kurdica (P. a. kurdica) gum as catalyst for the SMC in water.
104
 The Pd-NPs 
were employed as a heterogeneous catalyst in the SMC at low palladium loading (0.1 
mol%) under aerobic and ligand-free conditions in water. The system was 
characterized by high TONs (up to 980). The catalyst could be recycled at least eight 
times without loss of activity.  
The group of Martin reported the synthesis of stable Pd-NPs generated by 
electrochemical methods at room temperature via the electroreduction of an aqueous 
solution of H2PdCl4 in the presence of PVP.
105
 These Pd-NPs exhibited high catalytic 
activity in the SMC in aqueous medium. Particularly high turnover numbers (TON 10
4 
- 10
5
) were achieved with aryl iodides and bromides. Recently, Pore and co-workers 
reported ionic liquid promoted in situ generation of palladium nanoparticles (particle 
size between 3-9 nm) which efficiently catalyzed SMC in water.
106
 With 2 mol% 
Pd(OAc)2 and 20 mol% ionic liquid, they achieved upto 98% yield at 80 
o
C. The 
aqueous system containing ionic liquid along with Pd-NPs could be recycled seven 
times with any loss of activity. Maitra and co-workers reported hydrogel-stabilized 
palladium nanoparticles for SMC in water.
107
 They obtained upto 90% yield for biaryl 
synthesis with 0.15 mol% Pd loading. Recently Tang and co-workers reported Pd-NPs 
supported and stabilized by mesoporous graphitic carbon nitride (g-C3N4).
108
 The 
SMC proceeded smoothly with 97 % isolated yield (0.83 mol% Pd loading) in less 
than 30 minutes in water with PEG600 as the additive. Gholinejad and co-workers
109
 
reported a polymer containing phosphorus–nitrogen ligands for stabilization of 
palladium nanoparticles which was an efficient and recyclable catalyst for SMC in 
neat water. The biaryls products were obtained upto 99% yield with 0.08 mol% Pd 
loading in presence of 
t
BuOK as a base. Liu and coworkers
110
 developed a palladium-
catalyzed ligand-free SMC of heteroaryl halides with N-methyliminodiacetic acid 
(MIDA) boronates in excellent yields (up to 96%) with 2 mol% Pd loading. 
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2.3.3 Heterogeneous SMC for Chemical Biology Applications 
The first use of the SMC in mammalian cells was reported by Bradley and co-
workers.
56
 They trapped palladium nanoparticles within inert polymeric microspheres, 
with the catalysts derived from a recyclable, ligand-free heterogeneous palladium 
precursor. The resulting polystyrene microspheres were employed as ‘Trojan-horses’ 
to deliver the palladium nanoparticles into a cell, allowing to perform a SMC of 74 
and 75 to afford the fluorescent product 76 in cellulo (Scheme 2.55). 
64,65
 They used 
almost stoichiometric amount of catalyst and there is no mention of yield or TON in 
corresponding paper.  
 
Scheme 2.55 Palladium nanoparticles encapsulated within inert polymeric microspheres as catalyst for 
the SMC in cellulo.
56
 
The research group of Parker demonstrated that Pd(0)-nanoparticles produced by 
living plants  displayed excellent catalytic activity in the SMC.
66
 Certain strains of 
bacteria (e.g. Desulfovibrio desulfuricans, E. coli and Shewanella oneidensis) can 
reduce soluble Pd(II) from stock solutions or acid extracts of spent catalysts, forming 
metallic palladium nanoparticles. This protocol involves biosorption of Pd(II) cations 
on the surface of bacteria and a subsequent reduction to Pd(0) using an electron donor. 
The formed nanoparticles are supported either on the bacterial outer-membrane or in 
the periplasmic space and remain attached to the cells (“bio-Pd(0)”). Skrydstrup and 
50 
coworkers
69
 reported that the SMC can be catalysed by bio-generated palladium 
nanoparticles formed on the surface of Gram-negative bacteria (Scheme 2.56). 
 
Scheme 2.56 “bio-Pd(0)” catalyzed SMC developed by Skrydstrup and coworkers.69 
Biological macromolecules have gained significant attention as alternative template 
materials for the generation of well-dispersed metal nanoparticle via electroless 
deposition. Yi and coworkers
68
 demonstrated that the tobacco mosaic virus (TMV) is a 
suitable support for the generation of immobilized palladium (Pd) nanocatalysts which 
are active for the SMC in water. 
2.4 Conclusion   
In a green chemistry spirit, aqueous SMC has enjoyed an exponential growth in the 
past four years. In many cases however, the aqueous SMC require either high 
temperatures or the use of a co-solvent for chloride substrates. Future research will 
certainly be aimed to design more economical and high- performance catalysts. 
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CHAPTER 3 
 
Enantioselective Artificial Suzukiase for the 
Synthesis of Axially Chiral Biaryl Compounds 
Relying on the Streptavidin-Biotin Technology 
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3.1 Introduction 
The palladium-catalyzed Suzuki–Miyaura cross-coupling reaction (SMC 
hereafter) of organic halides with boronic acids is one of the most versatile methods 
for the synthesis of biaryls.
1–3
 Such structural motifs are present in numerous 
agrochemicals, natural products, pharmaceuticals, and polymers.
4,5
 For this purpose, 
the SMC has been widely studied.
6–11
 More recently, the SMC has found applications 
in the context of chemical biology. Indeed, both reactants and products can be 
regarded as bio-orthogonal.
12–18
 In this promising context however, high catalyst 
loadings are routinely required with reactions performed in a biological 
environment.
12,13,15,17,19–27
 
In stark contrast to the SMC, Nature relies on very different mechanisms to 
install (atropisomeric) Caryl–Caryl bonds.
28
 Despite numerous reports on asymmetric 
SMC in organic media,
6–8,29
 only two reports describe enantioselective SMC in 
water.
30,31
 Uozumi reported on an heterogeneous SMC in water requiring a high 
catalyst loading (TON < 10, 94% ee at  80 
o
C).
30
 More recently, Kündig et al. reported 
an asymmetric SMC in an water-organic solvent mixture (TON = 17, up to 80 % ee) at 
room temperature.
31
 To complement these efforts, we speculated that, thanks to their 
well-defined second coordination sphere, artificial metalloenzymes (ArMs hereafter) 
may offer a propitious environment to engineer an asymmetric “Suzukiase”- that is, an 
enzyme that catalyzes the SMC reaction. ArMs result from the incorporation of an 
abiotic cofactor within a macromolecule (protein or oligonucleotide).
13,14,32–35
 In this 
context, Ueno and coworkers anchored a palladium moiety within a ferritin container 
to yield an artificial Suzukiase. The resulting artificial Suzukiase however did not 
outperform the free cofactor (no enantioselectivity, turnover frequency: 3500 h
-1
).
13
 
Inspired by a seminal contribution by Whitesides in 1978,
32
 we report herein our effort 
to engineer an asymmetric artificial Suzukiase based on the biotin-streptavidin 
technology. 
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3.2 Aim of the Project 
Within this project a Pd-dependent artificial Suzukiase based on the biotin-strepavidin 
technology was to be developed. Within this context a set of milestones had to be 
accomplished:  
1. Diversify biotinylated ligands (phosphines and NHC-carbenes) 
2. Chemical optimization of the biotinylated cofactor (Pd-complexes) for the 
respective reaction 
3. Diversify of the genetic library to optimize the activity as well as the 
selectivity of the resulting constructs 
4. Perform catalysis at low catalyst loadings under near physiological conditions 
to approach in vivo implementation. 
5. Develop methods for performing catalysis with unpurified protein systems to 
accelerate the screening strategy. 
3.3 Outline of the Project 
As demonstrated in several chemical-biology applications, the SMC is a promising 
bio-orthogonal reaction. However, the systems reported to date require multiple 
equivalents of palladium to proceed in biological environments. Here we anticipate 
that screening more diverse Sav libraries will allow rapidly improving the 
performance of the artificial Suzukiase. With the aim of identifying the most suitable 
catalyst precursor, it is proposed to synthesize and screen biotinylated N-Heterocyclic 
Carbenes and phosphines.  
In order to ensure that the cross-coupling reaction is indeed catalyzed by the ArM (and 
not adventitious Pd-nanoparticles), we will focus on asymmetric C–C bond formation, 
while varying the nature of the activating groups (iodide, bromide, chloride as well as 
boronic acid, boronic ester and trifluoroborate). Both inter- and intramolecular 
reactions will be tested. We anticipate that an intramolecular version may allow to 
significantly decrease the concentration of the substrate, to ultimately allow the 
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catalytic reaction to be performed in vivo at low catalyst loading and substrate 
concentration. With this goal in mind, we will also screen substrates which lead to the 
formation of a fluorescent product. Ultimately, we believe that the artificial 
Suzukiases will allow to perform cross-coupling reactions on cellular extracts and 
ultimately in vivo with low catalyst loadings. 
3.4 Results and Discussion 
3.4.1 Chemical Optimizations 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.1 Biotinylated cofactors 1-5 tested in the presence of (strept)avidin as artificial Suzukiase for 
the synthesis of enantioenriched 2-methoxy-1,1’-binaphthyl 8b. 
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       With the aim of identifying suitable cross-coupling reaction conditions, we 
evaluated five different biotinylated catalyst precursors 1-5 in the presence of either 
avidin or streptavidin (Avi and Sav hereafter). For this purpose, the reaction of 1-
iodonaphthalene 6c with 2-methoxy-1-naphthaleneboronic acid 7c was selected as a 
model system (Scheme 3.1). Initial experiments revealed that protonolysis of the 
boronic acid led to modest cross-coupling yields. Systematic variation of the base, pH, 
and organic co-solvent led to the identification of suitable reaction conditions: sodium 
hydroxide in DMSO : water (1 : 9) proved to be particularly effective in preventing 
protonolysis. However, competing deboronation required the use of excess boronic 
acid (1.5 equivalents vs. aryl halide) to achieve full conversion. Gel electrophoresis of 
the reaction mixture revealed that Sav remained largely tetrameric and active toward 
biotin binding even after an SMC performed at 50 
o
C (see Appendix 1, Figure S3). 
3.4.2 Genetic Optimizations 
Having identified suitable reaction conditions, we screened biotinylated phosphine- 
and NHC ligands 1-5 combined with WT (strept)avidin (Table 3.1). This screening led 
to the identification of complexes 1, 2, and 3 as the most promising catalysts in 
combination with WT Sav. Complexes 1-3 were thus screened with a small library of 
Sav mutants. The results of the chemogenetic optimization for the synthesis of 2-
methoxy-1,1’-binaphthyl 8b are displayed as a fingerprint in Figure 3.1, and selected 
results are collected in Table 3.2. 
From these data, the following features emerge: 
a) Compared to the free cofactor, higher conversions are observed with the 
artificial Suzukiase. This demonstrates that the Sav host protein exerts a 
beneficial influence on both the activity (i.e. protein accelerated catalysis) and 
the selectivity. 
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Table 3.1 Identification of the most suitable ligand for the synthesis of 2-methoxy-1,1’-
binaphthyl 8b 
[a]
 
Entry Complex Protein ee [%]
[b]
 TON 
1 1 WT Sav 58 (R) 78 
2 2 WT Sav 10 (S) 73 
3 3 WT Sav 42 (R) 45 
4 4 WT Sav 6 (R) 8 
5 5 WT Sav rac. <5 
6 1 WT Avi 3 (R) 10 
[a] Reactions were carried out with 50 mM substrate in a total reaction volume 0.2 mL using 1 mol% complex 1-
5 (see Appendix 1 for experimental details). [b] ee value determined by HPLC on a chiral stationary phase; 
absolute configuration assigned by comparison with literature data. WT = wild-type, Sav = streptavidin, Avi = 
avidin. 
b) The electron-donating properties and bulkiness of the phosphine play a key 
role in determining the activity of the corresponding artificial Suzukiase. 
Accordingly, the (t-Bu)2P-bearing catalysts outperform the (Ph)2P-systems. 
Strikingly, both ligands 1 and 3 (Table 3.2, entries 10-13) show similar activity 
in case of S112M and S112A mutants 
c) The enantioenriched nature of the cross-coupled product 8b strongly supports 
the hypothesis that the SMC is indeed catalysed by a homogeneous protein-
embedded Pd-cofactor rather than Pd-nanoparticles.
12,25,26,36
 
d) Varying the spacer between the biotin anchor and the P(t-Bu)2 from ethyl to 
propyl affords opposite enantiomers of biaryl 8b for a given Sav mutant. The 
best ees in favour of (S)-8b were obtained with 2 · Sav K121A and 2 · Sav 
S112M Table 3.2, entries 8 and 9). 
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Figure 3.1. Fingerprint display of the results of the chemogenetic optimization for the synthesis of 2-
methoxy-1,1’-binaphthyl 8b,. The size of the circles is proportional to the conversion, and the color 
codes the enantiomeric excess. Numerical results are collected Table 3.2 and in Table S1 (Appendix 1). 
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Table 3.2 Selected results for genetic optimization of the artificial Suzukiase for the 
synthesis of 2-methoxy-1,1’-binaphthyl 8b  
Entry Temp [
o
C] Complex Protein ee [%] TON 
1 RT 1 - rac. 20 
2 RT 1 WT 58 (R) 78 
3 RT 1 K121E 76 (R) 50 
4 RT 1 K121D 34 (R) 7 
5 RT 1 K121Q 74 (R) 20 
6 RT 1 K121M 67 (R) 59 
7 RT 1 K121F 67 (R) 38 
8 RT 2 K121A 47 (S) 32 
9 RT 2 S112M 44 (S) 53 
10 RT 3 S112M 38 (R) 78 
11 RT 3 S112A 36 (R) 52 
12 RT 1 S112M 14 (S) 58 
13 RT 1 S112A 60 (R) 58 
14 RT 1 N118K-K121E 74 (R) 73 
15 RT 1 N118S-K121E 76 (R) 79 
16 RT 1 N118E-K121E 76 (R) 75 
17 RT 1 N118L-K121E 72 (R) 86 
18 RT 1 S112W-K121E 76 (R) 64 
19 RT 1 S112N-K121E 69 (R) 61 
20 RT 1 S112A-K121E 70 (R) 80 
21 RT 1 S112Y-K121E 80 (R) 90 
22 RT 1 S112Y-K121E 80 (R) 160
[a]
 
23 16 1 S112Y-K121E 84 (R) 50 
24 4 1 S112Y-K121E 86 (R) 50
[b]
 
25 4 1 S112Y-K121E 90 (R) 50
c]
 
[a] 0.50 mol % catalyst loading, 0.25 mol % Sav (tetramer) loading [b] 0.50 mol % catalyst loading, 
0.25 mol % Sav (tetramer) loading, after 7 days. [c] preparative scale (100 µmol) 
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Having identified 1 · Sav K121E as a promising first generation Suzukiase (Table 3.2, 
entry 3), we screened double mutants bearing a glutamate at position 121 (Figure 3.1 
and Table 3.2, entries 14-21): 
a) The double mutant 1 · Sav S112A-K121E (Table 3.2, entry 20) gives better ee 
and TON than the single mutant Sav S112A (Table 3.2, Entry 13). Likewise, 1 
· Sav S112Y-K121E gave the highest turnover with good ee (Table 3.2, entry 
22). This finding highlights the non-additive nature of multiple mutations.
37,38
 
Decreasing the temperature to 4
o
C leads to an improvement in 
enantioselectivity (86 % ee, Table 3.2, entry 24) albeit at the cost of a slower 
rate. 
b) Increasing the ratio of complex 1 vs. Sav tetramer (S112Y-K121E mutant) 
from one to four leads to a gradual erosion of enantioselectivity (from 80 to 
69% ee, see Table S4, Appendix 1). This suggests that an empty biotin binding 
site adjacent to a complex 1 within Sav is favorable for selectivity. 
c) On a preparative scale, up to 90% ee (R)-8b, were obtained using 0.50 mol % 
catalyst loading and 0.25 mol % Sav (tetramer) loading at 4 
o
C (Table 3.2, 
entry 25). 
3.4.3 Substrate Scope 
The artificial Suzukiase performed well on a range of hydrophobic substrates, leading 
to the following observations (Table 3.3):   
a) The nature of the aryl halide does not influence the enantioselectivity but to 
lower conversions on going from iodide to bromide to chloride 6c-6a (Table 
3.3, entries 6-8).   
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Scheme 3.2 Substrates tested for the asymmetric Suzuki-Miyaura cross-coupling reaction catalysed by 
1 · S112Y-K121E. 
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b) Substitution of the methoxy group by either a methyl and ethoxy group on the 
arylboronic acid (compare 7c to 7b and 7d) leads lower enantioselectivities 
(Table 3.3, entries 7, 10 and 12). 
c) The system affords the highest enantioselectivity for binaphthyls or naphtyl-o-
biphenyl products. In the presence of one smaller coupling partner,(e.g. 6h), 
the enantioselectivity is significantly lower. 
 
 
 
Table 3.3 Selected results for the SMC with 1 · S112Y-K121E Sav on a variety of 
substrates 
[a]
 
Entry ArX ArB(OH)2 Product Temp [
o
C] ee [%] TON 
1 6d 7a 8b RT 80 (R) 32 
2 6g 7e 8d 50 80 (S) 20 
3 6d 7e 8e 50 74 (R) 61 
4 6g 7f 8f 50 64 (S) 50 
5 6g 7h 8h RT 65 (R) 29 
6 6a 7c 8b RT 80 (R) 7 
7 6b 7c 8b RT 80 (R) 63 
8 6c 7c 8b RT 80 (R) 80 
9 6f 7a 8a RT 69 (S) 64 
10 6b 7b 8a 50 76 (S) 81 
11 6b 7b 8a 4 87 (S) 8
[b]
 
12 6c 7d 8c RT 68 (R) 88 
13 6e 7a 8b RT 77 (R) 55 
14 6h 7c 8g RT 35 (R) 80 
[a] Results are the average of two independent runs, see Supporting Information for experimental 
details. [b] after 7 days 
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3.4.4 X-ray Structure  
 
 
 
 
 
 
 
 
Figure 3.2. Close-up view of the structure of the artificial Suzukiase 1 · S112Y-K121E Sav. The 
solvent-excluded surface of two symmetry-related Sav monomers are highlighted in grey and magenta 
respectively. The biotinylated Pd-cofactor 1 and the mutated residues S112Y and K121E are displayed 
as stick. No electron density for the cinnamyl-moiety (turquoise) could be detected and was thus 
modelled, minimizing steric-clashes. 
 
         To gain structural insight on the second coordination sphere around the Pd 
moiety, crystals of Sav S112Y-K121E were grown and soaked with a solution of 1 in 
DMSO (For details, see Supporting Information). The resulting crystals were 
subjected to X-ray diffraction at the beamline X06DA at the Swiss Light Source. In 
the resulting structure of complex 1 · S112Y-K121E Sav, there is strong residual 
electron density in the 2Fo-Fc difference map in the biotin-binding vestibule. The Pd 
atom was unambiguously assigned as a strong peak in the difference map (12σ) with a 
corresponding peak in the anomalous difference map (8σ). The density map clearly 
highlights the presence of the phosphine ligand, the palladium, and the chloride 
(Figure 3.3). However, the cinnamyl ligand could not be resolved, likely due to 
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disorder caused by ligand fluxionality. The amide linker exhibits two H-bonding 
interactions with the protein backbone: the amide nitrogen exhibits an H-bonding 
interaction with the side-chain of S88, and the carbonyl oxygen exhibits an H-bonding 
interaction with the backbone nitrogen of N49. The palladium atoms of two symmetry 
related-cofactors (face-to-face) are separated by 11.7 Å. The palladium was found in 
the vicinity of the O atoms of S112Y and K121E (Pd····O distance 6.4 Å and 7.1 Å 
respectively). The average B-factor of Pd is 36.10, suggesting that the complex may 
be fluxional or located in a shallow energy minimum. 
 
Figure 3.3 Close-up view of the X-ray structure of 1 ∙ S112Y- K121E Sav. The two monomeric chains 
(blue and gold) and biotinylated complexes are related by a twofold symmetry axis. The electron 
density around 1 (green) was generated from a 2Fo-Fc map (0.5 electrons/Å3). 
 
        Based on this structural insight, we hypothesize that π–π interactions between the 
tyrosine (Y112) and the naphthyl moiety may enhance the enantioselectivity. Similar 
interactions between both coupling partners were shown by DFT calculations to 
critically influence the enantioselectivity of the SMC reaction.
39
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3.5 Conclusions 
In summary, incorporation of an electron-rich phosphino-palladium moiety within Sav 
affords an artificial Suzukiase for the synthesis of enantioenriched binaphthyls (up to 
90 % ee and 50 TONs for 2-methoxy-binaphthyl 8b). Importantly, it was shown that 
the hybrid catalyst offers vast opportunities for chemogenetic optimization of the 
catalytic performance: site-directed mutagenesis leads to a significant increase in 
enantioselectivity. Current efforts are aimed at performing catalytic asymmetric SMC 
with artificial Suzukiases in vivo. 
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CHAPTER 4 
 
Development of Artificial Metathesase for Ring 
Closing Metathesis  
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4.1 Introduction 
In the past forty years, the olefin metathesis reaction has emerged and matured as a 
very efficient and elegant method for formation of C=C double bonds.
1
 It is widely 
used not only in small-scale laboratory research, but also in large-scale industrial 
production. Among the frontiers in olefin metathesis, one should mention: i) control of 
E/Z selectivity,
2,3
 ii) enantioselective ring-closing metathesis (enantioselective RCM 
hereafter),
4
 iii) the application of metathesis for the conversion of biomass into useful 
products,
5–8 
and iv) metathesis as a bioorthogonal ligation tool.
9,10
 In the latter context, 
aqueous-phase metathesis remains a challenge.
11–13
 
To address this challenge, we and others have relied on the creation of artificial 
metalloenzymes for olefin metathesis.
14–17
 There are a total of five artificial 
metathesases reported in the literature to date.
18
 Those are summarized in Table 4.1. 
The following features emerge from Table 4.1: i) the systems from the Hilvert group 
and Ward group do not require an inert atmosphere; ii) the substrate concentration in 
the metathesase based on hCA II is the lowest of all systems reported to date; iii) The 
highest turnover frequency was observed for the metathesase based on FhuA which 
however requires a surfactant iv) Hilvert reported highly acidic conditions whereas 
Schwaneberg, Ward and Matsuo group reported RCM at pH 7.0 and physiological 
conditions. v) Hilvert, Schwaneberg and Matsuo reported a covalent anchoring 
strategy of the Ru cofactor, whereas the Ward group relied on supramolecular and 
dative anchoring. Based on this comparison, we conclude that no general trend for the 
structure and reaction conditions for artificial metathesases can be identified. 
 
 
 
 
 
 
75 
Table 4.1 Summary of the catalytic performance of artificial metathesases reported to date 
 Hilvert
15
 Ward
14
 Schwaneberg
16,19
 Matsuo
17
 Ward
18
 
[Substrate] 
  
 
  
Reaction 
type 
RCM RCM ROMP RCM RCM 
Anchoring 
of  Ru-
cofactor 
Covalent Supramolecular Covalent Covalent Dative 
Host 
protein 
MjHSP
a
 
4 mol% 
Avidin 
4.8 mol% 
FhuA ΔDCVFtev b 
0.08 mol% 
α –
chymotrypsin 
0.63 mol% 
hCA II 
1 mol% 
Temp. 45 
o
C 40 
o
C 25 
o
C 25 
o
C 37 
o
C 
Time 12h 16h 68h 2h 4h 
pH 2 4 7 7 7 
Reaction 
conditions 
10 mM HCl, 
Water/ 
t-BuOH(4/1) 
under air 
0.1M acetate 
Water/ 
DMSO(5/1) 0.5 
M MgCl2, 
under air 
Water/THF(9/1) 
SDS 
1% under N2 
Degassed 100 
mM, KCl, 
under N2 
0.1 M 
phosphate 
Water/ 
DMSO 
(9/1) 
under air 
TON 25 20 955 20 28 
a
 MjHSP:M. jannaschii small heat shock protein. 
b
 FhuA ΔDCVFtev: engineered variants of the β-
barrel ferric hydroxamate uptake protein component A. ROMP 
 
The excellent stability of (strept)avidin combined  with  its  high  affinity towards 
biotinylated compounds offers a large number of promising applications (See Chapter 
1). In this context, we have been exploiting the biotin-streptavidin technology to create 
artificial metalloenzymes for a variety of transformations,
20,21
 including 
hydrogenation,
22 
transfer hydrogenation,
23
 allylic alkylation,
24
 benzannulation,
25
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sulfoxidation,
26
 dihydroxylation
27 
as well as olefin metathesis.
14,18,28
 Among these 
reactions, the olefin metathesis is an versatile means to create new C-C bonds. In view 
of the scarcity of olefins in metabolites, the olefin metathesis can be viewed as bio-
orthogonal: both substrates and products of the olefin metathesis will most probably 
not react with any of the enzymes present in a cell.
29
  
4.1.2 Mechanism of the Olefin Metathesis 
The first mechanistic hypothesis for the olefin metathesis was put forward by 
Chauvin.
30
 It has since been confirmed and is now  widely accepted (Scheme 4.1).
31,32
 
The direct [2+2] cycloaddition of two alkenes is formally symmetry forbidden and 
thus has a high activation energy. The Chauvin mechanism involves the [2+2] 
cycloaddition of an alkene double bond to a transition metal alkylidene 1/3 to form a 
metallacyclobutane intermediate 2/4. The metallacyclobutane produced can then 
cyclorevert to give either the original species or a new alkene 5 and alkylidene. 
Interaction with the d-orbitals on the metal catalyst lowers the activation energy 
enough so that the reaction can proceed rapidly at modest temperatures.   
 
 
Scheme 4.1 Mechanism of the olefin metathesis 
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4.2 Aim of the Project 
 In this project, we focused on exploiting the potential of streptavidin as  a  
biomolecular  scaffold  to broaden the scope of artificial metalloenzymes based on the 
biotin (strept)avidin technology. Traditionally, a chemogenetic optimization scheme is 
applied to improve catalytic performance of artificial metalloenzymes. Genetic 
diversity is created by introducing point mutations on the streptavidin gene. Chemical 
diversity is achieved by variation of the spacer between the anchor and the Ru-moiety. 
Previous experience clearly demonstrated that catalytic activity of artificial 
metalloenzymes is critically dependent on the first coordination sphere around the 
active metal and thus it is recommended to test a variety of different catalyst 
precursors. With this goal in mind, we focused on the synthesis and evaluation of the 
catalytic performance of nine biotinylated metathesis catalysts.  
The milestones are summarized as follows. 
 Create chemical diversity by preparing a library of biotinylated catalysts. 
Synthesize suitable substrates for high-throughput screening. 
 Identify a suitable expression system for in vivo screening. 
4.3 Outline of the Project 
 
Scheme 4.2 RCM reaction in the periplasm of E. coli to yield a fluorescent product  
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The olefin functionality is an underrepresented functional group in cellular 
media. In addition, this functionality displays only modest reactivity towards the 
various reactants present in this complex media. Our effort thus focused on developing 
biorthogonal reactions using olefins as partner.
20
 Previously, we had shown that such 
ArM are complementary with natural enzymes, thus opening interesting perspectives 
towards the implementation of non-natural reaction cascades for in vitro and in vivo 
selection.
33
 This approach could ultimately lead to the development of bacteria acting 
as molecular factories for the production of complex molecules resulting from non-
natural reaction cascades. As a proof-of-principle, it is proposed to use a ring closing 
metathesis reaction. The main idea is to transport streptavidin from the cytoplasm into 
the periplasm of E. coli cells. Then, addition of biotinylated catalyst will lead to the 
formation of artificial metalloenzyme which can catalyze the RCM reaction releasing 
a fluorescent product (Scheme 4.2). By detecting the fluorescence, a large library of 
mutants can be screened within a short time. This strategy will ultimately lead towards 
high throughput screening and directed evolution of ArM’s.  
This project was highly collaborative and was part of an EU project entitled 
METACODE. Two additional coworkers actively contributed to the results presented 
herein: Dr. Raphael Reuter, and MSc Biol Markus Jeschek. Their contributions are 
clearly highlighted throughout this chapter.  
Raphael Reuter synthesized the fluorescent substrate and screened single 
mutants. Markus Jeschek developed E. coli strain that express streptavidin inside the 
periplasm of E. coli and developed methods for high throughput screening of RCM 
activity in the periplasm of E. coli.  
 
4.4 Results and Discussion 
4.4.1 Synthesis of Biotinylated Metathesis Catalysts 
The Ward group previously reported on an artificial metathesase relying on 
combining either avidin or streptavidin with either Biot-1 or Biot-m-ABA-1.
14
 In this 
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study, we set out to vary the position of the biotin-anchor and to identify the most 
promising catalyst under various catalytic conditions. All complexes tested in this 
study are presented in Figure 4.1. 
 
 
Figure 4.1 Biotinylated metathesis catalysts prepared and tested in this study. 
 
While one N-mesityl substituent is critical for high RCM activity,
34
 we set out to link 
the biotin anchor on the other N-substituent of the N-heterocyclic carbene moiety. We 
evaluated both aromatic (e.g. Biot-3, Biot-m-ABA-3, and Biot-4, Biot-m-ABA-4), as 
well as aliphatic substituents (e.g. Biot-2 and Biot-m-ABA-2) at this position. 
With this aim, we set out to prepare the key Boc-protected imidazolium intermediate 
Boc-2. Reductive amination of the alkylated aniline 6
35 
yielded the 1,2-diamine 7 
(Scheme 4.3). Cyclisation with triethyl orthoformate provided the imidazolium salt 8. 
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Ligand exchange with Hoveyda-Grubbs first generation catalyst Hov I afforded the 
Boc-protected ruthenium NHC complex Boc-2. Deprotection with gaseous hydrogen 
chloride and coupling with either activated biotin or activated biotin m-aminobenzoic 
acid afforded Biot-2 and Biot-m-ABA-2 respectively. 
 
 
Scheme 4.3 Synthesis of the biotinylated complexes Biot-2 and Biot-m-ABA-2. 
 
The next biotinylated catalysts included two mesityl groups with a biotin linked to one 
of these. For this purpose, we used the procedure reported by Gilbertson et al.
 
relying 
on the unsymmetrical diamine 9.
36 
Rosenmund-von Braun cyanation followed by 
reduction and Boc-protection yielded compound 11. This latter was reacted with 
triethylorthoformate in the presence of ammonium chloride to provide the 
imidazolium salt 12. Reaction of 12 with chloroform and KOH yielded the chloroform 
adduct 13.
37
 Ligand exchange with Hov I catalyst provided the ruthenium NHC 
complex Boc-3 which after Boc-deprotection was reacted with activated biotin and 
biotin m-aminobenzoic acid to afford Biot-3 and Biot-m-ABA-3 respectively (Scheme 
4.4). 
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Scheme 4.4 Synthesis of the biotinylated complexes Biot-3 and Biot-m-ABA-3 
 
To evaluate the influence of the spacer length between the biotin-anchor and the NHC, 
we synthesized another type of catalysts (Biot-4 and Biot-m-ABA-4) which bear an 
additional carbon when compared to Biot-3 and Biot-m-ABA-3. The NHC ligand 14 
was synthesized according to a published procedure.
36
 Both Biot-4 and Biot-m-ABA-
4 were synthesized as racemate. Preparation of the chloroform adduct followed by 
reaction with Hov I yielded the ruthenium NHC complex Boc-4. After Boc 
deprotection and reaction with activated biotin derivatives, Biot-4 and Biot-m-ABA-4 
were obtained (Scheme 4.5).  
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Scheme 4.5 Synthesis of the biotinylated complexes Biot-4 and Biot-m-ABA-4 
 
4.4.2 Activity Test in Organic and Aqueous Organic Solvent 
The performance of the biotinylated catalysts was evaluated in the ring closing 
metathesis of two model substrates: the diallyl tosylamide 19 and the coumarin 
precursor 24. The second substrate was produced by Raphael Reuter from aldehyde 
21
38 
via a Wittig reaction followed by esterification with acryloyl chloride and 
deprotection of the hydroxy group (Scheme 4.7). 
 
Scheme 4.7 Synthesis of coumarin precursor 24, substrate for RCM reaction.
39
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The activity of the new biotinylated catalysts was compared with that of second-
generation Grubbs-Hoveyda complex Hov II. The results for RCM reaction of diallyl 
tosylamide 19 are summarized in Table 4.1 and Chart 4.1 and results for RCM 
reaction of coumarin precursor 24 are presented in Table 4.2 and on Chart 4.2. All 
RCM reactions were analysed by reversed phase HPLC and revealed no product 
isomerization.  
 
Table 4.1 Comparison of activity of catalysts in RCM of diallyl tosylamide 19. 
 [a]
 1 mol% of [Ru], 37 °C, 24h; 
[b] 
CH2Cl2, [19] = 0.1M; 
[c]
 CH2Cl2, [19] = 0.01M, 
[d] 
H2O/DMSO 84:16, 
[19] = 0.1M. Experiments were performed in triplicate (yield +/- 2 %, in case of low yields <10% all 
results were almost the same). See Appendix 2 for experimental details. 
 
Entry Catalyst
[a] 
Yield [%]
[b] 
Yield [%]
[c]
 Yield [%]
[d]
 
1
 
Hov II >99 >99 75 
2 Biot-1 93
 
83 13 
3 Biot-m-ABA-1 96
 
76 28 
4 Biot-2 43
 
18 1 
5 Biot-m-ABA-2 41
 
19 1 
6 Biot-3 79
 
70 17 
7 Biot-m-ABA-3 76
 
49 7 
8 Biot-4 69
 
35 12 
9 Biot-m-ABA-4 97
 
84 10 
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Chart 4.1 Comparison of catalysts activity in RCM reaction of diallyl tosylamide.  
 
As a starting point, we performed the RCM of diallyl tosylamide 19 with 1 mol% of 
biotinylated catalysts with a 0.1M substrate concentration at 37 °C in 
dichloromethane. The results reveal that most of biotinylated catalysts with two 
mesityl moieties bound to imidazoline ring, viz. Biot-1, Biot-m-ABA-1 and Biot-m-
ABA-4 exhibit the same activity as the parent Hov II catalyst and reached almost full 
conversion. Similar results were also observed for structurally related complexes, 
namely Biot-3, Biot-m-ABA-3 and Biot-4 with conversion around 70-80%. These 
results are consistent with previous observations suggesting that catalysts containing 
two bulky aromatic substituents in the NHC ligand have the highest activity and 
stability. Accordingly, Biot-2 and Biot-m-ABA-2, are less active. 
Upon decreasing the substrate concentration to 0.01 M, similar trends were observed. 
The presence of a biotin moiety led to marked decrease in conversion, especially with 
complexes bearing an alkyl substituent on the NHC (e.g. Biot-2 and Biot-m-ABA-2). 
Next, the reactions were performed in water: DMSO, 84:16 mixtures (DMSO was 
required to dissolve both substrate and catalyst while both substrates and all catalysts 
exhibit very low solubility in pure water). Except for Hov II (75 % yield), the yields 
were dramatically lower. The best biotinylated catalyst, Biot-m-ABA-1, reached only 
ca. 30% yield. In this case, the reason for such low yield of the RCM reactions may be 
low catalysts’ stability in a mixture of water : DMSO. During the reactions, all 
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reaction mixtures changed colour from green (Hoveyda-type catalysts) or purple 
(Grubbs-type catalyst) to brownish. Catalysts also underwent a slow decay in DCM 
but it seems that the reactions in this solvent were faster which made it possible to 
obtain a high yield of the desired product. 
 
Table 4.2 Comparison of activity of catalysts in RCM reaction of coumarin precursor 
24. 
 
Entry Catalyst
[a] 
Yield [%]
[b] 
Yield [%]
[c]
 
1
 
Hov II >99 4 
2 Biot-1 97
 
1 
3 Biot-m-ABA-1 70
 
3 
4 Biot-2 99
 
1 
5 Biot-m-ABA-2 88
 
1 
6 Biot-3 50
 
4 
7 Biot-m-ABA-3 48
 
1 
8 Biot-4 52
 
1 
9 Biot-m-ABA-4 50
 
1 
[a]
 5 mol% of [Ru], 37 °C, 24h; 
[b] 
CH2Cl2, [24] = 0.025M; 
[c]
 H2O/DMSO 84:16, [24] 
= 0.025M. Experiments were performed in triplicate (yield +/- 5 %; in reactions 
performed in H2O/DMSO all results were the same). See Appendix 2 for experimental 
details. 
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Chart 4.2 Comparison of catalysts activity in RCM reaction of 5-hydroxy-2-vinylphenyl acrylate in 
CH2Cl2. 
As the umbelliferone precursor 24 bears an electron withdrawing olefinic moiety 
which significantly decreases its reactivity, the corresponding RCM reactions were 
performed with 5 mol% biotinylated catalysts (Table 4.2) in 0.025M concentration at 
37 °C in dichloromethane. Under these conditions, the two biotinylated catalysts, 
Biot-1 and Biot-2 reached near quantitative conversions. The other biotinylated 
Hoveyda-type catalysts gave moderate yields approaching 50%. When reactions were 
performed in a water : DMSO mixture, < 5% conversion was obtained for all catalysts, 
including Hov II.  
In RCM reaction of diallyl tosylamide 19 Biot-2 used in  a 1 mol% loading gave 
relatively low yield, 43%, while in the reaction of a more demanding substrate, 
coumarin precursor 24, when 5 mol% of catalyst was used, it reached almost 
quantitative yield. This is probably due to the balance between the activity and the 
stability of this catalyst in DCM. Biot-2 can be very active and at the same time it may 
be subject to a rapid decomposition in an organic solvent. In such a situation, RCM 
reaction of even quite simple substrate like diallyl tosylamide 19 with a 1 mol% 
catalyst loading can produce low conversions. In the second reaction with the 
umbelliferone precursor 24, 5 mol% catalyst loading was used and due to its high 
activity almost quantitative yield was obtained. 
87 
N,N-diallyl tosylamine 19 was used as model substrate for the RCM reaction and its 
cyclization was performed in homogeneous water–organic solvent mixtures by several 
research groups. In most cases, 5 mol% either of classic (e.g. Gr II, Hov II) or water 
soluble complexes were used mostly in the mixture of water and organic solvent 
(EtOH, DME, MeOH and DMSO). Among the catalysts tested, when a reaction was 
performed in the mixture of DME : water (2:1), the classical Grubbs-Hoveyda second 
generation complex turned out to be the most effective, providing a very good 
conversion (>95%) of the substrate with a relatively low catalyst loading (1 mol%). 
When the reaction was performed with 5 mol% of Raines’40 or Blechert’s41 catalysts, 
the results were very good, as well. A reaction in pure water was also performed 
mainly with 5 mol% of catalyst. In these case either classic Gr I and Gr II were used 
in the presence of surfactants,
42
 calix[n]arenes
43 
or dendrimers
44 
or catalysts that bear 
groups acting as a surfactant.
45
 
Biotinylated catalysts presented in this study often gave lower conversions than the 
examples above; however, it is difficult to attempt to have any meaningful comparison 
due to the fact that each reaction was carried out under distinct conditions 
(temperature, substrate concentration, catalyst loading, and solvent). 
 
4.4.3 Comparison of Artificial Metalloenzymes 
 
Scheme 4.8 RCM catalyzed by artificial metalloenzyme 
88 
After comparison of biotinylated catalysts without protein, we tested all the 
biotinylated catalysts in acetate buffer at pH 4 in presence of streptavidin (Scheme 
4.8). As a starting point, we performed the RCM of the coumarin precursor 24 with 
25µM of biotinylated catalysts with a 10 mM substrate concentration at 37 °C in 
acetate buffer. The reaction without biotinylated catalyst was set as a control. The 
results reveal that Biot-3 outperformed all other catalysts (Chart 4.3). Moreover, this 
catalyst also showed protein acceleration, since the reaction showed a slightly better 
performance inside the protein scaffold than outside the protein. This result is 
important for screening purposes and suggests that the RCM reaction is indeed 
catalysed by the artificial metathesases rather than free catalyst. 
 
 
 
 
 
 
 
 
 
 
 
Chart 4.3 Comparison of catalyst activities in RCM reactions of 5-hydroxy-2-vinylphenyl acrylate 24 
in acetate buffer (pH 4) in the presence of streptavidin. All reactions were performed in duplicate. 
 
4.4.4 Screening of Different Mutants with Biot-3 Catalyst 
Docking studies with Biot-3 suggest that S112 and K121 residues lie in the 
immediate proximity of the metal centre upon incorporation within Sav.  
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We screened different single mutants to optimize the performance of Biot-3 catalyst in 
the RCM of 5-hydroxy-2-vinylphenyl acrylate 24 in acetate buffer (pH 4) (Scheme 
4.8). We found that neutral amino acids (glycine, alanine) are better than acidic 
(glutamic acid) or basic side aminoacid (arginine).  
 
 
Chart 4.6 Comparison of streptavidin single mutants in RCM reaction of 5-hydroxy-2-vinylphenyl 
acrylate 24 in acetate buffer (pH 4) using biot-3 as cofactor. RCM were performed in duplicate. 
 
Having identified Biot-3·S112G and Biot-3·S112A as a promising first generation 
metathesase, we screened selected double mutants (Chart 4.7). Our findings reveal that 
S112A-K121N outperformed among all other mutants tested. The activity inside the 
protein is significantly higher than outside of the protein. However, the turnover 
number remains below 1 in all cases. 
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Chart 4.7 Comparison of streptavidin mutants in RCM reaction of 5-hydroxy-2-vinylphenyl acrylate 24 
in acetate buffer (pH 4). The fluorescence obtained for 1 TON and 0.5 corresponds to 17,000 and 
10,000 AU respectively. 
 
4.4.5 HPLC measurements 
For quantitative determination of the yield, we rely on HPLC. Having identified Biot-
3 as the most active catalyst, we screened [Ru]/[Sav]mon ratio for RCM reaction of 
diallyl N-tosylamide 19 (Scheme 4.9) keeping the substrate- (2.5 mM) and ruthenium 
concentration (25 µM) constant. The result suggests that upon increasing the 
[Ru]/[Sav]mon ratio, the TON per Ru increases. 
 
Scheme 4.9 RCM reaction of diallyl tosylamide 
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Chart 4.4 Comparison of [Ru]/[Sav]mon ratio.  
 
 
Chart 4.5 Comparison of the total reaction volume 
 
With the aim of miniaturizing the screening, the reaction volume was decreased. For 
that purpose we screened different total reaction volumes with 25 µM catalyst (1 mol 
%) (Scheme 4.9, Chart 4.5). It was found, that volume modestly effects the total 
conversion. Importantly, the conversion remained unchanged when performing the 
reaction in the glass tubes instead of plastic tubes. 
Typical Sav production protocols require 1 mM EDTA to prepare cell free extracts. 
EDTA is chelating ligand and it may inhibit the catalysis by coordinating to the metal. 
To test the effect of this adjuvant combining with different salts on the artificial 
metathesase, pure Sav (12.5 µM) samples were spiked with EDTA (1 mM) and 
different salts (0.5 M) (Table 4.3). Since chloride is necessary for catalyst 
stabilization, we varied only the metal ions. The result revealed that the presence of 
excess EDTA did not inhibit the catalysis. Varying metal ions did not effect on the 
conversion of RCM. 
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Table 4.3 The effect of EDTA and salts in RCM reaction of diallyl N-tosylamide 19  
Entry Protein (12.5 µM) Salt (0.5 M) Conversion (%) 
1 S112A-K121N MgCl2 6 
2 S112A-K121N CaCl2 6 
3 S112A-K121N NaCl 5 
4 S112A-K121N KCl 5 
5 S112A-K121N MgCl2 + EDTA 6 
6 S112A-K121N CaCl2 + EDTA 6 
7 S112A-K121N NaCl + EDTA 4 
8 S112A-K121N KCl + EDTA 5 
9 S112A-K121N - 0 
10 - MgCl2 30 
11 - CaCl2 35 
12 - NaCl 40 
13 - KCl 30 
14 - MgCl2 + EDTA 35 
15 - CaCl2 + EDTA 40 
16 - NaCl + EDTA 30 
17 - KCl + EDTA 40 
18 - - 6 
Reaction conditions: 25 µM catalyst, 12.5 µM Sav, 2.5 mM Sub 19, acetate buffer (pH 4), 37 
o
C. 
 
4.4.6 Catalysis in the Periplasm of E. coli with Biot-3  
In a first attempt, catalysis was performed within E. coli with varying degrees 
of success. The reducing environment of the cytoplasm, where Sav is expressed and 
localized, is not ideal for catalysis. Indeed, we hypothesize that the presence of 
millimolar concentrations of glutathione irreversibly inhibits catalysis. Additionally, 
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the complexity of metabolites and proteins present in the cytoplasm further 
complicates catalysis. Consequently, the bacteria were genetically modified to secrete 
all Sav into the periplasmic space, found between the inner cell wall and the outer 
membrane in gram-negative bacteria. The periplasm contains far fewer molecules than 
the cytoplasm and the oxidising environment ensures that most thiols are present as 
disulphides. To test the activity of biotinylated catalysts in cellular media, Markus 
Jeschek from ETH Zurich engineered E. coli strains to secrete streptavidin into the 
periplasm after expression. 
E. Coli cells (strain BL21(DE3)-pET30-T7sav-OmpA) were grown at 37°C, 
200 rpm in TP media (137 mM NaCl, 1.5% yeast extract, 2% tryptone, 2% Na2HPO4 
stock solution (457 mM) and 1% KH2PO4 stock solution (735 mM) in deionised 
water) with kanamycin (50 mg/mL stock, final concentration 50μg/mL) overnight. A 
fresh batch of sterilised TP medium was inoculated with the preculture to OD600 0.05, 
kanamycin (50 mg/mL stock, final concentration 50 μg/mL) was added and the culture 
incubated at 37°C, 200 rpm for 2 hours. The temperature of the incubator was reduced 
to 23°C and the cells incubated for a further hour. Isopropyl β-D-
thiogalactopyranoside (IPTG, 50 mM stock, final concentration 50 μM) was added 
and the cells incubated at 23°C, 200 rpm for 5 hours. The cells were harvested by 
centrifugation (4600g, 10 mins). The biotinylated catalyst (25 μM) was incubated with 
the cell pallets for 30 minutes at 37 
o
C. After that, cell pallets were washed with the 
washing buffer two times and then centrifuged (4600g, 10 mins). The cell pallets were 
resuspended in reaction buffer (acetate buffer, pH 4, 0.5M MgCl2). The substrate was 
added and stirred for overnight under air at 37
o
C. 
We tested diallyl N-tosylamide 19 (2.5 mM) for RCM in the periplasm of E. coli with 
25µM Biot-3 catalyst (1 mol%) in acetate buffer at pH 4. With WT and S112A 
mutant, we were able to achieve 2% yield which corresponds to only 2 TON (Table 
4.4), whereas S112A-K121N failed to give any product. The empty vector also gave 
2% yield. Yield was measured in reverse phase HPLC. All reactions were performed 
in duplicate.  
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Table 4.4 RCM reactions of diallyl tosylamide 19 in cell 
Entry Cell TON 
1 Empty 2 
2 WT 2 
3 S112A 2 
4 S112A-K121N 0 
5 No cell, only medium 0 
 
4.5 Conclusion 
In this study, a series of biotinylated ruthenium-based catalysts were 
synthesized and their activity was evaluated for two model RCM reactions with either 
diallyl tosylamide 19 or the umbelliferone precursor 24. While all biotinylated 
catalysts performed reasonably well in concentrated dichloromethane, their 
performance decreased significantly in aqueous solution. In our opinion, the decreased 
stability of the biotinylated catalysts in aqueous solutions can play a key role. In 
organic solvent, the high reaction rate and the slow catalyst decomposition make it 
possible to obtain the desired products with average to good yields. In aqueous 
solvents however, catalyst decomposition is faster
11
 and 20 and 25 were only obtained 
in low yield. For umbelliferone precursor 24, modest to good conversions were 
observed in dichloromethane. In stark contrast, RCM in water does not proceed. In the 
context of artificial metalloenzyme design, this substrate, which upon RCM yields the 
fluorescent umbelliferone 25, lead to significant improvement in conversion by 
95 
generating a hydrophobic pocket which might shield the substrate-catalyst complex 
from water. After performing RCM inside the protein, we moved to the next 
development step and performed RCM inside the periplasm of E.coli to avoid the 
laborious protein purification process. In order to improve the activity, we rely on high 
throughput screening. Currently we are investigating the method for high throughput 
screening and directed evolution in close collaboration with Prof. Sven Panke, ETH 
Zurich.  
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CHAPTER 5 
 
An Asymmetric C–H Activation Reaction 
Catalyzed by an Artificial Benzannulase Using 
Unpurified Protein Samples 
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5.1 Introduction 
During the past decade, catalyzed C–H bond activation reactions have emerged 
as attractive tools for atom- and step-economical C–C and C–heteroatom bond 
forming processes.
1–5
 Unactivated C–H bonds possess high bond dissociation energies 
(BDE), and their pKa values range from 41 to 51, as estimated in aqueous solutions,
6
 
or from 41 to 56, as measured in DMSO.
7
 Representative examples of typical 
unactivated hydrocarbons include benzene (pKa  ̴ 43,
6
 BDE ≈ 474 kJmol-1)8, methane 
(pKa  ̴ 48,
6 BDE ≈ 440 kJmol-1)8 or ethane (pKa  ̴ 50,
6 BDE ≈ 465 kJmol-1)8. C–H bonds 
are generally unreactive; however, there are several methods for activating and 
functionalizing C–H bonds. For  over a century,  it  has  also  been  known  that  
transition  metals  can  mediate or  catalyze  C–H  functionalization  reactions.9–15 For  
organic  chemists,  this  is  of  particular  interest  because  of  the  diverse  reactivity 
of  different  transition  metals  and  the  coordination  environment  around the metal. 
The selectivity and reactivity can thus be finely tuned through ligand design. 
 
5.1.1 Biocatalysts for C–H Activation 
In nature, C–N bonds are typically formed through the transamination of carbonyl 
substrates. A compelling synthetic strategy, the direct catalytic amination of C–H 
bonds, is an example where biological variations are almost entirely absent. Matthews 
et al.
16
 took a step toward filling this gap by demonstrating that a bacterial aliphatic 
halogenase SyrB2 2 can be coaxed to install nitrogenous anions in place of unactivated 
aliphatic C–H bonds 1, generating C–N bonds 6-7 through chemistry not previously 
observed in nature (Scheme 5.1). 
Arnold and coworkers
17,18
 showed that cytochrome P450s can access metallocarbenoid 
and nitrenoid insertion reactions when provided with non-natural diazoacetate and 
sulfonazide reagents. This is an example of bio-catalytic C–H bond functionalization 
which had not previously been observed in Nature. 
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Scheme 5.1 Repurposing an iron-dependent halogenases into a C–N bond forming enzyme. In the 
native enzyme, the carbon-based radical recombines with an iron-bound hydroxide (hydroxylase) or 
chloride (halogenase) to afford an hydroxylase (X = Asp) or an halogenase (X = Cl
–
) (yellow box). 
Substituting the chloride ligand in halogenase SyrB2 (structure shown; PDB code 2FCT) with the 
nitrogenous anions (i.e. N3
−
 or NO2
−
) results in C-N bond coupling reactions not previously observed in 
nature (purple box). R1 = SyrB1 carrier protein; R2 = carboxylate substrate.
19
 
 
5.1.2 Biotin-(strept)avidin Artificial Metalloenzyme 
Technology 
The cleavage of unactivated C–H bonds is one of the most challenging 
reactions chemistry. Metalloenzymes can efficiently perform these transformations 
with exquisite selectivity. Metalloenzymes based on the biotin-(strept)avidin artificial 
metalloenzyme have been developed in the Ward group to effect a C–H activation 
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ultimately leading to benzannulated products.
20
 The biotin-(strept)avidin system was 
selected thanks to the affinity of biotin for streptavidin (Ka = 10
14
 L/mol). Importantly, 
derivatization of the valeric acid side chain of biotin does not significantly decrease 
the affinity, thus allowing to expoit this anchoring strategy to ensure localization of a 
biotinylated metal cofactor within streptavidin. (Strept)avidin is a 16.1 kDa protein 
expressed by Streptomyces Avidinii. The secondary structure of the homotetrameric 
protein consists mainly of anti-parallel β-sheets assemble into β-barrels.21 Biotin binds 
inside the β-barrel with the carboxylate residue pointing towards the surface of the 
biotin-binding vestibule. The tetramer binds four equivalents of biotin, with two of the 
biotin moieties sitting within 18-19 Å (distance between two carboxylate oxygen 
atoms) of one another. This protein has been particularly popular in the field of 
biotechnology thanks to its high affinity for substrates bearing a biotin anchor.
22
 
Furthermore, the protein has exceptional stability at high temperatures (Tm = 112.2 ºC 
fully ligated in phosphate buffer or Tm = 75.5 ºC unligated in phosphate buffer) and 
organic solvents.
23
 
 
5.1.3 Prior Works 
Hyster et. al. reported in 2012 the creation of a bifunctional artificial 
metalloenzyme in which a glutamic acid or aspartic acid residue engineered into 
streptavidin acts in concert with a docked biotinylated rhodium(III) complex 12 to 
enable catalytic asymmetric C–H activation (Scheme 5.2).20 The coupling of 
benzamides 8 and alkenes 9 to access dihydroisoquinolones 10, 11 proceeded with up 
to nearly a 100-fold rate acceleration compared with the activity of the isolated 
rhodium complex. Enantiomeric ratios (er hereafter) up to er 93:7 were obtained.  
 
 
102 
 
 
Scheme 5.2 Synthesis of dihydroisoquinolones 10, 11 via C–H activation. Catalyst precusor 12 and 
postulated transition state 13 for the rate determining C–H activation step. 
 
In a related report (using a traditional organometallic catalyst), Cramer and coworkers 
developed the use of chiral cyclopentadienyl ligands 18 for the Rh(III) catalyzed 
synthesis of isoquinolones 16 (Scheme 5.3).
24
 Cramer used a tartrate-based ligand and 
obtained excellent levels of enantioselectivity with sterically bulky alkenes.  
 
Scheme 5.3 Concurrent work by the Cramer group.  
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5.2 Aim of the Project 
Rhodium (III) complexes bearing Cp-ligands proved highly enantioselective 
catalysts for directed C–H bond functionalization of hydroxamic acid derivatives.25–28 
Previous work
20
 proved that high levels of both selectivity and reactivity could be 
achieved by an artificial metalloenzyme by genetically engineering a basic carboxylate 
residue in proximity of the metal center. Our current efforts were centered on the 
asymmetric C–H activation in the presence of cellular extracts. The aims of the project 
were following. 
 Neutralize detrimental Glutathione (GSH)  
 Ensure access of both the substrate and the catalyst in the periplasm of E. coli 
 Identify a buffer compatible with both cells and the reaction conditions 
 Develop a suitable screening method  
 
5.3 Outline of the Project 
In a first attempt, we set out to adapt the artificial benzannulase for catalysis 
using unpurified Sav samples. Purification of Sav isoforms is the bottleneck of the 
entire optimization process: Screening unpurified protein samples would allow to 
significantly decrease the screening time from 21 days (for purified Sav samples) to 8 
days (unpurified samples). To address this challenge, five different approaches were 
investigated.  
 
Firstly, since Rh(III) catalyst 19 is coordinately unsaturated, there is high 
probability to nucleophilic attack at the metal by GSH 20, resulting in deactivation of 
the catalyst. To circumvent this challenge we set out to test a coordinately saturated 
Rh(I) precursor complex 21 eventually minimizing GSH attack (Scheme 5.4). 
 
Secondly, Wilson et al. have shown that various Michael acceptors and 
oxidizing agents may neutralize the detrimental effect of GSH on precious metal 
catalyst.
29
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Thirdly, we synthesized different precatalysts that may better tolerate the 
complex cellular extracts.  
 
Fourthly, we considered testing catalysis with semipurified Sav.  
 
Finally, we tested an imino-biotin bead batch purification to isolate Sav from 
cellular extracts at pH 9.  
 
 
Scheme 5.4 Coordinatively unsaturated{CpRh(III)} 19 vs. coordinatively saturated{CpRh(I)} 21 
catalyst precursors to avoid GSH attack 
 
 
5.4 Results and Discussion 
Inspired by Cramer’s report, we synthesized a biotinylated Rh(I) complex 24 
bearing a cyclopentadiene (Cp) and a cyclooctadiene (cod) ligand as an artificial 
cofactors with the objective of catalyzing C-H activation to form 
dihydroisoquinolones. The Cp and cod ligands bind to the Rh metal with η5- and η4-
coordination modes respectively, Scheme 5.5. Cracking dicyclopentadiene led to its 
monomer 21. Upon deprotonation by NaH and addition of [ClCH2CH2NH2·HCl] in 
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THF led to [C5H5CH2CH2NH2] which was converted to Li[C5H5CH2CH2NH2 ] 22 via 
the dropwise addition of n-BuLi in hexane at 0 
o
C under argon. Addition of 
[Rh(cod)Cl]2 in THF afforded the Rh(I) complex 23 which was isolated in 50 % 
overall yield. Biotin conjugation was achieved by addition of biotin-pentafluorphenyl 
ester (biot-PFP) in DMF in the presence of NEt3, Scheme 5.5. With the aim of 
introducing more labile ligands, the synthesis of the corresponding bis ethylene 
complex 25 was attempted.  Unfortunately, all attempts were vain as only <5% could 
be isolated.   
 
 
Scheme 5.5 Synthesis of Rh(I) complex. 
Previous work in the group revealed that water-methanol (or acetate-methanol) 
mixtures  were most efficient.
20
 We thus selected these solvent mixtures for Rh(I) 
complex (0.5 mM) using O-pivaloyl benzhydroxamic acid 8 (50 mM) and methyl 
acrylate 9 (50 mM) as substrate. As reported by Cramer, we used dibenzoylperoxide 
17 (0.5 mM) for the in-situ oxidation of the Rh(I) to Rh(III). The activity with or 
without Sav was found to be nearly identical: 4 TON (Table 5.1).  
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Table 5.1 Synthesis of the dihydroisoquinolones 10 (major) via C–H activation.a 
Entry Protein Solvent/MeOH (4:1) Conversion (%) 
1 - Acetate buffer 4 
2 - water 4 
3 Sav WT Acetate buffer 4 
4 Sav WT water 4 
a
 [Sub] = 50 mM, [24] = 0.5 mM, [DBPO] = 0.5 mM, reaction volume = 200 µL 
 
We speculated that the system reported by Cramer may not be suitable for the 
substrates 8, 9 that we had been testing. Indeed, Cramer focused on styrene 15 (rather 
than acrylic acid derivatives 9) and benzamides containing carbonate 14 (rather than 
an ester 8) as internal oxidant. We thus tested catalyst 24 (1 mM) with 14 and 15 (50 
mM) as substrates. Under these conditions, we obtained 4 % conversion using 20 % 
MeOH in acetate buffer or water. Upon increasing the amount of organic solvent 
(from 20% to 50%), the conversion increased to 15%, but the product was formed as a 
racemate (Table 5.2).  
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Table 5.2 Synthesis of the dihydroisoquinolones 16 via C–H activation.a 
Entry Protein Solvent/MeOH 
(4:1) 
Solvent/ MeOH 
(1:1) 
Conv. 
(%) 
er 
1 - Acetate buffer - 4 ND 
2 - water - 4 ND 
3 Sav WT Acetate buffer - 4 ND 
4 Sav WT water - 4 ND 
5 Sav WT - Acetate buffer 15 50:50 
6 Sav WT - water 15 54:46 
a
 [Sub] = 50 mM, [24] = 1 mM, [DBPO] = 1 mM, reaction volume = 200 µL. ND = not determined 
 
These exploratory results suggest that, under the reaction conditions required 
for the creation of artificial metalloenzymes, the biotinylated Rh(I) precursor 24 is not 
an efficient catalyst for the production of dihydroisoquinoline 10 or 16. We thus 
selected the Rh(III) complex for further investigation of C-H activation in the presence 
of unpurified Sav samples.  
For the synthesis of the {Cp*Rh(III)} complex, the procedure developed by 
Zimbron was used (Scheme 5.6).
30
 Treatment  of  2,3,4,5-tetramethylcyclopent-2-
enone 26 with  deprotonated  acetonitrile  in  THF at -80°C  afforded  the  hydroxy  
intermediate. Upon acidic treatment, dehydration yielded the corresponding exocyclic 
diene 27. Reduction followed by complexation with RhCl3 and coupling with biotin 
pentafluorophenyl ester yielded the final compound 12.  
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Scheme 5.6 Synthesis of biotinylated dirhodium complex 12. 
 
To perform the C-H functionalization reaction in the cell free extract or in a 
cellular medium, it is necessary to perform the catalysis at very low catalyst 
concentration as the Sav concentrations are usually < 50 M. Turning back to the 
system reported by Hyster (i.e. using the catalyst precursor 12), we selected O-
pivaloyl benzhydroxamic acid 8 and methyl acrylate 9 as substrates. While 
maintaining the same catalyst loading (1 mol%), we decreased the catalyst 
concentration as well as substrate concentration to identify the lowest concentration 
that yields detectable product. The result is summarized in Table 5.3. The activity with 
0.5 mM and 0.25 mM (entries 1, 2) are same. Further decreasing the catalyst 
concentration resulted significantly lower TON (entries 3-6).  
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Table 5.3 Screening of catalyst concentrationa 
Entry Protein Solvent Cat. Conc. 
(M) 
Sub Conc. 
(mM) 
er TON 
1 S112Y-K121E water 500 50 88:12 90 
2 S112Y-K121E water 250 25 88:12 90 
3 S112Y-K121E water 125 12.5 88:12 54 
4 S112Y-K121E water 60 6 88:12 25 
5 S112Y-K121E water 30 3 88:12 7 
6 S112Y-K121E water 15 1.5 88:12 4 
a
 Catalyst loading = 1 mol%, reaction volume = 200 µL. 
 
The reaction of O-pivaloyl benzhydroxamic acid 8 and methyl acrylate 9 with 
Rh(III) complex 12 was reported by Hyster to require long reaction time (72 hrs).
20
 
Our screening efforts led to the realization that the reaction is complete in 20 hrs with 
S112Y-K121E (instead of 72 hours) mutant and in 10 hrs with N118-K121E mutant 
(Table 5.4). Although good er were obtained, these were systematically lower than 
those reported by Hyster. Upon longer reaction time, conversion and ee did not 
change. 
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Table 5.4 Optimized reaction time for the Rh-catalyzed benzannulation a 
Entry Protein Solvent Time er Conv. 
1 S112Y-K121E water 20 hrs 88:12 90 
2 N118K-K121E water 10 hrs 80:20 93 
a
 [Sub] = 50 mM, [12] = 0.5 mM, 20% MeOH in water, rt, reaction volume = 200 µL. 
 
Typical Sav production protocols in the group require the presence of MOPS 
or Tris buffer containg 20 % Sucrose. For cell lysis, 1 mM EDTA is added to prepare 
cell free extracts. To test the effect of these adjuvents on the artificial benzannulase, 
pure Sav samples were spiked with Tris (5 mM), sucrose (20%) and EDTA (1 mM) 
(Table 5.5).  The presence of EDTA and Tris completely inhibited catalysis. The 
presence of sucrose did not inhibit the catalysis at all. 
 
Table 5.5 Effect of cell free extract adjuvants on the performance of the artificial 
benzannulase.a 
Entry Protein Solvent Adjuvant er Conv. 
1 S112Y-K121E water - 88:12 90 
2 S112Y-K121E water 20 % Sucrose 88:12 90 
3 S112Y-K121E water 5 mM Tris - - 
4 S112Y-K121E water 1 mM EDTA - - 
a
 [Sub] = 50 mM, [12] = 0.5 mM, 20% MeOH in water, rt, reaction volume = 200 µL. 
 
In the context of an artificial metathesase, Markus Jeschek (in the group of 
Prof. Panke, dbsse ethz@basel) developed a Sav production secreted to the periplasm. 
The key incentive for this effort was the realization that the periplasm is oxidizing, 
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resulting in the presence of oxidized glutathione (GS—SG). Furthermore, the 
periplasm contains significantly fewer proteins, thus reducing the potential inhibition 
of the Rh-catalyst by endogeneous proteins. Isolation and purification of both Sav 
samples from the cytoplasm and from the periplasm revealed no notable difference 
between both cytoplasmic and periplasmic Sav. This suggests that the periplasm may 
be a propitious environment to compartmentalize the artificial benzannulase for in vivo 
screening.  
From our result (Table 5.6) it is very clear that there is no functional difference 
between periplasmic and cytoplasmic streptavidin.  
 
Table 5.6 Cytoplasmic vs. periplasmic Sav.a 
Entry Protein Solvent er Conv. 
1 WT Acetate buffer 75:25 46 
2 Periplasmic Sav Acetate buffer 75:25 46 
a
 [Sub 8] = 50 mM, [12] = 0.5 mM, rt, reaction volume = 200 µL. 
 
We selected Michael acceptors and oxidizing agents known to react with GSH 
to yield the corresponding thioether and disulfide, respectively. The following Michael 
acceptors were tested: methyl acrylate 32, maleinimide 33, 2-iodo-1-phenylethanone 
31, and 3-phenyl-2-propynenitrile 30. The following oxidizing agents were selected: 
oxone 37, 1,4-benzoquinone  34, K3[Fe(CN)6] 36 and diamide 35, Figure 5.1. For this 
purpose, solutions with Sav were spiked with 1.5 mM GSH and incubated overnight in 
the presence of different concentrations of a particular GSH neutralizing agent before 
adding the Rh-catalyst 12. The screening results were summarized in a bubble chart, 
Figure 5.2. 
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Figure 5.1 Michael acceptors and oxidizing agents used to neutralize the detrimental effect of GSH 
 
 
 
Figure 5.2 Bubble chart results summarizing the screening of Michael acceptors and oxidizing agents 
(GNA : glutathione neutralizing agent) used to neutralize the detrimental effect of spiked GSH (1.5 
mM). The concentration of the neutralizing agent is given. Size of the bubble and intensity of the color 
correspond to conversion (%) and ee (%) respectively.  Reaction conditions: [Sub] = 50 mM, [Cat] = 
0.5 mM.  
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From the result obtained in Figure 5.2, we thus conclude that oxidizing GSH or 
deriving its thiol function could not prevent inhibition of Rh(III) catalyst. 
 
Finally, new Rh(III) precatalysts were synthesized and tested for their performance as 
catalyst in the benzannulation. Three different water soluble catalysts 40, 39 and 41 
were prepared according to literature procedures
31,32
 with moderate yield (40 – 60%) 
(Scheme 5.7). Prior to preparing the biotinylated catalysts, catalysts 40, 39 and 41 
were evaluated for the benzannulation between O-pivaloyl benzhydroxamic acid 8 and 
methyl acrylate 9, Scheme 5.8. 
 
 
 
Scheme 5.7 Synthesis of the Rh(III) precatalysts. 
114 
 
 
Scheme 5.8 Synthesis of dihydroisoquinolones 10 via C–H activation. 
 
Table 5.7  Precatalyst screening for the synthesis of dihydroisoquinolones 10. a 
Entry Catalyst (1 mol%) Conversion (%) 
1 Compound 40 4 
2 Compound 39 6 
3 Compound 41 6 
a
 [Sub] = 50 mM, [catalyst] = 0.5 mM, rt, reaction volume = 200 µL. 
 
From this result (Table 5.7), we conclude that catalysts 41, 41 and 43 are not suitable 
precursors for C-H activation reactions. 
 
Having failed in identifying suitable reaction conditions to screen crude 
cellular extracts containing Sav isoforms, we set out to test affinity purification of Sav 
using iminobiotin-sepharose beads. For this purpose, cell free extracts containing Sav 
(400 µl in PBS buffer) were transferred into a 24 deep-well plates. Iminobiotin 
binding buffer (1 ml, IB hereafter) was added to each well to adjust the pH ~ 9. The 
iminobiotin-sepharose beads (100 µl of a thoroughly shaken suspension prior to 
pipetting) were added and incubated with rapid shaking (800 rpm, RT, 1 h). The plate 
was centrifuged (5300 g, 15 min.) and the supernatant was discarded. The beads were 
resuspended in IB-buffer (1 ml), centrifuged (5300 g, 15 min.) and the supernatant 
was discarded. This washing step was repeated three times. Next, the thoroughly 
washed beads were used for catalysis. Those beads were resuspended in acetate buffer 
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(pH 5.6) and the catalyst and substrates were added. At acidic pH, Sav is released 
from the iminobiotin-sepharose beads as the guanine moiety is protonated,
33
 resulting 
in an homogeneous ArM. Unfortunately, the conversions remained very modest (4-5 
%, corresponding to <10 TON). We hypothesized that at pH 5.6, the Sav remains 
bound to the iminobiotin-matrix as the guanine moiety is not protonated.  
To solve this problem, we performed catalysis in the presence of semi-purified 
Sav. For that purpose, cell free extracts were subjected to dialysis with guanidinium 
hydrochloride (6 M, pH 1.5) to remove biotin followed by dialysis in Tris/HCl 
(20mM, pH 7.4) to neutralize the pH. Dialysis against water to remove the salts 
yielded a semi-purified Sav. To our delight, good conversions (20 TON) were 
obtained with this purification protocol for the C-H activation catalyzed by Rh(III) 
catalyst in this semi purified system. Although TON is improved compared to 
previous approaches, this process remains time consuming for high-throughput 
screening purposes. 
 
5.5 Conclusion 
In this study we have applied different strategies aiming at performing a C-H 
activation reaction in cellular extracts. Unfortunately, none of them gave satisfactory 
result to address this problem. So we speculated that cellular extracts contains 
something that is coordinating to metal and inhibiting catalysis. The major problem is 
associated with the catalyst system, which did not allow performing catalysis at the 
low catalyst concentration (< 0.1 mM).  
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Chapter 6 
 
 
Conclusion and Outlook 
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In this thesis, efforts at developing bio-orthogonal C–C bond forming reactions 
catalyzed by artificial metalloenzymes based on the biotin (strept)avidin technology 
are presented. In this study, we have tested three important C-C bond forming 
reactions – Suzuki cross-coupling, olefin metathesis and C-H activation reactions in 
the context of bio-orthogonal chemistry.  
At the very beginning of the thesis, in Chapter 2, we reviewed recent 
developments in the palladium catalyzed Suzuki-Miyaura cross-coupling reaction in 
water. This review covers the period from 2011 to August 2015.  
In Chapter 3, we have developed a new artificial Suzukiase incorporating of an 
electron-rich phosphino-palladium moiety within Sav for the synthesis of 
enantioenriched binaphthyls (up to 90 % ee and 180 TONs). Importantly, it was shown 
that the hybrid catalyst offers vast opportunities for chemogenetic optimization of the 
catalytic performance: site-directed mutagenesis leads to a significant increase in 
enantioselectivity. Future efforts can be aimed at performing catalytic asymmetric 
SMC with artificial Suzukiases in vivo. Our system may be useful for many synthetic 
biology and chemical biology applications (red biotechnology). For example vaccine 
and antibody production, bio-based chemicals, plastics and textiles production etc. 
In Chapter 4, we have developed a new artificial metathesase incorporating 
Hoveyda-Grubbs type catalyst within streptavidin. We also present our efforts to 
develop the ring closing olefin metathesis in vivo using E. coli cells. Since our system 
showed protein acceleration, this may have a high potential for high-throughput 
screening and directed evolution of artificial metalloenzymes (white biotechnology). 
In summary, the studies presented in this thesis provide the great potential of 
artificial metalloenzymes to complement both homogeneous and enzymatic catalysts. 
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APPENDIX 1 
 
Enantioselective Artificial Suzukiase for the 
Synthesis of Axially Chiral Biaryl Compounds 
Relying on the Straptavidin-Biotin Technology 
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General: All Chemicals were of reagent grade and used as commercially purchased 
without further purification. 
1
H and 
13
C spectra were recorded on a Bruker 400 MHz. 
Chemical shifts are reported in ppm (parts per million). Signals are quoted as s 
(singlet), d (doublet), t (triplet), brs (broad) and m (multiplet). Analysis of the catalytic 
runs were performed on an Agilent 1100 normal phase HPLC with an analytical 
Chiracel OJ-H column (5μm, 250 x 4.6 mm) of Daicel Chemical Ind. 
Protein expression and purification:  
Native, egg avidin was obtained from Belovo and used without further purification. 
Recombinant streptavidin isoforms were engineered, expressed, purified and 
quantified as previously described.
1
 
Synthesis of biotinylated catalysts: 
 
Scheme 1 Synthesis of complex 1 
Complex 1: The Biotin-PFP ester
2
 (200 mg, 0.49 mmol) was set in a schlenk flask. 
The flask was evacuated and backfilled with nitrogen three times and dry THF was 
added. The 2-(Di-t-butylphosphino)ethylamine (10 wt. % in THF, 1 ml, 0.49 mmol) 
was added slowly to the suspension. The reaction mixture was stirred at room 
temperature overnight (18-20 h). Then [Pd(cinnamyl)(μ-Cl)]2 (130 mg, 0.25 mmol) 
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was added to the clear solution and stirred for 2 h at room temperature. After this time, 
THF was removed under reduced pressure and the crude product was purified by flash 
chromatography on silica gel (MeOH : CH2Cl2 5:95) to afford the complex 1 as 
yellow solid (240 mg, 74%).  
1
H NMR (400 MHz, CDCl3): δ = 7.49 (d, J = 7.7 Hz, 2H), 7.42 – 7.29 (m, 3H), 5.88 – 
5.72 (m, 1H), 5.23 (dd, J = 13.2, 9.2 Hz, 1H), 5.07 (s, 1H), 4.44 – 4.32 (m, 1H), 4.23 
(dd, J = 14.6, 7.5 Hz, 1H), 3.97 (s, 1H), 3.59 (s, 2H), 3.13 (s, 1H), 2.81 – 2.62 (m, 1H), 
2.22 – 2.05 (m, 2H), 1.76 – 1.53 (m, 6H), 1.54 – 1.15 (m, 24H).  
13
C NMR (100 MHz, CDCl3): δ = 173.5, 164.1, 136.5, 128.7, 128.2, 127.9, 108.7, 
101.8, 61.7, 60.0, 56.0, 48.1, 40.8, 37.1, 35.8, 30.0, 28.1, 27.8, 25.6, 21.5, 21.4.  
31
P NMR (162 MHz, CDCl3): δ = 62.3.  
HRMS [ESI(+)TOF]: calculated for C29H47N3O2PPdS [M-Cl]+ 638.2156; found 
638.2172. 
 
 
 
 
                                                  Scheme 2 Synthesis of complex 2 
Complex 2: Complex 2 was synthesized following the same procedure used for the 
synthesis of Complex 1, using Biotin-PFP ester (90 mg, 0.49 mmol), 3-(Di-t-
butylphosphino)propylamine (10 wt. % in THF, 0.5 ml, 0.22 mmol) and 
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[Pd(cinnamyl)(μ-Cl)]2 (67 mg, 0.12 mmol). The crude product was purified on silica 
gel by 5% MeOH/CH2Cl2 to yield the title product as yellow solid (140 mg, 87%). 
1
H NMR (400 MHz, CDCl3): δ = 7.58 – 7.30 (m, 5H), 5.89 – 5.67 (m, 1H), 5.38 – 
5.24 (m, 1H), 4.88 (d, J = 20.4 Hz, 1H), 4.40 – 4.31 (m, 1H), 4.25 – 4.05 (m, 1H), 3.93 
(dd, J = 6.9, 5.4 Hz, 1H), 3.28 (s, 2H), 3.15 (s, 1H), 2.92 (s, 1H), 2.77 – 2.57 (m, 2H), 
2.17 (t, J = 7.3 Hz, 2H), 2.12 – 1.82 (m, 4H), 1.79 – 1.46 (m, 6H), 1.44 – 1.11 (m, 
20H).  
13
C NMR (100 MHz, CDCl3): δ = 174.3, 163.6, 136.5, 129.3, 128.8, 128.2, 127.9, 
108.9, 103.2, 61.6, 59.9, 55.8, 40.6, 40.5, 35.8, 34.9, 34.8, 30.1, 30.0, 27.8, 25.7, 18.5.  
31
P NMR (162 MHz, CDCl3): δ = 66.7. 
HRMS [ESI(+)TOF]: calculated for C30H49N3O2PPdS [M-Cl]+ 652.2312; found 
652.2325. 
 
 
 
 
Scheme 3 Synthesis of complex 3 
Complex 3: Complex 3 was synthesized following the same procedure used for the 
synthesis of Complex 1, using Biotin-PFP ester (181 mg, 0.44 mmol), 3-(Di-t 
butylphosphino)propylamine (10 wt. % in THF, 85 µl, 0.22 mmol) and 
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[Pd(cinnamyl)(μ-Cl)]2 (67 mg, 0.12 mmol). The crude product was purified on silica 
gel by 5% MeOH/CH2Cl2 to yield the title product as yellow solid (140 mg, 87%). 
1
H NMR (400 MHz, CDCl3): δ = 7.63 – 7.28 (m, 18H), 6.18 (s, 1H), 5.99 (dt, J = 13.2, 
9.4 Hz, 2H), 5.40 – 5.19 (m, 2H), 4.44 – 4.31 (m, 1H), 4.29 – 4.17 (m, 1H), 3.49 (dd, J 
= 16.3, 6.0 Hz, 2H), 3.31 – 2.94 (m, 1H), 2.76 (s, 2H), 1.93 (t, J = 7.3 Hz, 2H), 1.75 (s, 
2H), 1.63 – 1.36 (m, 3H), 1.30 (d, J = 6.5 Hz, 2H).  
13
C NMR (100 MHz, CDCl3): δ = 173.6, 163.7, 136.2, 132.8, 132.7, 132.6, 130.6, 
129.0, 128.9, 128.5, 127.9, 111.5, 100.7, 100.4, 61.4, 59.8, 56.5, 35.6, 28.1, 27.9, 27.8, 
27.6, 25.4.  
31
P NMR (162 MHz, CDCl3): δ = 18.4. 
HRMS [ESI(+)TOF]: calculated for C33H39N3O2PPdS [M-Cl]+ 678.1530; found 
678.1551. 
 
 
 
 
Scheme 4 Synthesis of complex 4 
Complex 4: Complex 4 was synthesized following the same procedure used for the 
synthesis of Complex 1, using Biotin-PFP ester (123 mg, 0.3 mmol), 3-(Di-t-
butylphosphino)propylamine (10 wt. % in THF, 97 mg, 0.4 mmol) and 
[Pd(cinnamyl)(μ-Cl)]2 (67 mg, 0.12 mmol). The crude product was purified on silica 
gel by 5% MeOH/CH2Cl2 to yield the title product as yellow solid (140 mg, 87%). 
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1
H NMR (400 MHz, CDCl3): δ = 7.63 – 7.29 (m, 15H), 6.19 – 5.83 (m, 3H), 5.43 – 
5.26 (m, 1H), 5.16 (s, 1H), 4.34 – 4.19 (m, 1H), 4.20 – 4.06 (m, 1H), 3.26 (s, 4H), 
2.76 – 2.36 (m, 3H), 2.18 (t, J = 7.0 Hz, 2H), 1.87 – 1.51 (m, 8H), 1.35 (br, 2H).  
13
C NMR (100 MHz, CDCl3): δ = 173.9, 163.5, 137.0, 136.4, 136.3, 132.7, 130.6, 
129.2, 128.9, 128.8, 128.5, 128.3, 127.8, 127.7, 111.1, 111.0, 101.0, 100.0, 61.1, 59.6, 
54.5, 39.7, 35.8, 27.7, 27.4, 25.5, 25.0, 24.8, 24.1.  
31
P NMR (162 MHz, CDCl3): δ = 24.6. 
HRMS [ESI(+)TOF]: calculated for C34H41N3O2PPdS [M-Cl]+ 692.1686; found 
692.1703. 
 
 
 
 
 
 
Scheme 5 Synthesis of complex 5 
Biot-NHC (10): Complex 9 was synthesized according to literature procedure.
3 
Complex 9 (236 mg, 0.5 mmol) was dissolved in CH2Cl2 (2 ml) and HCl gas was 
bubbled through the solution for 1 hour at room temperature. The gaseous HCl was 
generated by the dropwise addition of concentrated H2SO4 to NH4Cl. The solution was 
stirred for 2 hours at room temperature. The deprotection step was monitored by thin-
layer chromatography (MeOH/CH2Cl2 1:9). The solvent was evaporated and the 
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resulting solid was dissolved in DMF (2 ml). Biotin pentafluorophenol (164 mg, 0.4 
mmol) and Et3N (1.4 ml, 10 mmol) was added to the solution and stirred for 16 h at 
room temperature. The solvent was removed at reduced pressure. The crude product 
was purified on silica gel by 10% MeOH/CH2Cl2 to yield compound 10 as white solid 
(197 mg, 82%). 
1
H NMR (400 MHz, CD2Cl2): δ = 9.38 (d, J = 5.3 Hz, 1H), 8.86 (br, 1H), 7.05 – 6.90 
(m, 4H), 6.72 (s, 1H), 6.32 (s, 1H), 5.16 (br, 1H), 4.52 (s, 2H), 4.31 (s, 1H), 4.11 (s, 
1H), 3.67 (d, J = 42.9 Hz, 1H), 3.32 (d, J = 9.9 Hz, 1H), 3.27 – 3.13 (m, 1H), 2.79 – 
2.69 (m, 1H), 2.62 (dd, J = 19.7, 12.8 Hz, 1H), 2.50 – 2.21 (m, 20H), 2.12 (s, 2H), 
1.71 – 1.38 (m, 4H). 
13
C NMR (100 MHz, CD2Cl2): δ = 174.7, 160.2, 140.9, 140.7, 135.9, 135.8, 135.7, 
130.8, 130.7, 130.4, 130.2, 129.7, 129.6, 62.8, 62.2, 62.0, 60.5, 56.3, 56.2, 56.1, 46.2, 
40.9, 35.8, 28.5, 28.4, 25.9, 25.6, 21.3, 21.2, 19.2, 18.7, 8.8. 
HRMS [ESI(+)TOF]: calculated for C32H44N5O2S [M-Cl]+ 562.3215; found 562.3212. 
Complex 5: Compound 10 (201 mg, 0.34 mmol), [Pd(cinnamyl)(μ-Cl)]2 (82 mg, 0.16 
mmol) and KO
t
Bu (38 mg, 0.34 mmol) were set in a schlenk flask. The flask was 
evacuated and backfilled with nitrogen three times, then 9 ml dry THF was added. The 
flask was cooled at -78 
o
C for 1h and then warmed to RT and stirred for another 1h. 
The solvent was removed under reduced pressure. The crude product was purified on 
silica gel using 10% MeOH/CH2Cl2 to yield compound 5 as yellow solid (52 mg, 
40%). 
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1
H NMR (400 MHz, CD2Cl2): δ = 7.36 – 6.90 (m, 9H), 6.49 (s, 1H), 5.83 (s, 1H), 4.94 
– 4.68 (m, 1H), 4.54 – 4.31 (m, 2H), 4.17 (d, J = 11.8 Hz, 2H), 4.01 (t, J = 10.7 Hz, 
1H), 3.91 – 3.76 (m, 1H), 3.50 (br, 1H), 3.36 – 3.07 (m, 3H), 2.88 (m, 2H), 2.65 (d, J 
= 8.4 Hz, 1H), 2.55 – 2.20 (m, 18H), 2.15 – 1.98 (m, 3H), 1.75 – 1.42 (m, 6H). 
13
C NMR (100 MHz, CD2Cl2): δ = 209.8, 168.0, 162.1, 145.7, 136.4, 135.1, 127.7, 
126.9, 125.9, 125.3, 122.9, 107.6, 89.8, 61.6, 60.3, 58.6, 54.3, 52.8, 45.0, 31.6, 27.1, 
27.0, 26.8, 25.3, 24.2, 23.3, 22.5. 
HRMS [ESI(+)TOF]: calculated for C41H52N5O2PdS [M-Cl]+ 784.2876; found 
784.2890. 
General procedure for Catalysis on an analytical scale: 
 
 
 
 
Apart from the extraction and the purification of the products everything was carried 
out in the glove-box using nitrogen-flushed solvents. 
A stock solution of Sav (0.20 μmol, 0.02 eq.) in mQ water and the catalyst (0.10 μmol, 
0.01 eq.) in DMSO were prepared, added together and stirred for ten minutes at room 
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temperature. Stock solutions of NaOH (20 μmol, 2.00 eq.) in mQ water, aryl-halide 
(10 μmol, 1.00 eq.) and boronic acid (15 μmol, 1.50 eq.) in DMSO were prepared, 
added to the mixture and stirred overnight. The reactions were performed with 
iodonaphthalene, bromonaphthalene and chloronaphthalene derivatives at two 
different temperatures (RT and 50 °C) in the scale of 50 mM in 200 μL total volume.   
Upon completion of the reaction, the reaction vessel was removed from the glove box 
and 1,2,4-trimethylbenzene (100 μL, 10.0 mM in TBME, as internal standard) was 
added. It was then extracted with TBME (700 μL), dried over Na2SO4. The conversion 
and enantiomeric excess were determined by chiral HPLC using an Analytical 
Chiracel OJ-H column (4.6 mm x 250 mmL, particle size 5μm) and a hexane / 
isopropanol mixture as eluent. 
Reactions on 100 µmol scale (preparative scale), general procedure: 
Following the above protocol 1-Iodonaphthalene (15 µl, 100 µmol) and 2-methoxy-1-
naphthaleneboronic acid (30 mg, 150 µmol) were allowed to react for 7 days at 4 
o
C in 
a sealed vial under nitrogen. The reaction mixture was extracted with EtOAc (3 x 10 
ml). After  drying  of  the  organic  phases  and  removal  of  volatiles,  the crude    
product    was    purified    by    column    chromatography over silica    gel    with 
EtOAc/cyclohexane  (1 :  10). The product was obtained as colourless oil (7 mg, 25 %, 
90 % ee). See SI Figure 1 and 2 for 
1
H NMR and chiral phase HPLC-analysis. 
1
H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 9.0 Hz, 1H), 7.96 (dd, J = 8.2, 4.1 Hz, 2H), 
7.88 (d, J = 8.2 Hz, 1H), 7.63 (dd, J = 8.3, 7.0 Hz, 1H), 7.50 – 7.42 (m, 3H), 7.37 – 
7.27 (m, 3H), 7.25 – 7.21 (m, 1H), 7.17 (dd, J = 9.1, 0.6 Hz, 1H), 3.77 (s, 3H). 
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Supporting Figure 1 
1
H NMR of isolated product 8b. 
 
  
 
Supporting Figure 2  Chiral phase HPLC data of isolated product. 
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SDS-Page Analysis of reaction mixtures: 
 
 
 
 
 
 
 
 
 
 
 
 
Supporting Figure 3 SDS-Page Gels. Right - B4F Stain, Left - Commassie Stain. 
It is well established that non-denatured, active streptavidin can be detected by SDS-
PAGE using biotinylated fluorescein as a specific marker (right side of SI Fig. 3).
4,5 
The same SDS-PAGE gels can also be stained with comassie-blue to visualize all 
proteins (left side of Fig. 4). Under non-denaturing conditions, streptavidin migrates 
primarily as an active tetramer, although the protein also has a tendency to aggregate 
to form oligomers (in some cases, dimers and monomers of streptavidin are also 
commonly detected as minor, active species). In the present study, under catalytic 
conditions (including 75 equivalents of boronic acid and 100 equivalents of NaOH), 
 
 
 
Oligomeric 
 
 
Tetrameric 
 
Dimeric 
 
 
Monomeric 
       1    2      3      4     5      6        1      2       3      4     5       6 
 
1 = protein ladder 
2 = S112Y-K121E 
3 = S112Y-K121E + Catalyst +DMSO  
4 = S112Y-K121E + Catalyst +DMSO + NaOH 
5 = S112Y-K121E + Catalyst +DMSO + NaOH + substrate 
6 = S112Y-K121E + Catalyst +DMSO + NaOH + substrate + 24 hr 
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the reaction mixture formed a suspension; upon microcentrifugation at 14’000 rpm, 
this suspension could be separated into a pellet and a clear supernatant. The 
supernatant contained active streptavidin (Non-denatured), which was binds 
biotinylated fluorescein. The migrating properties of the protein in this supernatant 
were similar to a Sav control (Non-denatured S112Y-K121E), with the corresponding 
expected molecular weight (Protein Ladder). 
These figures show that as each solvent and compound is added to  the  reaction,  the  
Sav  isoform  remains  largely  as  the  active  tetramer. The isolated precipitate 
reactions is largely starting material and product.  
Ee and conversion over the time course of the reaction: 
Following the general protocol for catalysis, 13 individual vials were prepared. The 
reactions were extracted at the indicated time points as described for the reactions on 
an analytical scale and analysed by HPLC. 
 
 
 
 
 
 
 
 
Supporting Figure 4 Conversion over the time course of the reaction. 
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Supporting Table 1. Complete list of catalytic experiments carried out for the 
chemogenetic optimization (see fingerprint display, Figure 1) with complex 1, 2 and 3. 
Enantiomeric excess > 0 corresponds to [S] > [R]; enantiomeric excess < 0 [R] > [S] 
 
Complex Mutant TON ee [%] 
1 WT 55 -57 
1 S112Y 14 +16 
1 S112L 59 -26 
1 S112V 60 -38 
1 S112F 55 -54 
1 S112M 58 +14 
1 S112T 58 -49 
1 S112Q 43 -50 
1 S112C <5 -48 
1 S112R 14 +16 
1 S112G 48 -56 
1 S112H 26 -50 
1 S112A 58 -60 
1 WT 53 -57 
1 K121R 6 -62 
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1 K121E 50 -76 
1 K121D 7 -34 
1 K121A 39 -4 
1 K121Y 46 -64 
1 K121F 38 -67 
1 K121M 59 -67 
1 K121N 52 -50 
1 K121H 17 -53 
1 K121C 37 -62 
1 - 20 rac 
2 WT 44 +19 
2 S112Y 37 -3 
2 S112L 51 +45 
2 S112V 39 +18 
2 S112F 49 +7 
2 S112M 53 +44 
2 S112T 26 +33 
2 S112Q 8 +33 
2 S112C <5 -3 
2 S112R <5 +44 
2 S112G 6 +31 
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2 S112H 22 -11 
2 S112A 46 Rac 
2 WT 42 +19 
2 K121R 33 +19 
2 K121E 30 -9 
2 K121D <5 +12 
2 K121A 32 +47 
2 K121Y 9 +14 
2 K121F 35 +11 
2 K121M 12 Rac 
2 K121N 36 +43 
2 K121H <5 +47 
2 K121C 17 +7 
2 - - - 
3 WT 45 -42 
3 S112Y <5 +28 
3 S112L <5 +37 
3 S112V <5 +5 
3 S112F <5 -15 
3 S112M 78 -38 
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3 S112T <5 -9 
3 S112Q - - 
3 S112C - - 
3 S112R <5 -60 
3 S112G 32 -50 
3 S112H <5 -50 
3 S112A 52 -36 
3 K121R <5 -9 
3 K121E <5 +13 
3 K121A 5 -13 
3 K121Y <5 +23 
3 K121F <5 +19 
3 K121M 5 -15 
3 K121N <5 Rac. 
3 K121H <5 -9 
3 K121C <5 +4 
3 K121G <5 -9 
3 S112D <5 -45 
3 S112E - - 
3 S112K 5 -56 
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Supporting Table 2. Complete list of control experiments carried out with complex 1 
at RT for the synthesis of enantioenriched 2-methoxy-1,1’-binaphthyl 8b 
Entry Catalyst 
(Complex 
1) 
μmol 
S112Y-
K121E 
Sav 
μmol 
Phosphine 
Ligand 
without 
biotin 
μmol 
[Pd(cinnamyl)(μ-
Cl)]2 μmol 
Biotin 
μmol 
TON ee 
[%] 
1 0.1 - - - - 20 Rac. 
2 - 0.2 - - - -    - 
3 - 0.2 - 0.1 - -    - 
4 0.1 0.2 - - 0.2 5 -47 
5 - 0.2 - 0.1 0.2 -    - 
6 0.1 0.2 - - - 90  -80 
7 - - 0.1 - - -    - 
8 - - 0.1 0.1 - -    - 
 
Supporting Table 3. Complete list of optimization of co-solvent and overall conc. of 
aryl halide carried out with complex 1 and WT Sav at RT for the synthesis of 
enantioenriched 2-methoxy-1,1’-binaphthyl 8b 
Entry Co-solvent ArX (6c) Conc. (mM) TON ee [%] 
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1 MeOH 50 72 -52 
2 DMSO 50 80 -57 
3 THF 50 62 -57 
4 Dioxane 50 36 -56 
5 DMSO 100 78 -57 
5 DMSO 25 50 -55 
6 DMSO 12 63 -54 
7 DMSO 6 50 -50 
8 DMSO 3 45 -49 
 
Supporting Table 4. Complete list of optimization of co-solvent amount, base 
amount and partial Sav loading carried out with complex 1 and S112Y-K121E Sav at 
RT for the synthesis of enantioenriched 2-methoxy-1,1’-binaphthyl 8b 
Entry Pd : Sav 
tetramer 
ratio 
Equivalents 
base added 
DMSO in 
water (%) 
TON 
(vs. 
Pd) 
ee [%] 
1 1/4 2 10 73 -78 
2 2/4 2 10 77 -78 
3 3/4 2 10 74 -76 
4 4/4 2 10 89 -69 
5 2/4 1 10 48 -79 
138 
5 2/4 1.5 10 57 -80 
6 2/4 3 10 34 -79 
7 2/4 5 10 5 -56 
8 2/4 2 5 53 -81 
9 2/4 2 15 65 -78 
10 2/4 2 20 70 -77 
11 2/4 2 25 37 -74 
12 2/4 2 30 52 -70 
13 2/4 2 35 - - 
 
 
Supporting Table 5. Retention times measured on an analytical Chiracel OJ-H 
column (5μm, 250 x 4.6 mm) at 40 °C with a flow rate: 1.00 ml/min (λ = 254 nm): 
Compound          Eluent 
(hexane/isopropanol) 
(R) enantiomer (S) enantiomer 
         8b 
         95:5 14.28 min 9.21 min 
           8a 
         95:5 6.58 min  9.49 min 
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     8c 
         95:5 11.12 min 7.66 min 
            8d 
          90:10 4.75 min 13.27 min 
       8e 
          90:10 13.68 min 4.79 min 
          8f 
          90:10 7.62 min 23.38 min 
       8g 
         95:5 7.48 min 10.46 min 
         8h 
         95:5 7.60 min 5.02 min 
 
Protein Crystallography  
(This work entirely performed by Aaron D. Finke, Laura Vera, May Marsh at the PSI) 
 
Crystallization. The crystallization screens were carried out by sitting drop vapor 
diffusion with 1 μl equivolumetric drops of protein and reservoir solution using 
CrysChem plates that were equilibrated at 20°C. The reservoir solution consisted of 
15-25% PEG 1500, 100mM SPG buffer (mixed succinic acid, sodium dihydrogen 
phosphate and glycine in the ratio 2:7:7; 75% at pH 4 and 25% at pH 10).
6
  Good 
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quality crystal could be obtained when drops were streak seeded
7
 in low PEG 
concentration immediately after setting up the drops with crystals growing from high 
PEG concentration. 
The crystals were transferred and soaked for 20 minutes in a cryo-protecting solution 
containing the biotinylated complex 1. The cryo-protecting solution consisted of the 
condition C7 from CryoProtX (Molecular Dimensions)
8
 mixed to 20% PEG 1500, 
100mM SPG buffer (75% at pH 4 and 25% at pH 10). 0.5uL of ligand 5 at 20mM in 
100% DMSO was added to 10µL of the cryo-protecting solution and crystals were 
flash-cooled in liquid nitrogen. 
 
 
Data Processing and Refinement. X-ray diffraction data were collected at beam line 
X06DA at the Swiss Light Source. Data were processed with the XDS software 
package.
9 
The structures were solved by molecular replacement with the Phaser-MR 
routine of the Phenix
10
 software package, using the 1LUQ structure from the PDB 
with the waters and ligand removed as a model compound. Structure refinement was 
performed with the phenix.refine utility.
10
 Crystallographic details are given in Table 
1.  
 
The Sav S112Y-K121E protein contains two monomers in the asymmetric unit related 
by non-translational NCS, which form a tetramer by application of the twofold axis. 
The 12 residues at the N-terminus and the 26 residues at the C-terminus are not 
resolved. There is strong residual electron density in the 2Fo-Fc difference map in the 
biotin binding pocket and vestibule. There is a significant peak in the anomalous 
difference map (8) at the interface of the vestibule near Y112, correlating with a 
strong peak in the density map (12); this position was determined to be the Pd atom. 
Pd atoms display significant anomalous scattering at 1 Å (2e). No other significant 
peak was found in the anomalous difference map. The density map clearly shows the 
presence of the phosphine ligand, Pd, and chlorine, but the cinnamyl ligand could not 
be resolved, likely due to disorder caused by ligand fluxionality. Generation of the 
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initial model and restraints for ligand 1 (without cinnamyl ligand) was done with the 
eLBOW
11
 routine in Phenix. The bond lengths and angles for the phosphine ligand, 
palladium, and chlorine were referenced from a related structure, [(t-Bu2(4-
dimethylanilino)P)PdCl(cinnamyl)],
12
 and the biotin and amide linker geometries were 
optimized with the generalized Amber forcefield in Avogadro v1.1.1
13
 (the Pd metal 
center and ligands were fixed during this step). The amide linker exhibits two H-
bonding interactions with the protein backbone: the amide nitrogen exhibits an H-
bonding interaction with the sidechain of S88, and the carbonyl oxygen exhibits an H-
bonding interaction with the backbone nitrogen of N49.   
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Wavelength (Å) 1.00 
Resolution Range 48.62  - 1.792 (1.856  - 1.792) 
Space Group C 2 2 21 
Unit Cell a = 81.368, b = 81.46, c = 90.811 
 = 90° 
Total Reflections 329716 (25103) 
Unique Reflections 27986 (2541) 
Multiplicity 11.8 (9.9) 
Completeness (%) 97.60 (89.28) 
Mean I/sigma(I) 18.18 (3.20) 
Wilson B-factor 18.93 
R-merge 0.09055 (0.7346) 
R-meas 0.09459 
CC1/2 0.999 (0.914) 
CC* 1 (0.977) 
R-work 0.2231 (0.3084) 
R-free 0.2558 (0.3121) 
Number of non-hydrogen atoms 
Macromolecules 
Ligands 
Water 
1973 
1863 
60 
50 
Protein residues 245 
RMS(bonds) 0.007 
RMS(angles) 1.11 
Ramachandran favored 97 
Ramachandran allowed 0 
Ramachandran outliers 0 
Clashscore 2.73 
Average B-factor 24.20 
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Macromolecules 
Ligands 
Solvent 
23.80 
36.10 
25.00 
Statistics for the highest-resolution shell are shown in parenthesis. 
General procedure for racemic products synthesis:  
A Schlenk-tube was charged with the boronic acid (1.05 eq.), Pd(OAc)2 (0.05 eq.), 
K3PO4 (2.00 eq.) and solid aryl-halide (1.00 eq.) and set under the nitrogen 
atmosphere. Dry toluene (0.5 mL) and the aryl-halide (1.00 eq.), if present as a liquid, 
were added via syringe. The reaction mixture was stirred overnight at 100 °C and 
checked by TLC. It was extracted with ethyl acetate (3 x 10 mL), washed with brine (2 
x 5 mL), dried over Na2SO4 and concentrated. The residue was further purified by 
column chromatography using hexane or hexane-ethyl acetate mixtures as eluents. 
2-Methyl-1,1’-binaphthyl (8a): Following the general procedure from 1-
iodonaphthalene (37.5 μL,  0.250 mmol, 1.00 eq.) and 2-methyl-1-naphthaleneboronic 
acid (76.6 mg, 0.375 mmol, 1.05 eq.) the product was isolated as a clear liquid (8a) 
(64.7 mg, quant. yield). 
Retention times: Measured on an analytical Chiracel OJ-H column (5μm, 250 x 4.6 
mm) with hexane/isopropanol (95:5) as the mobile phase at 40 °C and flow rate: 1.00 
ml/min: enantiomer (R): 6.40 min; enantiomer (S): 9.50 min.
 
 
1
H-NMR: (400 MHz, CDCl3): δ = 7.96 (d, 1H, 
3
JHH = 8.40 Hz), 7.88 (dd, 2H, 
3
JHH = 
8.40 Hz, 
4
JHH = 2.00 Hz), 7.62 (m, 1H), 7.51-7.14 (m, 9H), 2.11 (s, 3H). 
 
2-Methyl-4’-methyl-1,1’-binaphthyl (8d): Following the general procedure 
from 1-bromo-2-methylnaphthalene (55.3 mg, 39.2 μL, 0.250 mmol, 1.00 eq.) and  
144 
4-methyl-1-naphthaleneboronic acid (48.8 mg, 0.263 mmol, 1.05 eq.) the product was 
isolated as a liquid (8d) (77.1 mg, quant. yield). 
Retention times: Measured on an analytical Chiracel OJ-H column (5μm, 250 x 4.6 
mm) with hexane/isopropanol (90:10) as the mobile phase at 40 °C and flow rate: 1.00 
ml/min: enantiomer (R): 4.90 min; enantiomer (S): 14.9 min.
 
 
1
H-NMR: (400 MHz, CDCl3): δ = 8.11 (d, 1H, 
3
JHH = 8.40 Hz), 7.87 (dd, 3H, 
3
JHH = 
8.40 Hz, 
4
JHH = 4.00 Hz), 7.53-7.16 (m, 8H), 2.82 (s, 3H), 2.12 (s, 3H). 
 
2-Methoxy-4’-methyl-1,1’-binaphthyl (8e): Following the general procedure 
from 1-bromo-2-methoxynaphthalene (55.3 mg, 39.2 μL, 0.250 mmol, 1.00 eq.)  and  
2-methyl-1-naphthaleneboronic acid (0.375 mmol, 76.6 mg, 1.50 eq.) 2-methoxy-1,1’-
binaphthyl was isolated as a white solid (8e) (44 mg, 59% yield). 
Retention times: Measured on an analytical Chiracel OJ-H column (5μm, 250 x 4.6 
mm) with hexane/isopropanol (90:10) as the mobile phase at 40 °C and flow rate: 1.00 
ml/min: enantiomer (R): 4.90 min; enantiomer (S): 14.9 min.
 
 
1
H-NMR: (400 MHz, CDCl3): δ = 8.13-7.95 (m, 4H), 7.86 (d, 1H, 
3
JHH = 8.00 Hz), 
7.57-7.16 (m, 7H), 3.76 (s, 3H), 2.12 (s, 3H). 
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1-(2-Biphenyl)-2-methylnaphthalene (8h): Following the general procedure 
from 1-bromo-2-methylnaphthalene (0.250 mmol, 37.5 μL, 1.00 eq.) and 2-methyl-1-
naphthaleneboronic acid (0.375 mmol, 76.6 mg, 1.50 eq.) 2-Methyl-1,1-binaphthyl 
was isolated as a clear liquid (8h) (106 mg, 144% yield). 
Retention times: Measured on an analytical Chiracel OJ-H column (5μm, 250 x 4.6 
mm) with hexane/isopropanol (95:5) as the mobile phase at 40 °C and flow rate: 1.00 
ml/min:enantiomer (R): 4.40 min; enantiomer (S): 7.80 min.
 
 
1
H-NMR: (400 MHz, CDCl3): δ = 7.78 (m, 1H), 7.66 (d, 1H, 
3
JHH = 8.40 Hz), 7.55-
7.30 (m, 8H), 7.19 (d, 1H, 
3
JHH = 8.40 Hz), 7.05-6.99 (m, 5H), 1.98 (s, 3H). 
 
4-(2-Methylnaphthalen-1-yl)pyrene (8f): Following the general procedure from 1-
bromo-2-methylnaphthalene (0.250 mmol, 37.5 μL, 1.00 eq.) and 2-methyl-1-
naphthaleneboronic acid (0.375 mmol, 76.6 mg, 1.50 eq.) 2-Methyl-1,1’-binaphthyl 
was isolated as a clear liquid (8f) (125 mg, 58% yield). 
Retention times: Measured on an analytical Chiracel OJ-H column (5μm, 250 x 4.6 
mm) with hexane/isopropanol (90:10) as the mobile phase at 40 °C and flow rate: 1.00 
ml/min: enantiomer (R): 8.00 min; enantiomer (S): 34.0 min.
 
 
1
H-NMR: (400 MHz, CDCl3): δ = 8.32 (d, 1H, 
3
JHH = 8.00 Hz), 8.23 (d, 1H, 
3
JHH = 
7.60Hz), 8.20-8.13 (m, 3H), 8.02 (t, 1H, 
3
JHH = 7.60 Hz), 7.95-7.87 (m, 4H), 7.56 (d, 
1H, 
3
JHH = 8.40Hz), 7.48 (d, 1H, 
3
JHH = 9.2 Hz), 7.41 (t, 1H, 
3
JHH = 8.00 Hz), 7.19 (t, 
1H, 
3
JHH = 6.80 Hz), 7.09 (d, 1H, 
3
JHH = 8.4 Hz), 2.13 (s, 3H). 
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Synthesis of the naphthalene halide substrates: 
2-Methoxy-chloronaphthalene (6d): A suspension of 2-methoxy-
bromonaphthalene (190 mg, 0.8 mmol, 1.00 eq.) and CuCl (87.1 mg, 0.88 mmol, 1.10 
eq.) in DMF (15 ml) was refluxed overnight. After cooling to room temperature, the 
mixture was filtered and the solvent evaporated. The residue was then purified by 
column chromatography using a hexane/ethyl acetate gradient to obtain the product as 
white crystals (6d) (186 mg, quant. yield, Lit.
[12]
: 93%). 
1
H-NMR: (400 MHz, CDCl3): δ = 8.23 (d, 1H, 
3
JHH = 8.80 Hz), 7.79 (d, 2H, 
3
JHH = 
8.40 Hz), 7.59-7.55 (m, 1H), 7.43-7.39 (m, 1H), 7.31 (d, 1H, 
3
JHH = 9.2 Hz), 4.04 (s, 
3H). 
 
Calibration curves to determine HPLC yield: 
The calibration curve was prepared using 1,2,4-Trimethylbenzene in TBME as 
an internal standard and the measurement was carried out on an analytical Chiracel 
OJ-H column (5μm, 250 x 4.6 mm) using a hexane / isopropanol mixture as eluent. 
The calibration curves (Table 1; Fig. 3-8) are shown below. 
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    Table 6: Sample preparation for the calibration curve 
 
 1 2 3 4 5 6 7 8 
substrate [mM]  0 0.100 0.500 1.00 2.00 5.00 8.00 10.0 
internal standard [mM]   10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 
TBME [μL]  900 895 875 850 800 650 500 400 
 
 
Fig. 5: Calibration curve of 2-Methyl-4’-methyl-1,1’-binaphthyl 8d 
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Fig. 6: Calibration curve of 2-Methyl-1,1’-binaphthyl 8a 
 
 
Fig. 7: Calibration curve of 2-Methoxy-4’-methyl-1,1’-binaphthyl 8e 
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Fig. 8: Calibration curve of 4-(2-Methylnaphthalen-1-yl)pyrene 8f 
 
 
Fig. 9: Calibration curve of 1-(2-Biphenyl)-2-methylnaphthalene 8h 
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HPLC Traces: 
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Spectra for complex 1: 
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Spectra for complex 2: 
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Spectra for complex 3: 
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Spectra for complex 4: 
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Spectra for complex 5: 
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APENDIX 2 
 
Biotinylated Metathesis Catalysts: Synthesis and 
Performance in Ring Closing Metathesis 
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Experimental Section 
General: 
1
H and 
13
C spectra were recorded on a Bruker 400 MHz and 500 MHz. 
Chemical shifts are reported in ppm (parts per million). Signals are quoted as s 
(singlet), d (doublet), t (triplet), brs (broad) and m (multiplet). Electron Spray 
Ionization Mass Spectra (ESI-MS) were recorded on a Bruker FTMS 4.7T bioAPEX 
II. Analysis of the catalytic runs was performed on an Agilent 1100 reverse phase 
HPLC. All solvents were degassed prior to use. 
 
 
 
tert-butyl 4-((2-(mesitylamino)ethyl)amino)piperidine-1-carboxylate 7:
1
 
N-Mesitylethane-1,2-diamine 6 (1.09 g, 6.11 mmol, 1.00 eq.), N-tert-butoxy-carbonyl-
4-piperidone (1.24 g, 6.11 mmol, 1.00 eq.) and acetic acid (0.350 ml, 6.11 mmol, 1.00 
eq.) were suspended in DCE (15 mL) and the reaction mixture was heated at 40 °C for 
10 min. resulting in the formation of an orange suspension. After cooling to room 
temperature and stirring for an additional hour, NaBH3CN (576 mg, 9.16 mmol, 1.50 
eq.) was added portionwise resulting in the dissolution of the solid. The reaction was 
stirred overnight.Then concentrated HCl was added dropwise. The solution was stirred 
until gas evolution ceased. The solution was evaporated to dryness, and the solid was 
triturated with water. Then NaOH was added until the whole solution became cloudy. 
Extraction with diethyl ether and drying under vacuum yielded diamine 7 as an 
essentially pure yellow oil (2.12 g, 98%). 
1
H NMR (400 MHz, CDCl3): δ = 6.82 (s, 
166 
2H), 4.82 (brs, 2H), 3.81- 3.87 (m, 1H), 3.21-3.24 (m, 4H), 2.76 (t, 
3
JHH = 8 Hz, 2H), 
2.25 (s, 6H), 2.22 (s, 3H), 2.08-2.11 (m, 2H), 1.62-1.72 (m, 2H), 1.46 (s, 9H). ESI-MS 
for C21H35N3O2: 362.3 [M+H]
+
. 
 
 
 
3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1-mesityl-4,5-dihydro-1H-imidazol-3-
ium chloride 8: 
Anoven-dried round-bottom flask equipped with a magnetic stir-bar was charged with 
7 (1.95 g, 5.40mmol, 1.00 eq.), NH4Cl (289 mg, 5.40mmol, 1.00 eq.), and HC(OEt)3 
(18.4 mL, 108 mmol, 20.0 eq.). The flask was equipped with a condenser and purged 
with N2 prior to heating to 120 °C. The reaction was allowed to stir at 120 °C for 16 
hours under a positive N2 pressure. The reaction mixture was allowed to cool to room 
temperature, and the product precipitated upon adding ether. The grey precipitate was 
isolated by vacuum filtration and rinsed generously with ether to yield 1.70 g (78 %) 
of imidazolium salt 8. 
1
H NMR (400 MHz, CDCl3): δ = 9.99 (s, 1H), 6.93 (s, 2H), 
4.86-4.92 (m, 1H), 4.19-4.21 (m, 1H), 4.14-4.17 (m, 4H), 2.82-3.02 (m, 2H), 2.31 (s, 
6H), 2.28 (s, 3H), 2.11-2.15 (m, 2H), 1.86 (s, 1H), 1.60-1.70 (m, 2H), 1.46 (s, 9H). 
13
C 
NMR (100 MHz, CDCl3): δ = 159.1, 154.3, 140.2, 135.1, 130.6, 129.9, 99.9, 80.0, 
55.6, 50.6, 45.5, 30.0, 28.3, 20.9, 17.9. ESI-MS for C22H34ClN3O2: 372.3 [M-Cl]
+
. 
 
 
167 
 
 
 
 
Boc-2: 
A N2-filled schlenk-flask equipped with a magnetic stir-bar was charged with 
imidazolium salt 8 (94 mg, 0.23 mmol, 1.2 eq.), KHMDS (0.40 mg, 0.23 mmol, 1.2 
eq.), and dry, degassed toluene (3.3 mL). The suspension was allowed to stir for 1 
hour at room temperature. Hov I (0.11 mg, 0.19 mmol, 1.0 eq.) was added to the 
reaction mixture and the reaction was allowed to stir for 10 minutes at 65 °C. 
Purification was accomplished by flash column chromatography with 50% ethyl 
acetate in cyclohexane (product loaded with CH2Cl2). The green compound Boc-2 was 
obtained in 64 % yield (85 mg). 
1
H NMR (400 MHz, CD2Cl2): δ = 16.16 (s, 1H), 7.55-
7.59 (m, 1H), 7.09 (s, 2H), 6.95-7.00 (m, 3H), 5.14-5.20 (m, 2H), 4.33 (d, 
3
JHH = 12 
Hz, 2H), 3.84-3.99 (m, 4H), 2.82-3.02 (m, 2H), 2.46 (s, 3H), 2.38-2.41 (m, 2H), 2.19 
(s, 6H), 1.75-1.85 (m, 2H), 1.74-1.75 (d, 
3
JHH = 4 Hz, 6H), 1.49 (s, 9H). ESI-MS for 
C32H45Cl2N3O3Ru : 656.5 [M-Cl]
+
. 
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Biot-2:
2
 
Complex Boc-2 (31 mg, 0.045 mmol, 1.0 eq.) was dissolved in CH2Cl2 (2 mL) and 
HCl gas was purged through the solution for 1 h at room temperature. The gaseous 
HCl was generated by dropwise addition of concentrated H2SO4 to NH4Cl. The 
solution was stirred for an additional 2 h at room temperature. Upon completion of the 
reaction as revealed by TLC (hexane/AcOEt 2:1), the solvent was evaporated under 
reduced pressure. The green solid was dissolved in DMF (2 mL) and biotin 
pentafluorophenol (18 mg, 0.045 mmol) and Et3N (0.13 mL, 0.91mmol) were added to 
the solution, followed by stirring at RT for 16 h. The solvent was removed under 
reduced pressure and the crude product was purified on silica gel using 10% 
MeOH/CH2Cl2 to yield Biot-2 as a green solid (25 mg, 67%). 
1
H NMR (400 MHz, 
CD2Cl2): δ = 16.17 (s, 1H), 7.97 (s, 1H),7.55-7.60 (m, 1H), 7.09 (s, 2H), 6.95-7.00 (m, 
3H), 5.14-5.20 (m, 2H), 4.84-4.96 (m, 2H), 4.53-4.57 (m, 1H), 4.35-4.38 (m, 1H), 
4.07-4.11 (brs, 1H), 3.87-3.96 (m, 4H), 3.22 (m, 2H), 2.95 (s, 6H), 2.86 (s, 4H), 2.69-
2.77 (m, 2H), 2.52 (m, 2H), 2.46 (s, 3H), 2.18 (s, 6H), 1.90 (m, 1H), 1.74 (d, 
3
JHH = 4 
Hz, 6H). HRMS [ESI(+)]calculated for C37H51ClN5O3RuS: 782.2445 [M-Cl]
+
; found 
782.2414. 
 
 
 
 
 
169 
Biot-m-ABA-2:
2
 
Complex Biot-m-ABA-2 was synthesized following the same procedure used for the 
synthesis of Biot-2, using Biot-m-ABA-OC6F5 (19 mg, 0.036 mmol, 0.80 eq.) and 
Boc-2 (31mg, 0.045 mmol. 1.0 eq.). The crude product was purified on silica gel by 
10% MeOH/DCM to yield Biot-m-ABA-2 as a green solid (28 mg, 83%). 
1
H NMR 
(400 MHz, CDCl3): δ = 16.22 (s, 1H), 7.80-7.99 (m, 4H), 7.47-7.50 (m, 2H), 7.03 (s, 
2H), 5.28-5.32 (m, 2H), 5.15-5.18 (m, 2H), 4.52 (brs, 3H), 3.91-3.94 (m, 6H), 3.44 (m, 
2H), 2.95 (s, 5H), 2.87 (s, 4H), 2.43 (s, 4H), 2.15-2.19 (m, 10H), 1.76-2.01 (m, 9H). 
HRMS [ESI(+)]calculated for C44H56ClN6O4RuS: 901.2818 [M-Cl]
+
; found 901.2825. 
 
 
4-((2-(mesitylamino)ethyl)amino)-3,5-dimethylbenzonitrile 10:
3
 
The mixture of 9 (1.50 g, 4.14 mmol, 1.00 eq.) and copper (I) cyanide (749 mg, 8.28 
mmol, 1.00 eq.) in NMP (7 mL) was stirred at 160°C overnight. The reaction mixture 
was cooled to room temperature and water (10 mL) and ammonium hydroxide (10 
mL) were added. The product was extracted with ethyl acetate (2×50 mL). The 
product was purified by flash chromatography (CH2Cl2) to give white solid (700 mg, 
86%). 
1
H NMR (400 MHz, CDCl3): δ = 7.25 (s, 2H), 6.85 (s, 2H), 3.40 (t, 
3
JHH = 8 
Hz, 2H), 3.13 (t, 
3
JHH = 8 Hz, 2H), 2.30 (s, 6H), 2.26 (s, 6H), 2.24 (s, 3H). 
13
C NMR 
(100 MHz, CDCl3): δ = 150.7, 142.7, 133.0, 132.5, 130.5, 129.7, 127.4, 120.1, 102.7, 
48.8, 48.3, 20.7, 19.2, 18.3. ESI-MS for C20H25N3 : 308.2 [M+H]
+
. 
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tert-butyl (4-((2-(mesitylamino)ethyl)amino)-3,5-dimethylbenzyl) carbamate11: 
A solution of 10 (2.27 g, 7.41mmol, 1.00 eq.) in THF (10 mL) was added dropwise to 
a suspension of LiAlH4 (0.702 g, 18.5 mmol, 2.50 eq.) in THF (30 mL). The reaction 
mixture was refluxed for 3 hours and cooled to room temperature. The reaction 
mixture was quenched with 1.0N NaOH aqueous solution. The precipitate was filtered 
off and the solvent was evaporated in vacuo to provide the crude product, which can 
be used without purification. 
1
H NMR (400 MHz, CDCl3): δ = 6.95 (s, 2H), 6.84 (s, 
2H), 3.74 (s, 2H), 3.16-3.20 (m, 4H), 2.32 (s, 6H), 2.28 (s, 6H), 2.24 (s, 3H). 
13
C NMR 
(400 MHz, CDCl3): δ = 144.8, 143.3, 137.0, 131.6, 129.9, 129.8, 129.6, 127.8, 49.2, 
49.1, 46.1, 20.6, 18.7, 18.4. ESI-MS for C20H29N3: 295.3 [M-NH2]
+
. A round-bottom 
flask, equipped with a magnetic stir-bar,was purged with nitrogen and charged with 
the above crude product, Boc2O (1.4 g, 6.4 mmol, 1.0 eq.), and degassed CH2Cl2 (3 
mL). The flask was cooled to 0 °C with an ice/water bath prior to the addition of 
DMAP (79 mg, 0.64 mmol, 0.10 eq.). The reaction was stirred at 0 °C for an 
additional 30 minutes prior to warming to room temperature and stirring for 2 hours. 
The reaction mixture was extracted with water followed by brine. The organic layer 
was dried over Na2SO4, and the CH2Cl2 evaporated. Chromatography on silica-gel 60 
(15% EtOAc in hexanes) yielded 2.0 g (85%) carbamate 11 as a white powder. 
1
H 
NMR (400 MHz, CDCl3): δ = 6.91 (s, 2H), 6.83 (s, 2H), 4.73 (brs, 1H), 4.18 (d, 
3
JHH = 
171 
4 Hz, 2H), 3.31 (brs, 1H), 3.12-3.20 (m, 4H), 2.29 (s, 6H), 2.27 (s, 6H), 2.23 (s, 3H), 
1.46 (s, 9H). 
13
C NMR (100 MHz, CDCl3): δ = 155.9, 145.4, 143.3, 131.7, 130.0, 
129.7, 129.6, 128.3, 110.1, 49.2, 49.1, 28.5, 27.0, 20.6, 20.0, 18.7, 18.5. ESI-MS for 
C25H37N3O2 : 412.3 [M+H]
+
. 
 
 
3-(4-(((tert-butoxycarbonyl)amino)methyl)-2,6-dimethylphenyl)-1-mesityl-4,5-
dihydro-1H-imidazol-3-ium chloride 12: 
Anoven-dried round-bottom flask equipped with a magnetic stir-bar was charged with 
carbamate11 (2.00 g, 5.05 mmol), NH4Cl (270 mg, 5.05 mmol, 1.00 eq.), and 
HC(OEt)3 (16.6 mL, 101 mmol, 20.0 eq.). The flask was equipped with a condenser 
and purged with N2 prior to stirring under an N2 atmosphere at 120 °C for 16 hours. 
After cooling to RT, the product precipitated by addition of ether. The solid was 
isolated by vac-filtration and rinsed with ether to yield 2.20 g (95 %) of product12 as a 
grey powder. 
1
H NMR (400 MHz, CDCl3): δ = 9.54 (s, 1H), 7.00 (s, 2H), 6.91 (s, 2H), 
5.35 (brs, 1H), 4.51 (s, 4H), 4.15 (d,
 3
JHH = 4 Hz, 2H), 2.36 (s, 6H), 2.34 (s, 6H), 2.25 
(s, 3H), 1.41 (s, 9H). 
13
C NMR (400 MHz, CDCl3): δ = 163.9, 160.1, 155.9, 141.4, 
140.0, 135.3, 134.7, 131.5, 130.1, 129.7, 127.8, 79.2, 57.3, 51.5, 43.5, 28.1, 20.8, 17.7. 
ESI-MS for C26H36ClN3O2 : 422.3 [M-Cl]
+
. 
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Chloroform adduct 13:
4
 
Following the procedure of Grubbs, dry, degassed toluene (15 mL) was added to an 
oven-dried, 50 mL Schlenk flask equipped with stir bar and a reflux condenser. A 
large excess of powdered potassium hydroxide (5.37 g, 95.6 mmol, 127 eq.) was 
added to the flask, and the resulting suspension was stirred. Chloroform (0.405 mL, 
5.00mmol, 6.67 eq.) was then added to the suspension. After 10 min at RT, 12 (0.344 
g, 0.750mmol, 1.00 eq.) was added and the reaction mixture was heated at 60 °C for 
75 min. The mixture was allowed to cool to room temperature and filtered. The filtrate 
was concentrated under vacuum to give a light brown solid. This crude product was 
purified by column chromatography (20% ethyl acetate/hexane, Rf = 0.2) to yield 
0.185 g (45 %) of the desired chloroform adduct 13as a light yellow solid. 
1
H NMR 
(400 MHz, CDCl3): δ = 6.95 (s, 1H), 6.92 (s, 1H), 6.87 (s, 1H), 6.83 (s, 1H), 5.58 (s, 
1H), 4.76 (brs, 1H), 4.22 (d, 
3
JHH = 4 Hz, 2H), 3.89-3.92 (m, 2H), 3.25-3.35 (m, 2H), 
2.49 (s, 3 H), 2.47 (s, 6H), 2.45 (s, 3H), 2.25 (s, 3H), 1.47 (s, 9H). 
 
 
 
 
Boc-3: 
An oven-dried, 10 mL Schlenk tube was charged with Hov I (36 mg, 60µmol, 1.0 
eq.), the chloroform adduct 13 (65 mg, 0.12 mmol, 2.0 eq.), and dry, degassed toluene 
(2 mL). The reaction mixture was heated at 70 °C for 90 min under a nitrogen 
173 
atmosphere. After cooling to room temperature, the solvent was removed under 
vacuum. The dark-brown solid was passed through a short silica gel column using 
ethyl acetate/cyclohexane (1:1) as eluent. The green band was collected and 
concentrated to give a green solid (27 mg, 60%). 
1
H NMR (400 MHz, CDCl3): δ = 
16.52 (s, 1H), 7.48 (t, 
3
JHH = 8 Hz, 1H), 7.16 (s, 2H), 7.07 (s, 2H), 6.92-6.96 (m, 1H), 
6.83-6.87 (m, 1H), 6.79 (d, 
3
JHH = 8 Hz, 1H), 4.84-4.94 (m, 1H), 4.36 (d,
 3
JHH = 4 Hz, 
2H), 4.18 (s, 4H), 2.51 (s, 6H), 2.46 (s, 6H), 2.41 (s, 3H), 1.50 (s, 9H), 1.26 (d,
 3
JHH = 
4 Hz, 6H). ESI-MS for C36H48Cl2N3O3Ru : 706.3 [M-Cl]
+
. 
 
 
 
 
Biot-3: 
Complex Biot-3 was synthesized following the same procedure used for the synthesis 
of Biot-2, using Biot-OC6F5 (13 mg, 0.032 mmol, 0.80eq) and Boc-3(30 mg, 
0.041mmol, 1.0 eq.). The crude product was purified on silica gel by 10% 
MeOH/CH2Cl2to yield Biot-3 as a green solid (19 mg, 67%). 
1
H NMR (400 MHz, 
CDCl3): δ = 16.52 (s, 1H), 7.50 (t, 
3
JHH = 8 Hz, 1H), 7.17 (s, 2H), 7.07 (s, 2H), 6.94-
6.96 (m, 1H), 6.83-6.89 (m, 1H), 6.80 (d, 
3
JHH = 8 Hz, 1H), 4.87-4.92 (m, 2H), 4.40-
4.49 (m, 3H), 4.17 (s, 4H), 2.82 (s, 1H), 2.49(brs, 10H), 2.40 (s, 3H), 2.28-2.30 (m, 
3H), 2.18-2.23 (m, 1H), 1.42-1.50 (m, 2H), 1.17-1.32 (m, 12H), 0.83-0.94 (m, 3H). 
HRMS [ESI(+)]calculated for C41H53ClN5O3RuS: 832.2602 [M-Cl]
+
; found 832.2593 
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EA calculated for C41H53Cl2N5O3RuS: C, 56.35, H, 6.33, N 8.54; found: C, 56.74; H, 
6.15; N, 8.07. 
 
 
 
 
Biot-m-ABA-3: 
Complex Biot-m-ABA-3 was synthesized following the same procedure used for the 
synthesis of Biot-2, using Biot-m-ABA-OC6F5 (6.8 mg, 0.012 mmol, 0.75eq) and 
Boc-3 (12 mg, 0.016 mmol, 1.0 eq.). The crude product was purified on silica gel by 
10% MeOH/CH2Cl2 to yield Biot-m-ABA-3 as a green solid (11 mg, 83%). 
1
H NMR 
(400 MHz, CDCl3): δ = 16.56 (s, 1H), 8.01 (s, 1H), 7.45 (t, 
3
JHH = 8 Hz, 1H), 7.05-
7.08 (m, 4H), 6.93-6.95 (m, 2H), 6.82-6.86 (m, 2H), 6.78-6.80 (m, 2H), 4.87-4.91 (m, 
1H), 4.16 (s, 6H), 3.80 (s, 2H), 3.45 (brs, 2H), 2.50 (brs, 6H), 2.46 (brs, 6H), 2.41 (brs, 
3H), 1.90-1.94 (m, 4H), 1.67-1.72 (m, 4H), 1.57-1.61 (m, 2H), 1.27 (d, 
3
JHH = 4 Hz, 
6H). HRMS[ESI(+)]calculated for C48H58ClN6O4RuS: 951.2975 [M-Cl]
+
; found 
951.2963 
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Boc-4: 
An oven-dried, 10 mL Schlenk tube was charged with Hov I (118 mg, 0.197 mmol, 
1.00 eq.), chloroform adduct 15 (242 mg, 0.394 mmol, 2.00 eq.), and dry, degassed 
toluene (20 mL). The reaction mixture was heated at 70 °C for 90 min under a 
nitrogen atmosphere. After cooling to RT, the solvent was removed under vacuum. 
The dark-brown solid was passed through a short silica gel column using ethyl 
acetate/cyclohexane (1:1) as eluent. The green band was collected and concentrated to 
give a green solid (0.720 g, 45%). 
1
H NMR (400 MHz, CDCl3): δ = 16.56 (s, 1H), 
7.48 (t, 
3
JHH = 8 Hz, 1H), 7.07 (s, 2H), 7.00-7.03 (m, 1H), 6.97 (s, 2H), 6.84-6.88 (m, 
1H), 6.79 (d, 
3
JHH = 8 Hz, 1H), 5.04 (brs, 1H), 4.87-4.93 (m, 1H), 4.63 (brs, 1H), 4.16 
(s, 4H), 3.78 (s, 3H), 3.06-3.22 (m, 2H), 2.48 (brs, 12H), 2.40 (s, 3H), 1.56 (s, 9H), 
1.28 (d, 
3
JHH = 4 Hz, 6H).ESI-MS for C39H51Cl2N3O5Ru : 778.3 [M-Cl]
+
. 
 
 
 
 
Biot-4 
Complex Biot-4 was synthesized following the same procedure as for Biot-2, using 
Biot-OC6F5 (8.8 mg, 0.021 mmol, 0.77eq) and Boc-4(22 mg, 0.027 mmol, 1.0). The 
crude product was purified on silica gel by 10% MeOH/CH2Cl2to yield Biot-4 as a 
green solid (10 mg, 50%).
1
H NMR (400 MHz, CDCl3): δ = 16.54 (s, 1H), 7.48 (t, 
3
JHH 
= 8 Hz, 1H), 7.07 (s, 2H), 6.94-6.97 (m, 3H), 6.86 (t, 
3
JHH = 8 Hz, 1H), 6.79 (d, 
3
JHH = 
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8 Hz, 1H), 4.85-4.93 (m, 2H), 4.64 (brs, 1H), 4.53 (brs, 1H), 4.32 (brs, 1H), 4.16 (s, 
4H), 3.76 (s, 3H), 3.12-3.18 (m, 2H), 2.94-2.96 (m, 1H), 2.68-2.72 (m, 2H), 2.45 (brs, 
12H), 2.39 (s, 3H), 1.81-1.85 (m, 2H), 1.57 (brs, 8H), 1.25-1.29 (m, 6H). HRMS 
[ESI(+)]calculated for C44H57ClN5O5RuS : 904.2815 [M-Cl]
+
; found 904.2816. 
 
 
 
 
Biot-m-ABA-4 
Complex Biot-m-ABA-4 was synthesized following the same procedure used for the 
synthesis of Biot-2, using Biot-m-ABA-OC6F5 (11 mg, 0.021 mmol, 0.77 eq.) and 
Boc-4(22 mg, 0.027 mmol, 1.0 eq.). The crude product was purified on silica gel by 
10% MeOH/CH2Cl2 to yield Biot-m-ABA-4 as a green solid (12 mg, 50%). 
1
H NMR 
(400 MHz, CDCl3) δ = 16.56 (s, 1H), 8.01 (s, 1H), 7.45 (t, 
3
JHH = 8 Hz, 1H), 7.05-7.08 
(m, 6H), 6.82-6.86 (m, 2H), 6.79 (d, 
3
JHH = 8 Hz, 2H), 4.87-4.93 (m, 1H), 4.16 (s, 6H), 
3.80 (s, 3H), 3.47 (brs, 2H), 2.50 (brs, 6H), 2.46 (brs, 6H), 2.41 (brs, 3H), 1.90-1.94 
(m, 4H), 1.63-1.72 (m, 4H), 1.53-1.61 (m, 2H), 1.27 (d, 
3
JHH = 4 Hz, 6H), 1.06-1.11 
(m, 6H). ESI-MS for C51H62Cl2N6O6RuS : 1029.8 [M-Cl]
+
. 
 
General procedure for ring closing metathesis of N-tosyldiallylamine in CH2Cl2. 
A 10mM stock solution of the complex (Hov II, Biot-1 to Biot-5 and Biot-m-ABA-1 
to Biot-m-ABA-4) was prepared by adding CH2Cl2 (60μL) to an aliquot of the 
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complex (0.61μmol). A 111mM stock solution of N-tosyldiallylamine (65 mg, 0.24 
mmol in 2.2 ml CH2Cl2) was prepared in a separate vial. In a pyrex tube was added the 
solution of N-tosyldiallylamine (90 μL), followed by the addition of the catalyst’s 
stock solution (10μL) and the reaction flask was placed in a shakingincubator for 24 h 
at 37°C and 200 rounds per minute. 
Upon completion of the reaction the reaction mixture was transferred to an eppendorf 
tube and MeOH (800 μL) was added to the tube. The solution was filtered, transferred 
into an HPLC vial and the sample was subjected to RP-HPLC to determine the 
conversion. 
For experiments preformed with ten-fold lower concentration of substrate 5μL of 
previously prepared stock solutions of each complex was transferred into separate 
vials and 45 μL of CH2Cl2was added to each of them. In the other vial 11 mMstock 
solution of N-tosyldiallylamine was prepared by adding CH2Cl2 (1800μL) to 200 μL 
of previously used stock solution. Reactions were performed according to the same 
procedure.  
General procedure for ring closing metathesis of N-tosyl/diallylamine in a 
mixture DMSO/H2O. 
A 12.5 mM stock solution of the complex (Hov II, Biot-1 to Biot-5 and Biot-m-ABA-
1 to Biot-m-ABA-4) was prepared by adding DMSO (46 μL) to an aliquot of the 
complex (0.57 μmol). A 1.25 M stock solution of N-tosyldiallylamine (50.0 mg, 187 
μmol in 149 μL DMSO) was prepared in a separate vial. In a pyrex tube was added 
water (84μL), followed by the addition of the catalyst’s stock solution (8 μL) and the 
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N-tosyldiallylamine (8 μL of the stock solution), and the reaction flask was placed in 
an incubator for 24 h at 37°C. 
Upon completion of the reaction the reaction mixture was transferred to an Eppendorf 
tube and MeOH (800 μL) was added to the tube. The solution was transferred to an 
eppendorf tube and centrifuged at 14’000 rpm for 2 minutes. The supernatant (500 μL) 
was transferred in an HPLC vial and the sample was subjected to RP-HPLC to 
determine the conversion. 
 
General procedure for ring closing metathesis of 5-hydroxy-2-vinylphenyl 
acrylate in CH2Cl2. 
A 2.5 mM stock solution of the complex (Hov II, Biot-1 to Biot-5 and Biot-m-ABA-1 
to Biot-m-ABA-4) was prepared by adding CH2Cl2 (92 μL) to an aliquot of the 
complex (0.230μmol). A 27.8 mM stock solution of 5-hydroxy-2-vinylphenyl 
acrylate(15.0 mg, 78.8 μmol in 2839 μL CH2Cl2) was prepared in a separate vial. 
Reactions were performed according to the same procedure as reactions of N-
tosyldiallylamine in CH2Cl2. 
General procedure for ring closing metathesis of 5-hydroxy-2-vinylphenyl 
acrylate in a mixture DMSO/H2O. 
A 3.125 mM stock solution of the complex (Hov II, Biot-1 to Biot-5 and Biot-m-
ABA-1 to Biot-m-ABA-4) was prepared by adding DMSO (184 μL) to an aliquot of 
the complex (0.575 μmol). A 312.5 mM stock solution of 5-hydroxy-2-vinylphenyl 
acrylate(12 mg, 63 μmol in 202 μL DMSO) was prepared in a separate vial. Reactions 
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were performed according to the same procedure as reactions of N-tosyldiallylamine 
in DMSO/H2O. 
HPLC analysis. Column: XDB-C18, Eclipse by Agilent: 150 x 4.6 mm; 5 μm with 
guard column. Method: Vinjected: 6 μl. Eluent (Solvent A: H2O), (Solvent B: CH3CN) 
10% B at 0 min, 10% B at 5 min; 90% B at 15 min; 90 % B at 20 min. Detection at 
210 nm.  
Retention times: Phenylethanol (internal standard): 10.7 min; N-tosyl-3-pyrroline 20: 
13.5 min; N-tosyldiallylamine 19: 15.3 min; umbelliferone25: 9.4 min; 5-hydroxy-2-
vinylphenyl acrylate 24: 12.9 min. 
General Procedure for RCM with pure protein 
In a 96 well-plate, 50 µM Sav in acetate buffer and 25µM of biotinylated catalyst in 
DMSO were added. After that, 10 mM coumarin precursor 24 is added to the reaction 
mixture at 37 °C in acetate buffer. The reaction mixture was incubated for 19 hours at 
37 °C under air and measured by Tecan plate reader between 50 and 250 nm 
wavelengths. The fluorescence intensity were compared at maximum wavelength (100 
nm) to determine relative activity.  
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Spectra of the compounds: 
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APENDIX 3 
 
Asymmetric C–H Activation Reaction Catalyzed 
by an Artificial Benzannulase Using Unpurified 
Protein Samples 
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General Methods  
 
All reactions were carried out in 0.5 dram sealed vials under an atmosphere of air with 
magnetic stirring without drying or degassing of the vial. Conversions and 
regioselectivities were determined by GC with a calibrated internal standard (1,3,5 
trimethoxybenzne). Enantiomeric ratio was determined by Chiral HPLC.  
  
Site-Directed Mutagenesis  
 
 A pET11b plasmid containing the gene encoding for streptavidin fused with a T7-tag 
was used as a template for PCR. Primers were designed following the method 
described by Zheng et al. and tested in silico to minimize hairpin formation.
1
 Primers 
were obtained from Microsynth. PCR reactions of 50 µL total volume contained 5 – 
25 ng of template plasmid, forward and reverse primers (300 nM each, Microsynth), 
dNTPs (0.1 mM each, Stratagene), DMSO (5 %), Pfu buffer (1x, Stratagene), 
polymerase Pfu turbo (3.75 U, Stratagene). The cycle conditions were: initial 
denaturation (95 °C, 5 min), followed by 16 cycles of denaturation (1 min at 95 °C), 
annealing (1 min at 50 – 60 °C, depending on the primers used), elongation (10 min at 
68 °C). The final elongation was performed at 68 °C for 1 h. PCR products were 
analysed by gel electrophoresis (1 % agarose). The initial DNA template was digested 
by DpnI (1 h at 37 °C, New England Biolabs). 5 µl of PCR product were used to 
transform chemically competent XL1-blue E. coli cells (produced in-house). Plasmids 
were purified using a Wizard Plus SV Miniprep DNA purification System (Promega) 
and were sequenced either by Microsynth.  
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Production of Recombinant Streptavidin  
Chemically competent BL21(DE3)pLysS E. coli cells (produced in-house) were 
transformed by the plasmids containing the desired mutations. Transformed cells were 
plated on LB-Lennox agar plates containing ampicillin (50 µg/mL, AppliChem), 
chloramphenicol (34 µg/mL, AppliChem) and glucose (2 % w/v), and incubated 
overnight at 37 °C. The culture medium (300 mL total, 20 g/L bactotryptone (BD), 1.3 
g/L Na2HPO4, 1 g/L KH2PO4, 8 g/L NaCl, 15g/L bacto yeast extract (Merck) 
containing ampicillin (50 µg/mL), chloramphenicol (34 µg/mL), and glucose (2% 
w/v) was inoculated with a single colony. This preculture was incubated overnight on 
an orbital shaker (37 °C, 250 rpm). The fermentation was performed in a 30 L 
fermenter (NLF22, Bioengineering). The culture medium (20 L) containing ampicillin 
(50 µg/mL), chloramphenicol (34 µg/mL) and glucose (0.4 % w/v) was inoculated 
with the whole preculture. To avoid the formation of inclusion bodies, cells were 
grown at 20 °C, 30 °C or 37 °C, depending on the mutant. When an OD600 of 2 – 3 
was reached the expression of streptavidin was induced by addition of isopropyl β-D-
1- thiogalactopyranoside (final concentration 0.4 mM, AppliChem). The cells were 
harvested 3 - 4 h after induction (expression at 30 °C and 37 °C) or after overnight 
expression (20 °C) by centrifugation (3600 x g, 10 min, 4 °C). The supernatant was 
discarded and the pellet was frozen at -20 °C until it was thawed for purification. 
Protein expression was confirmed by SDS-PAGE analysis.  
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Protein Purification   
 
The pellet was thawed and resuspended in Tris-HCl buffer (20 mM, pH 7.4, 500-1000 
ml / 150 - 450 g pellet). DNase I (2 - 3 mg, Roche) and phenylmethylsulfonyl fluoride 
(to a final concentration of 1 mM, AppliChem) were added and the resuspended cells 
were incubated at RT under vigorous shaking until the mixture became less viscous. 
The sample was dialyzed against 6 M guanidinium hydrochloride (Acros), pH 1.5 at 
room temperature for 24 hours. Two further dialysis steps were performed (20 mM 
Tris-HCl, pH 7.4, 4 °C, followed by 50 mM Na2CO3, pH 9.8, 0.5 M NaCl, 4°C) to 
prepare the proteic extract for affinity chromatography. The proteic extract was 
centrifuged (18000 x g, 30 min, 4 °C) to remove cell debris. The supernatant was 
filtered (Whatman paper filter) and applied to a 2-iminobiotin sepharose column 
(Affiland) equilibrated at pH 9.8 (50 mM Na2CO3, 0.5 M NaCl). Pure streptavidin was 
eluted with 1% acetic acid, immediately dialyzed against Tris- buffer (10 mM Tris-
HCl, pH 7.4) for 24 h at 4 °C, followed by distilled water for 24 h and finally two 
times against mQ-water for 24 h at 4 °C. The purified protein solution was frozen at -
80 °C, lyophilized, and the lyophilized protein stored at 4 °C. The molecular weight of 
the purified protein was assessed by ESI-MS. 
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Synthesis of Rh(I) Complex : 
 
 
Complex 23 was synthesized according to the literature procedure.
1
 The complex 23 
was prepared in DMF (2 mL) and biotin pentafluorophenol (18 mg, 0.045 mmol) and 
Et3N (0.13 mL, 0.91mmol) were added to the solution, followed by stirring at RT for 
16 h. The solvent was removed under reduced pressure and the crude product was 
purified on silica gel using 10% MeOH/CH2Cl2 to yield 24 as a yellow solid (25 mg, 
67%). 
1
H NMR (400 MHz, CD2Cl2): δ = 6.17 (dd, J = 15.5, 9.7 Hz, 2H), 5.25 – 5.17 
(m, 1H), 5.10 (t, J = 1.8 Hz, 2H), 5.02 (t, J = 1.9 Hz, 2H), 4.55 – 4.44 (m, 1H), 4.31 
(dd, J = 7.1, 5.2 Hz, 1H), 3.46 – 3.37 (m, 2H), 3.15 (td, J = 7.3, 4.7 Hz, 1H), 2.99 – 
2.85 (m, 2H), 2.73 (d, J = 12.8 Hz, 1H), 2.35 (dt, J = 13.9, 4.1 Hz, 2H), 2.27 – 2.12 
(m, 6H), 1.96 – 1.86 (m, 4H), 1.79 – 1.58 (m, 6H), 1.52 – 1.39 (m, 2H). ESI-TOF-MS 
(Positive mood) calculated for C27H36N3O2RhS: 567.0, [M+H]
+
; found 568.0. 
General Synthesis for Dihydroisoquinolone 10: 
 
A  0.5  dram  flask  is  charged  with  an  oven  dried  stir  bar  and  the  appropriate 
tetrameric strept(avidin) mutant  (0.66  mol  %,  6.6  x  10
-5
 mmol,  4.3  mg).  The 
solution was  dissolved  in  deionized  water  (160  μl) and allowed to stir for 2 
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mintues. A solution of [RhCp*biotinCl2]2 (1 μl of a solution in DMSO (0.1 M, 1 
mol %, 0.11 mg)) was added to the solution and stirred at 500 rpm. After 5 minutes, a 
solution of pivaloyl protected hydroxamic acid in MeOH (0.25M solution, 40 μl, 1 
equiv., 2.12 mg) was added to the reaction and stirred for 30 seconds. After alkene 
was added (1 equiv, 0.9 mg) the reaction is sealed and allowed to stir at 23 °C. After 
36 hours the reaction is quenched with 400 μl of ethyl acetate and a 50 μl solution of 
1,3,5 trimethoxybenzene in ethyl acetate (0.2M). The reaction is allowed to stir for 10 
minutes (1000 rpm) before 200 μl of the organic layer was removed. Yield and 
diastereoselectivity was determined via GC, enantioselectivity was determined by 
HPLC. 
This compound has been previously reported. Absolute configuration determined by 
HPLC trace of enantiopure sample. Included is the 
1
H NMR. 
1
H (400 MHz, CDCl3) δ 
= 8.08 (dd, J = 7.7, 1.1 Hz, 1H), 7.49 - 7.45 (m, 1H), 7.38 (t, J = 7.5 Hz, 1H), 7.24 (d, 
J = 7.5 Hz, 1H), 6.50 (s, 1H), 4.41 (ddd, J = 10.0, 5.1, 1.9 Hz, 1H), 3.80 (s, 3H), 3.33 
(dd, J = 15.7, 5.1 Hz, 1H), 3.21 (dd, J = 15.7, 10.0 Hz, 1H). Chiral HPLC: IA 
Column; 90:10 Hexane/
i
PrOH. 
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